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Abstract
The hypothesis that the adipocyte hormone leptin has modulatory effects on the 
secretion of insulin in the presence of glucose by the islets of Langerhans of normal male 
rats, and which was postulated to be inhibitory, was investigated. Evidence obtained 
indicated that the modulatory effect was mediated through the possible combination of 
neural and endocrine parameters. A previously unreported humoral connection between 
the intestine and the pancreas was demonstrated, by which incretins could potentially 
mediate their effects on the production of insulin and other endocrine functions. In the 
study, an ex vivo perfusion of the pancreas was used, in a purposely designed perfusion 
system with a surgery platform, and an artificial perfusion medium (KRBB medium) with 
combinations of concentrations of 4, 8, 12 & 16mM glucose and leptin at 0, 5, 10, 15 & 
20ng/ml, in the aim of developing an index for the modulatory effect of leptin on insulin 
secretion. Insulin output was measured by radioimmunoassay and the results were 
statistically assessed and analyzed.
It was confirmed that insulin secretion from the ex-vivo perfused pancreas in 
response to glucose stimulation follows a bi-phasic secretion pattern. Leptin reduced 
insulin secretion at 8 and 12 mmol/L stimulatory concentrations of glueose but either 
stimulated or had no effect at 4 and 16 mmol/L glucose. A U-shaped dose-response 
relationship was observed when the range of leptin and glucose concentrations of 5, 10, 
15 and 20 ng/ml and 4, 8, 12 and 16 mmol/L respectively were examined, where minimal 
suppressions were observed at low and high concentrations of both leptin and glucose. In
addition, leptin showed distinct suppressive effects on phase one and phase two 
concentrations depending on the glucose concentration used. This suggested the presence 
of two or more interdependent intracellular cascades responsible for the secretion and 
synthesis of insulin in the P-cells of the pancreas, through which leptin exerts its effects 
on both phases. The presence of various potential incretins together with the newly 
reported humoral connection between the duodenum and the pancreas implicates other 
factors controlling insulin secretion and the manner by which leptin modulates insulin 
secretion.
It was concluded that leptin possesses both an inhibitory and a stimulatory effect 
on insulin secretion and synthesis in a dose-dependent manner and in the presence of 
different glucose concentrations. This modulatory effect may depend on the presence of 
eertain incretins, possibly including Glucagon Like Peptide (GLP-1), where the common 
intracellular pathways present potential common sites of action for the inhibitory cascade 
of leptin.
1. Introduction
1.1 Preamble
Obesity is the accumulation of excess adipose tissue to an extent that impairs both 
physical and psychosocial health and well-being. It is progressively becoming a global 
health crisis, of great and growing proportion in developed and developing countries, due 
to its association with an increased risk of non-communicable diseases such as 
cardiovascular diseases, diabetes, dyslipidaemia, and cancer resulting in increased 
mortality rate (James 2004). Statistics indicate that its outcomes are affecting 
approximately 9% of the world’s population on the break of the new millennium, and in 
particular the young, where the prevalence in children has increased to about 20-25%, 
with a higher proportion in Pima Indians, Mexican Americans, and African Americans 
(Cole TJ, Bellizi MC, Flegal KM and Dietz MH 2000) implying variation among ethnic 
groups. The occurrence of obesity in western and westernizing countries has doubled 
over the past decade, with 20% of males and 25% of females now classified as obese in 
the United States alone (Caterson and Gill 2002) with alarming increase in child obesity 
associated with diabetes at young ages (Bundred P, Kitchiner D, and Buehan I 2001, and 
Chinn and Rona 2001). The sex distribution showed approximately 35% of women and 
31% of men older than 19 years, obese or overweight (Cole 2000). This remarkable 
difference between men and women is associated with the capacity of men to deposit 
more lean (muscle) than fat tissue when energy imbalance occurs with weight gain (Rose 
1991). The rate of variation in percentage between sexes during the middle age (45-60 
years), ranges from 5% in parts of Africa to nearly 80% in Eastern Europe as indicated in
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Figure 1 below.
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Figure 1: Prevalence of the obesity and overweight in persons aged 45-49 in different 
parts of the world (James 2004).
Africa D: Nigeria, Algeria and Ghana 
Africa E: Ethiopia, Congo, and South Africa 
America A: United States, Canada, and Cuba 
America B: Brazil, Mexico, and Colombia 
America D: Peru, Ecuador, and Guatemala 
Eastern Med B: Iran, United Arab Emirates, and Saudi 
Arabia
Eastern Med D: Pakistan, Egypt, and Sudan
Euro A: Germany, France, and the United Kingdom
Euro B: Turkey, Poland, and Uzbekistan
Euro C: Russian Federation, Ukraine, and Kazakhstan
S.E. Asia B: Indonesia, Thailand, and Sri Lanka
S.E. Asia D: India, Bangladesh, and Singapore
W. Pacific A: Japan, Australia, and Singapore
W. Pacific B; Vietnam, and the Philippines
Data have been reported from several developing nations, particularly from Asia 
(Malaysia, Japan and China), where an epidemic of obesity in the last three decades has 
been paralleled with major concerns of relevant morbidities (Chinn and Rona 2001 and 
Caterson and Gill 2002). Data from the Middle-Eastern countries of Bahrain, Saudi 
Arabia, Egypt, Jordan, Tunisia, and Lebanon exhibit this same trend with alarming levels
of obesity often exceeding 40% of the populations, and particularly in women of the 
Sunni sect of Islam, as is evident through crude demographic observations. Most 
investigators generally see this ethnically based difference as an indication of 
involvement of genetic predisposing faetors. Research suggests that environmental 
factors are of great significance, because considering this rapid increase in the global 
prevalence of obesity, and since relevant genetic alterations could not possibly account 
for such a rapid change in phenotype, it is indicative of tacit evidence for potent 
environmental influences on body fatness. This discernible magnitude of intervening 
environmental factors, which include diet, and the modem sedentary way of life, is 
elearly expressed in the development of obesity, and thus could be a consequence of 
economic development, and technological advances, which tend to bring a progressive 
reduction in the demands for physical activity in daily living. In most countries, a clear 
inverse relationship is observed between education level/ socioeconomic status and 
obesity prevalence where the latter is more pronounced among the poor societies (Pena 
and Bacallao 2000). This is possibly associated with increased availability of energy- 
dense dietary choices, which may be determined by the relative cheapness of its 
processing, where energy is derived from fats and sugars in the increasingly available 
“fast foods”. It is worth noting that television watching augments sedentary habits, 
which, again is more prevalent among the poorer communities since it is a relatively 
cheap form of entertainment.
Since the co-morbidities related to obesity lead to early disabilities and potential 
death, it reflects negatively on national economic growth due to its association with the
size and efficiency of a country’s work force and thus reflected on that of the globe. 
Since obesity is a non-border associated concern to humanity, its repercussions are 
international. A preliminary assessment of the disease’s burden attributable to overweight 
and obesity was made. It showed that the maximum impact, in terms of the number of 
years lost and those with disability in men and women of age ranging between 55-64 
years of age, where women had the most disabled and limited years from approximately 
age 55 and onwards (State of Victoria Burden of Disease Study 1999).
The term overweight is defined as excess body weight for height as a result of 
positive energy balance leading to an increased ratio of energy intake to energy 
expenditure (Uwaifo and Arioglu 2000). Because differences in weights among 
individuals are only partly due to fat mass, body weight is a rather limited index of 
obesity. Several classifications and definitions exist for the degrees of obesity (Pouliot 
MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A and 
Lupien PJ 1994). The most widely accepted definition is the World Health Organization 
(WHO) (WHO/IASO/IOTF 2000) criterion, the Body Mass Index (BMI), also know as 
the Quetelet Index (BMI = body wt (kg)/ht^ (m)). Under this convention for adults, grade
1 overweight (commonly and simply called overweight) is a BMI of 25-29.9kg/m^. Grade
2 overweight (commonly called simple obesity) is a BMI of 30-39.9kg/m^. Grade 3 
overweight (commonly called severe or morbid obesity) is a BMI greater than or equal to 
40kg/m^ (Uwaifo and Arioglu 2000). In children, the cut-off point has been extrapolated 
from the centile of body mass index (BMI) corresponding to values of >25kg/m^ (over 
weight) and 30kg/m^ (obese) at age of 18, while BMI at various young age groups
changes substantially (Cole 2000). BMI categories are useful for the development of 
plans for clinical management, for illustrating changes in the obesity epidemic, and for 
presenting comparative data from different countries. In fact the prevalence of obesity is 
crucially dependent on the shift in the distribution of the whole population (Rose 1991). 
Thus, modest shifts in the mean of the BMI distributions will cause substantial and 
predictable increases in the prevalence of population obesity, which necessitates the 
intervention of Governments to conduct focused awareness campaigns aiming at avoiding 
the relevant morbidities. The implications of such analysis implicate that total population 
strategy should be the primary focus of obesity prevention schemes. So, as an example, a 
mean population BMI of <23 is needed if the prevalence of obesity with BMI>30 is to be 
decreased.
Concerns about high prevalence of diabetes and hypertension in Asian 
populations, at very modest increases in BMI lead to the introduction of an alternative 
system where the BMI cutoff point of only 25 signifies obesity (Le Feuvre RA, Aisenthal 
L and Rothwell NJ 1991). Accordingly, analyses from Japan, China, and India suggest 
that the increased prevalence of hypertension and diabetes at any BMI level in Asian 
populations relates to the impact of early programming events with hypertension, 
particularly related to birth weight and diabetes being predicted from both birth weight 
and the mother’s BMI during pregnancy. A correlate of this amplified risk is the 
increased susceptibility of those bom small, to the selective deposition of excess fat in the 
tmncal region and particularly within the abdominal viscera. Many of the genetically 
similar cohorts of the above mentioned high risk ethnic and racial groups have far less
prevalence for obesity in their country of origin, but this changes significantly when such 
groups have migrated to the affluent Northern Hemisphere, with altered dietary and 
activity habits (Uwaifo and Arioglu 2000).
On the other hand, the common belief that obesity is largely the result of a lack of 
will, though widely held, is unsatisfactory (Stellar 1951). Moreover, dieting is not usually 
successful in long-term maintenance of reduced body weight, and most dieted obese 
individuals eventually regain the lost weight (Wadden 1993). Therefore, relative stability 
of weight, achieved through constancy of total body energy stores, could be considered as 
a possible dual control of nervous-endocrine feedback loops (Bray GA and York DA 
(1979).
As a probable candidate for obesity control, leptin (Zhang Y, Proenca R, Maffei 
M, Barone M, Leopold L and Freidman JM 1994), the hormone expressed by the obesity 
{oh) gene, provided some clarification and defined a satiety factor that was previously 
implicated in parabiosis experiments some thirty years ago (James 2004). Since leptin is 
secreted principally by adipose tissue in proportion to its mass (Ostlund RE, Yang JW, 
Klein S and Gingerich R 1996), mainly targets the hypothalamus (Albaranji KA, 
Buckingham RE and Haynes AC 1996; Mercer 1996; Schwartz MW, Seeley RJ, 
Campfield LA, Bum P and Baskin DG 1996; Haynes WG, Morgan DA, Walsh SA, Mark 
AL and Sivitz WI 1997; Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro 
PR, Kuhar MJ, Saper CB and Elmquist JK 1998; Kristensen P, Judge ME, Thim L, Ribel 
U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen CD, Vrang N, Sven PJ
and Hastmp 1998), as well as peripheral organs including the liver, skeletal muscles 
(Chinookoswong N, Wang J and Shi Z 1999), and pancreas (Pallett AL, Morton NM, 
Cawthorne MA and Emilsson V 1997), then a probable direct receptor-mediated, 
(Tartaglia TA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, 
Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, 
Mays GG, Woolf EA, Monroe CA and Tepper RI 1995; Kieffer TJ, Heller RS and 
Habener C 1996; Emilsson V, Liu YL, Cawthorne MA, Morton NM and Davenport
1997) hormone based communication between adipose tissue and the rest of the body 
including the pancreas exists. It is cleared primarily through the kidney glomerulus 
receptor-mediated transfer from the blood into the organ, followed by its metabolic 
breakdown (Cumin F, Baum HP and Levens N 1996), and this may provide feedback 
signals relating to somatic fat stores.
Evidence for the existence of an adipo-insular axis, a dual hormonal feedback 
loop involving leptin and insulin has been frequently demonstrated (Zhang et al 1994, 
Mueller WM, Grégoire FM, Stanhope KL, Mobbs CV, Mizuno TM, Warden CH, Stem 
JS and Havel PJ 1998; DAdamo M, Buongiomo A, Maroccia E, Leonetti F, Barbetti F, 
Giaccari A, Zorretta D, Tamburrano G and Sbraccia P 1998; Hardie LJ, Rayner DV, 
Holmes S and Trayhum P 1996; Zheng D, Jones JP and Dohm SJ 1998; Harvey J, 
Mckenna F, Herson PS, Spanswick D and Ashford ML 1997; Chen NG, Swick AG and 
Romsos DR 1997; Kieffer TJ, Heller RS, Leech CA, Holz GG and Habener JF 1997; 
Morton NM, Emilsson V, De Groot RP, Pallet AL and Cawthome MA 1999; Fehmann 
HC, Peiser C, Bode HP, Stamm M, Staats P, Hedetoft C, Lang RE and Goke B 1997b;
Poitout V, Rovault C, Guerre-Millo M, Briaud I and Reach G 1998; Tanizawa Y, Okuya 
S, Ishihara H, Asano T, Yada T and Oka Y 1997; Cases JA, Gabriely I, Ma XH, Yang 
XM, Michaeli T, Fleischer N, Rossetti L and Barzilai N 2001; Kulkami RN, Wang ZL, 
Wang RM, Hurley JD, Smith DM, Ghatei MA, Withers DJ, Gardiner JV, Bailey CJ and 
Bloom SR 1997; Kim Y, Uotani S, Rierroz DD, Flier SJ and Kahn BB 2000; Wang J, 
Obici S, Morgan K, Barzilai N, Feng Z and Rossetti L 2000). Insulin, being adipogénie, 
increases body fat mass (Cushman SW and Wardzala LJ 1980), and stimulates the 
synthesis and secretion of leptin (DAdamo 1998; Kolaczynski JW, Nyce MR, Considine 
RV, Boden G, Nolan JJ, Henry R, Mudaliar SR, Olefsky J and Caro JF 1996b; Barr VA, 
Malide D, Zamowski MJ, Taylor SI and Cushman, SW 1997), which in turn acts 
centrally, via the hypothalamus, to reduce food intake and increase energy expenditure 
(Margetic S, Gazzola C, Pegg GG and Hill RA 2002; Sainsbury A, Cooney GJ and 
Herzog H 2002), and probably also acts peripherally to regulate a variety of endocrine 
functions. By both means, leptin is believed to suppress insulin secretion (Pallett 1997; 
Harvey J, Hardy SC, Irving AJ and Ashford ML 2000a; Meier and Gressner 2004). In 
obese subjects, hyperinsulinaemia (Hanm PW and Forhman LA 1970; Berthoud HR and 
Jeanrenaud B 1979; DAdamo et al 1998) and hyperglycaemia (Czech MP and Corvera S 
1999) in association with either leptin resistance (Caro JF, Kolaczynski JW, Nyce MR, 
Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK and 
Considine RV 1996), or deficiency in leptin production (HeY, Chen H, Quon MJ and 
Reitman M 1995), further increases the fat mass, and are thus assoeiated with obesity.
Although leptin in rodents may be acting as a satiety factor terminating food 
intake, in humans, however, it has a more complex features as there is a lack of 
postprandial surge in lean, obese, or diabetic individuals (Kolaczynski JW, Considine 
RV, Ohannesian J, Marco C, Opentanova I, Nyce MR, Myint M and Caro JF 1996a) as 
illustrated during a 3-day hyperglycaemic clamp experiment where a rise in leptin was 
observed during the last 24hrs of the study, implying a time factor and a possible indirect 
association (Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E 
and Melloul D 1999).
The aim of the present study is to investigate the modulatory effect of leptin ex- 
vivo, on the production of insulin in normal rats using physiological techniques including 
perfusion, which might aid the elucidation of the dynamic interaction between leptin and 
the islets of Langerhans.
1.2 Obesity
Before the domestication of animals and the development of technologies that 
amplified the input effort to result in work, the realization of mills powered by wind or 
water, the activities of human ancestors, like those of all other free-living organisms, 
were entirely dependent on individual physical exertion. There was a compulsory and 
natural association between caloric acquisition as food energy, and caloric expenditure as 
physical activity. This relationship existed throughout the long course of human and pre­
human evolution, exerting ongoing adaptive pressure that affected selection of genes
related to the biochemistry of the cardio-respiratory and musculoskeletal systems as well 
as the internal metabolism of our progenitors (Eaton SB, Eaton SB 2003). These natural 
selections impose variations in the cellular metabolism that could represent one of many 
extremes in the range of genetic expression, which might result in survival of the fittest 
with the relatively highest adaptive capacity among a population under pressure. Physical 
activity is relatively no longer a requirement for daily quests; the relationship between 
eating and physical work has been severely disrupted. This discordance or mismatch 
between our contemporary lives and our genetic makeup has important patho­
physiological implications. Obesity results when dietary energy intake is greater than 
energy utilization to the point at which the BMI exceeds a pathologic cutoff point based 
on morbidity and mortality rate associated with excess body fat as mentioned above 
(Stunkard AJ, Harris JR, Pederson NL and McCleam GE 1990). However, the level of 
energy storage “fatness” at which current or future morbidity (e.g. diabetes, 
dyslipidaemia, and hypertension) is increased is highly individualized (Larsson B, 
Svardsudd K, Welin L, Wilhelmsen L, Bjomtorp P and Tibblin G 1984; Manson JE, 
Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE and 
Hennekens CH 1990; Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman 
D, Colditz GA and Willett WC 1995).
The body fat composition of an individual’s body mass is a critical determinant of 
morbidity risk, and it cannot be measured directly by BMI. Relative centrality (android) 
of distribution of body fat, as compared with gynoid distribution (waist/hip ratio >0.90 in 
females; >1.0 in males) is associated with a higher risk of morbidity, including stroke.
ischemic heart disease, diabetes, and mortality. The more peripheral distribution of body 
fat in the gynoid form (waist/hip ratio <0.75 in males; <0.85 in females) is associated 
with lower risk of morbidity and mortality (Pouliot et al 1994). Hence, the relative 
distribution of body fat may be a more sensitive indicator of morbidity risk than absolute 
body fat mass. An interesting alternative mechanistic view of the association between 
intraabdominal fat mass and inereased risk of coronary artery disease, diabetes, and 
hypertension has been suggested where psychological stress, through the effects on the 
adrenal axis and autonomic nervous system may cause both the increase in intra­
abdominal fat deposition and the associated morbidities (Smagin GN, Howell LA, 
Redmann SJ, Ryan DH and Harris, R 1999; Baker RA, Herkenham M and Brady LS 
1996; Rosmond R, Dallman MF and Bjomtop P 1998). Considerable studies have shown 
that classic neurotransmitters such as noradrenalin (NA), dopamine, and serotonin and 
stress hormones (corticotropin-releasing hormone [CRH]) have a contributory role (Ueta
2003). The center of the physiological endocrine response to stress is the hypothalamic- 
adrenal (HPA) axis. Corticotropin releasing hormone (CRH) produced in the 
paraventricular nucleus (PVN) of the hypothalamus triggers secretion of adreno- 
corticotropin hormone ACTH from the anterior pituitary into the systemic circulation 
leading to the secretion of adrenal-cortical hormones (glucocorticoids) from the adrenal 
cortex. The fact that central administration of CRH causes various stress-induced 
responses in animal experiments indicates that CRH is a stress hormone in the central 
nervous system (CNS). Intracerebroventricular administration of CRH in rats also 
inhibits feeding behavior (Le Feuvre 1991).
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Obesity can be considered from at least three different perspectives, including the 
neural, genetic and dietary (Bray GA 1991). This concept has clearly developed to 
include either, a genetic cause or at least a genetic predisposition for obesity and its 
related syndromes, since obesity is a multi-factorial condition (Isse N, Ogawa Y, Tamura 
N, Masuzaki H, Mori K, Okazaki T, Satoh N, Shigemoto M, Yoshimasa Y, Nishi S, 
Hosoda K, Inazawa J and Nakao K 1995). Environmental risk factors related to a 
sedentary life-style and unlimited access to food applies constant pressure on the subjects 
with a genetic predisposition to gain weight. The fact that genetic defects can result in 
human obesity has been unequivocally established over the past 6 years with the 
identification of the genetic defects responsible for different monogenic forms of human 
obesity (Bray and York 1979, Bray GA and Gallagher T 1975; Considine RV, Considine 
EL, Williams CJ, Nyce MR, Magosin SA, Bauer TL, Rosato EL, Colberg J and Caro JF 
1995; Hamilton BS, Paglia D, Kwan YM and Deitel M 1995): the leptin, leptin receptor, 
pro-opiomelanocortin, pro-convertase-1 and melanocortin-4 receptor genes and PPAR-y. 
Relatively rare instances of heritable syndromic obesity (Prader-Willi syndrome, etc...) 
are well known. The common forms of obesity are, however, polygenic (Uwaifo 2000). 
The examination of specific genes for involvement in the susceptibility to common 
obesity has not yet yielded convincing results. The completion of the human genome 
sequence draft, the potential benefit of positional cloning (Zhang et al 1994) and single 
nucleotide polymorphisms association studies for identifying risk conferring alleles, and 
developing functional genomics technologies (polymerase chain reaction with its 
continually updated diverse protocols) promises to accelerate obesity gene discovery. 
These advances, used with current evaluative tools (murine molecular genetic techniques)
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(Kowalski 2004), may bridge the evolving information at the genetic and molecular level 
to the well established information at the physiological level and thus increase our 
conceptualization of human obesity, and ultimately provide a more accurate diagnosis 
and approaches to potential treatments.
Since the hypothalamus is the center for integration of vegetative endocrine and 
neural signals arising from adipose tissue, the gastrointestinal tract, various endocrine 
organs, autonomic nervous system, liver, and other parts of the brain, its contribution in 
the obesity physiological network is of primary importance, especially in humans (Havel
2004). The hypothalamus is comprised of several nuclei that represent aggregations of 
functionally distinct, cell-rich areas separated by cell-sparse areas. It provides efferent 
signals to higher cortical centers, the brain stem, autonomic nervous system, and the 
anterior pituitary gland affecting food intake, energy expenditure, and the partitioning of 
nutrients between adipose tissue and lean tissues (Mercer 1996 and Kristensen et al
1998). Within the brain, and especially within the nuclei of the hypothalamus, a series of 
orexigenic and anorexigenic neuropeptides and their cognate receptors mediate the 
central nervous system processes related to energy homeostasis (Chua SC Brown AW, 
Kim J, Hennessey KL, Leibel RL and Hirsch J 1991). The orexigenie peptides include 
neuropeptide [NPY] (Erickson JC, Hollopeter G and Palmiter RD 1996), galanin. 
Melanin Concentrating Hormone [MCH], hypocretin, HCRT/orexin and receptors and 
agouti-related peptide [AGRP] (Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli 
RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, 
Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA,
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Elshourbagy NA, Bergsma DJ and Yanagisawa M 1998). Anorexigenic neuropeptides 
include melanocyte stimulating hormone [MSH] and its associated MC-4 reeeptor, 
corticotrophin releasing factor [CRF] (Rohner-Jeanrenaud F, Walker CL, Greco-perotto 
R and Jeanrenaud B 1998), Urocortin and Cocaine and Amphetamine-Regulated 
Transcript [CART] (Kristensen et al 1998; Douglass J, Mckinzie AA and Couceyro P 
1995).
Peripheral afferent signals providing information to the central nervous system 
regarding energy status include signals proportional to fat mass (leptin and possibly 
insulin), gut-derived signals including cholecystokinin [CCK] (Matson CA, Wiater MF, 
Kuijper K and Weigie DS 1997), glucagon and glucagon-like peptide [GLP-1] (Turton 
MD, O'Shea D, Gunn I, Beak SA, Edwards MB, Meeran K, Choi SJ, Taylor GM, Heath 
MM, Lambert PD, Wilding PH, Smith DM, Ghatei MA, Herbert J and Bloom SR 1996), 
insulin (Banks WA, Kastin AJ, Huang W, Jaspan JB and Maness LM 1996) and NPY 
(Erickson 1996), stimulated by single meals. The arcuate nucleus of the hypothalamus 
contains neurons that express the receptor (GLP-IR) and thereby mediate the anorectic 
effects of GLP-1 (Balkan B and Li X 2000). The peptide GLP-1 is derived from 
processing preproglucagon, and is secreted from L-cells of the digestive system into the 
circulation (Hansen L, Deacon CF and Holst JJ 2000). In the hypothalamus, leptin causes 
coordinate changes in neuropeptide gene expression and release (decreased NPY 
(Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard 
DE, Porte D, Woods SC, Seeley RJ and Weigie, DS 1996a) and HCRT/Orexin (Sakurai 
et al 1998); increased CRF (Smagin 1999), proopiomelanocortin [POMC] (Baker 1996),
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and CART (Kristensen et al 1998) that reduce food intake. Deficiency of leptin produces 
the opposite changes. Damage to the hypothalamus in rodents and humans, when caused 
by head trauma, infection, or surgery, is regularly associated with obesity (Hetherington 
AW and Ranson SW 1942; Ono N, Kohga H, Zama A, Inoue HK and Tamura M 1996) 
associated with hyperphagia (Mark HV, Breier BH, Cutfield WS, Hofman PL and 
Gluckman PD 2000). Bilateral injuries to the hypothalamic ventromedial nuclei (VMN), 
the arcuate nuclei (ARC), the paraventricular nuclei (PVN) and the dorsomedial nuclei 
(DMN) result in hyperphagia, reduced energy expenditure, and obesity.
The hypothalamus and the hind-brain have reciprocal synaptic connections using 
neuropeptides and neurotransmitters (CRH, MCH, opioids, NE, dopamine, and 5-HT). 
Within the hindbrain, the parabrachial nucleus (PBN) and the nucleus of the solitary tract 
(NTS) are important modulators of feeding. The hindbrain and the gut have reciprocal 
connections via the vagus nerve (Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R 
and Nijima A 1996). At the peripheral end, the pancreas secretes circulating factors, such 
as insulin and glucagon, which may modulate energy balance. In addition, circulating 
glucose levels significantly affect vagal neural activity, which is important in the 
regulation of pancreatic functions, and which is expressed by systemic hypoglycemic 
stimulation of pancreatic efferent nerve firing through a central mechanism. Full 
expression of pancreatic nerve activities during hypoglycemia requires both the forebrain 
and the brain stem. In addition to activating neurons in the brain stem, central 
neuroglucopenia activates subpopulations of neurons in the lateral hypothalamic area that 
contain orexin. The released orexin acts on DMV neurons to stimulate pancreatic efferent
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nerve activities and thus regulate pancreatic functions (Wu X, Gao J, Yan J, Owyang C, 
and Li Y 2004).
In weanling rats, hypothalamic lesions do not increase food intake, yet they do 
produce an increase in fat and serum insulin levels (Frohman L, Bemardis L, Schantz J 
and Burek L 1969). Moreover, in pair-fed adult animals, those with ventromedial 
hypothalamic (VMH) lesions become obese and those without lesions do not. In addition, 
within the VMN, the type-2 corticotrophin-releasing hormone receptor (CRHR2), a G- 
protein coupled receptor binds members of the CRH family (CRH and urocortin). 
Because some of the anorectic effects of CRH and urocortin may be mediated by 
activation of the CRHR2 in the VMH, it is possible that the VMH lesions produce 
obesity, in part, by ablation of the CRHR2 signal transduction (Smagin 1999).
As with the syndrome of hypothalamic obesity, a hyperphagic model was 
proposed to explain the occurrence of obesity (Mark 2000), but critical studies 
demonstrated that hyperphagia alone is not essential to the development of obesity (Cox 
JE and Powley TL 1977). Thus, hyperphagia is not in this case a necessary component 
for the occurrence of obesity that follows VMH lesions. Neural connections between the 
hypothalamus and the pancreas were essential for the hyperphagia and obesity that 
follows VMH lesions as was deduced from vagotomy, which blocked rapid increases in 
insulin production after VMH lesions manifesting the basic role of central 
neurotransmitters in modulating insulin secretion.
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A high fat or carbohydrate diet produces dietary obesity (Levin B, Triscari J and 
Sullivan AC 1983). Predicting which animals will become obese by these diets can be 
done with a glucose challenge, which shows high adrenaline level in plasma during the 
glucose load of the group that will become obese (Levin B and Sullivan A 1987). This 
development of obesity requires corticosteroids, as do genetic and hypothalamic models 
of obesity mentioned above, and as has been demonstrated by use of the specific 
glucocorticoid receptor-blocking drug mifepiisone. When administered to high fat diet 
animals, their food intake and body fat were restored towards normal (Okada S, Bray G 
and York D 1990). The mechanism described is associated with ghrelin (Rosicka M, 
Krsek M, Matoulek M, Jarkovska Z, Marek J, Justova V, Lacinova Z 2003), a recently 
described gastrointestinal hormone that is elevated in the fasting state and low in the fed 
state, and is considered a major appetite-stimulating hormone, possibly involved in the 
generation of obesity and insulin resistance (Schulpis KH, Papassotihou I, Vounatsou M, 
Karikas GA, Tsakiiis S, and Chrousos GP 2004). Since ghrelin secretion may receive 
positive direct or indirect input from catecholamines, then its role is crucial in this web.
Investigating whether foetal undemutrition in pregnancy is a cause of obesity later 
in life (Mark 2000), a group of rats were given 30% of an ad libitum standard diet 
throughout gestation; the offspring were significantly smaller at birth than their ad libitum 
fed counter-group. Their food intake elevated significantly at an early postnatal age, and 
increased with advancing age and further amplified by hypercaloric nutrition. Offspring 
with early undemutrition also showed elevated systolic blood pressure and markedly 
increased fasting plasma insulin and plasma leptin concentrations (Mark 2000), indicative
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of leptin resistance. On the other hand, a significant percentage of offspring of 
gestationally diabetic Pima Indian women were obese by the age 15 to 19 years as 
compared to offspring of non-diabetic women, where these differences in the incidence 
of obesity are independent of the degree of maternal obesity (Pettit DJ, Biard HR, Allech 
KA and Knowler WC 1983). This suggests that high rates of foetal fat production and/or 
other metabolic consequences of the milieu of the diabetic mother may constitute an 
independent risk factor for subsequent obesity. In a recent study, among low-income 
children, maternal obesity in early pregnancy more than doubles the risk of obesity at 2 to 
4 years of age (Whitaker 2004). In developing strategies to prevent obesity in preschool 
children, special attention should be given to newborns with obese mothers.
Marked hyperinsulinaemia is characteristic of obese rat models designated by the 
oh/ob genotype, where no leptin is produced, and db/db where the leptin receptor is 
missing or mutated (He 1995; Chen NG and Romsos DR 1995; Ruth B and Harris S
1999). Many features of these animals could be attributed to the increased concentration 
of insulin in blood as a lipogenic agent (Kieffer TJ and Habener JF 2000). Although 
modulating insulin secretion may improve some features of these models of obesity, this 
clearly cannot account for the altered reproductive function or the hypothermia that also 
characterizes these animals (Bray GA, York DA and Fisler JS 1989). Type-1 diabetes in 
the rat model is associated with increased norepinephrine (NE) concentration (Levin and 
Sullivan 1987) in the paraventricular nucleus with a concurrent increase in serum 
corticosterone (Piet DV, Regis S, Johan A and Bart S 1995) and which effect is 
completely reversed upon treatment with insulin and leptin. The mechanism by which
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diabetes increases serum corticosterone could involve an increase in NE levels in the 
PVN or through indirect effect on the pancreas (Baroody GM and Howland RJ 1980). 
This is because the PVN of the hypothalamus has a large number of CRH cell bodies and 
receives rich noradrenergic innervations from the brain stem through the ventral 
noradrenergic bundle (Petrusez PI and Merchenthaler 1992). Thus, NE levels in the PVN 
play a stimulatory role in CRH secretion and could therefore mediate the effects of 
diabetes. In addition, type-1 diabetic patients with an impaired epinephrine response to 
hypoglycemia have lower plasma metanephrine levels than matched controls, reflecting 
decreased adrenomedullary stores of epinephrine and indicating reduced adrenomedullary 
capacity to secrete epinephrine (De Galan BE, Tack CJ, Willemsen JJ, Sweep GJ, Smits 
P, and Lenders JW 2004).
A locus on rat chromosome 2p21 (D2S1788) seems to be a major regulatory 
factor for circulating leptin, although the gene responsible has not been identified, but the 
pro-opiomelanocortin (POMC) gene is a strong candidate as POMC is a precursor of 
CRF (Lu XY, Barsh GS, Akil H, and Watson SJ 2003). Pro-opiomelanocortin (POMC) 
and a-melanocyte stimulating hormone (a-MSH) both act centrally on the melanocortin 
receptor-4 (MC-4) to reduce dietary intake. Genetic defects in both POMC production 
and mutation in the MC-4 gene have been described as monogenic causes of obesity in 
humans where, because of their diminished ACTH level controlled by CRH; they tend to 
have central adrenal insufficiency (Lu 2003). In addition, corticotropin-releasing 
hormone’s (CRH) loops may be a mechanism for the effect of adrenalectomy as CRH can 
reduce food intake and increase sympathetic activity (Egawa 1990). Importantly,
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however, centrally administered CRH or urocortin (Arase K, York DA, Shimizu H, 
Shargill N and Bray GA 1988) inhibits feeding and stimulates catabolism, in opposition 
to the role of CRH released from neurosecretory paraventricular nuclei (PVN) neurons, 
which stimulates glucocorticoid release and enhances energy storage. Furthermore, 
central administration of a CRH antagonist blocks stress-induced inhibition of feeding 
(Smagin 1999), implying that some of the inhibitory effects of stress on feeding may be 
mediated by central CRH pathways. The parvocellular portion of the PVN contains CRH 
neurons that receive innervations from both NPY and POMC neurons of the ARC (Lu 
2003). In addition, these CRH neurons express the ObRb isoform of the leptin receptor as 
well as the glucocorticoid receptor, and respond to caloric deprivation by decreasing 
CRH mRNA, which can be prevented by leptin infusion. Leptin increases the levels of 
corticotropin-releasing hormone (CRH) mRNA in the PVN, and stimulates release of 
CRH from perfused slices of both amygdala and the PVN (Rohner-Jeanrenaud 1998).
1.3 Adipose tissue
Adipose tissue, which consists of cells known as adipocytes found in a stromal 
framework, to which pre-adipocytes are tightly bound, is widely distributed within the 
body (Rob C, Galini T, Farmer SR and Kandror KV 2000). It occurs most prominently 
under the skin, in the abdominal cavity, in skeletal muscle, around blood vessels, and 
beneath the mammary glands. Imaging methods quantify "adipose tissue" volume as 
volume elements (Shen W, Wang Z, Punyanita M, Lei J, Sinav A, Krai JG, Imielinska C,
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Ross R, and Heymsfield SB 2004). While often referred to as "fat" according to the five- 
level body composition model (An P, Rice T, Borecki IB, Perusse L, Gagnon J, Leon AS, 
Skinner JS, Wilmore JH, Bouchard C and Rao DC 2000), adipose tissue and fat are 
different components. The distinction between fat and adipose tissue in common usage is 
usually irrelevant, and the terms are usually used interchangeably. However, in the body 
composition and metabolism field, "fat" and "adipose tissue" are distinct and different 
compartments, and their taxonomic separation is important when measuring their mass 
and metabolic characteristics (Shen et al 2004). Adipose tissue is a specialized loose 
connective tissue that is extensively laden with adipocytes. Adipose tissue has mainly 
been viewed as an energy storage depot, thermal insulator, and mechanical cushion in 
mammals where the 70-kg Reference Man has 15 kg of adipose tissue, representing 21% 
of body mass (Snyder WS, Cook MJ, Nasset ES, Karhausen RL, Howells GP and Tipton 
IH 1975). The percentage is higher in women, the elderly, and overweight subjects. 
Adipose tissue is anatomically distributed throughout the human body, and the pattern of 
adipose tissue distribution is influenced by many factors, including sex, age, genotype, 
diet, physical activity level, hormones, and drugs (Wu CH, Yao WJ, Lu EH, Yang YC, 
Wu JS and Chang CJ 2001). Among typical approaches, based on simple anatomic 
adipose tissue groupings, adipose tissue can be typically organized into simple categories 
such as subcutaneous adipose tissue, organ-surrounding adipose tissue, interstitial adipose 
tissue, and adipose tissue in bone marrow (Snyder 1975). Subcutaneous adipose tissue is 
known to gross anatomists as superficial fascia and is defined as the adipose tissue layer 
found between the dermis and the aponeuroses and fasciae of the muscles. Adipose tissue 
is sometimes named specifically for the organ it surrounds, as in "perirenal adipose
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tissue." Interstitial adipose tissue, however, is interspersed or infiltrated among the cells 
of different tissues so tightly that it is not readily dissectible (Mitsiopoulos N, 
Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D and Ross R 1998). Adipose 
tissue is of two types, brown adipose tissue (BAT) and white adipose tissue (WAT) 
where fully differentiated adipocytes are detectable in the human fetus by approximately 
15 weeks of gestation. Both adipocyte volume and number continue to increase 
throughout gestation, with maximal rates of change achieved after about the thirtieth 
week (Roh 2000).
The physiological mechanisms for the association between body fat distribution 
and related morbidities are not well known. Absolute and relative visceral adipose tissues 
have been associated with the greatest health risk (Bjomtorp P 1992). Because there are 
three main body cavities, it is reasonable to assume that visceral adipose tissue (VAT) 
consists of adipose tissue (AT) distributed in the three body cavities: intrathoracic 
(ITAT), intraabdominal (lAAT), and intrapelvic (IPAT). It has been suggested that the 
increased flux of non-esterified fatty acids (NEFA) through the hepatic portal circulation 
resulting from large intra-abdominal (visceral) fat depots provides substrates for 
triacylglycerol synthesis (some of which are then incorporated in low-density lipoproteins 
(LDL) and very low-density lipoproteins VLDL). In addition, this promotes insulin 
resistance by interfering with first pass hepatic catabolism of insulin (Stromblad G and 
Bjomtorp P 1986).
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The infant of the diabetic mother is a model for the influences of the foetal 
ovemutrition and partitioning on subsequent adiposity. Exposure of the fetus to high 
ambient glucose concentrations stimulates endogenous fetal insulin production, and 
lipogenesis (Knittle JL, Timmers K, Ginsberg-Fellner F, Brown RE and Katz DP 1979). 
Because gestationally diabetic mothers are often obese, it is difficult to separate the 
metabolic consequences of gestational obesity and/or diabetes on subsequent adiposity of 
the infant of a diabetic mother, from the possibility that the mother has transmitted a 
genetic tendency towards obesity to her offspring. Rat pups, whose dams are 
malnourished during the first two weeks of a 3-week gestation, display hyperphagia and 
an increase in adult adiposity (Mark 2000). During the first year of extra-uterine life, 
most adipose tissue growth occurs via enlargement (hypertrophy) rather than increased 
adipocyte number (hyperplasia), but after 2  years of age, there is little further increase in 
adipocyte volume in the non-obese child. In non-obese children, there is no significant 
change is fat cell volume from ages 2 to 14 years and only a slight increase in fat cell 
number from ages 2 to 10 years. In obese children, there is continual enlargement of 
adipocytes without hyperplasia during this same period. These observations are 
consistent with a model of adipose tissue growth in which adipocyte hyperplasia is 
triggered by achievement of a critical adipocyte volume (Prins JB and O’Rahilly S 1997). 
It is believed that there is a virtually unlimited pool of preadipocytes constituted by the 
pericytes of the pericapillary endothelium. These adipocyte precursors cannot be visually 
or biochemically distinguished from other fibroblasts and have no detectable lipogenic or 
lipolytic enzyme activity. Because the adipocyte differentiation cannot be reversed, an 
individual whose obesity was characterized by adipocyte hyperplasia will continue to
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have an increased number of fat cells, albeit substantially reduced in volume, even after 
body fat content is reduced to the level of never-obese individuals (Hirsch J and 
Batchelor B 1976). The adipose tissue cells are increased primarily in size and to a lesser 
extent in number in long-standing obesity, and that the number remains unchanged after 
weight reduction. In vivo, maximal adipocyte lipid content appears to be approximately 
Ipg lipid/cell, and once this degree of hypertrophy is reached, recruitment of new 
adipocytes appears to begin (Doglio 1987). In addition, insulin-mediated changes in 
transcription factors CCAAT/ Enhancer Binding Protein (C/EBP) (Hwang 1996), 
adipocyte determination differentiation dependent factor 1 / sterol regulatory element 
binding protein 1 (ADD/ SREBP-1) and peroxisome proliferator activated receptor 
(PPAR-y) expression and functional activity, may provide a connection between 
nutritional status (energy stores) and rates of adipocyte production (Spiegelman BM and 
Hier JS 1996).
Adipocytes produce and secrete in addition to leptin (Zhang et al 1994), a variety 
of physiologically important proteins namely, adipsin (Cook KS, Min HY, Johnson D, 
Chaplinsky RJ, Hier JS, Hunt CR and Speigelman BM 1987), adipocyte complement- 
related protein (ACRP-30) (Scherer PE, Williams S, Fogliano M, Baldini G and Lodish 
HF 1995) which is now known as adiponectin (Berg AH, Combs TP and Schere PE 
2002), tumor necrosis factor-1 (TNF-a) (Hotamisligil GS, Shargill NS and Spiegelman 
BM 1993), resistin (Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright 
CM, Patel HR, Ahima RS and Lazar MA 2001), and the enzyme lipoprotein lipase (LPL) 
(Garfinkel AS, Nilsson-Ehle P, and Schotz MC 1976)). Studies both in vivo and in vitro
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have demonstrated that secretion of these proteins from adipose cells have two 
components, constitutive and regulative. In other words, adipocytes continuously release 
leptin (Barr 1997), adipsin (Cook et al 1987), adiponectin (Bogan JS and Lodish HF 
1999), and LPL (Garfinkel 1976) and resistin (Rajala MW, Lin Y, Ranalletta M, Yang 
XM, Qian H, Gingerich R, Barzilai N and Schere PE 2002) into the medium, but this 
process may be acutely and substantially stimulated by insulin without any marked 
changes in the constitutive secretory pathway.
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There is growing body of evidence that adipocyte hormones are involved in lipid 
and carbohydrate metabolism (Havel 2004) with protective effects against cardiovascular 
diseases, especially with adiponectin (Stefan N and Stumvoll M 2002a). Low levels of 
adiponectin have been proposed to contribute to insulin resistance associated with obesity 
(Saltiel AR 2001) coinciding with decreased tyrosine phosphorylation of muscle insulin 
receptors (Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, 
Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA 2002b), and it is 
counteracted by administration of adiponectin, which lowers circulating glucose levels 
without stimulating insulin secretion in both normal mice and in mouse models of 
diabetes (Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001). Stephan et al. 
proposed that resistin is increased in type II diabetes, and suggested that it is a potential 
link between obesity and insulin resistance. The injection of recombinant resistin into 
mice reduces glucose tolerance and insulin action, whereas neutralization with anti- 
resistin antibodies improves insulin action.
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The acute effect of insulin on secretion precedes major changes in the 
biosynthesis of secreted proteins, and it is preserved, at least partially, in the presence of 
cycloheximide (Czech and Corvera 1999). This suggests that fat cells may possess 
regulatory pools of pre-synthesized secreted proteins that may be discharged by insulin. 
For example, the regulation of LPL secretion stimulated by insulin is related to post- 
translational changes in the LPL enzyme, at the level of the Golgi apparatus and the 
exocytotic vesicles. Genes encoding LPL were not differentially expressed in omental fat 
when compared with subcutaneous adipocytes (Pradines-Figureueres A, Vannier C and 
Ailhaud G 1988). However, in very obese individuals, omental adipocytes express lower 
levels of LPL proteins and mRNA than do subcutaneous fat cells. In effect, omental 
adipose tissue is known to be less sensitive to insulin, both in suppression of lipolysis and 
in stimulation of LPL. Significant differences were observed between men and women. 
The omental/subcutaneous LPL mRNA ratio was higher in men than in women, and 
omental LPL was more responsive to insulin plus dexamethasone in men. The increase in 
LPL in response to dexamethasone suggests that the steroid-induced adipose 
redistribution (especially in the abdomen) may be caused by increase in LPL, which 
could lead to a preferential distribution of plasma triacyglycerol, and NEFA to the 
abdominal depot. Leptin-treated animals required increased amounts of glucose infusion 
during hyperinsulinaemic-euglycaemic clamps which were found to be associated with 
enhanced insulin-sensitivity at the levels of both the liver and the peripheral tissues, 
especially the skeletal muscles (Czech and Corvera 1999). Enhanced hepatic insulin 
sensitivity results in augmented insulin-mediated suppression of hepatic glucose 
production, whereas enhanced insulin sensitivity in peripheral tissues is associated with
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greater extraction of glucose from circulation (Kahn CR and White MF 1988). It was also 
found that the effects of leptin are differential, dependent upon the specific tissue types, 
in modulating the actions of insulin in glucose and energy metabolism.
1.4 Leptin
The word leptin was derived from the Greek word leptos, which means thin 
(Zhang et al 1994). Leptin is a single chain proteohormone, with a molecular mass of 16 
KDa transcribed from the ob gene, mainly in white adipose tissue and is thought to play a 
key role in the regulation of body weight. Very small amounts are detected in brown 
adipose tissue, gastric fundic epithelium (Bado A, Levasseur S, Attoub S, Kermorgant S, 
Laigneau JP, Bortoluzzi MN, Moizo L, Lehy Th, Guerre-Millo M, Le Marchand-Brustel 
Y and Lewin MJM 1998), placenta and skeletal muscle (Masuzaki H, Ogawa Y, Sagawa 
N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T and 
Nakao K 1997), mammary epithelium (Casabiell X, Pineiro V, Tome MA, Peino R, 
Dieguez C and Casanueva FF 2004) and the liver (Baratta M 2002). Leptin achieves most 
of its metabolic effects by interacting with specific receptors located in the central 
nervous system (CNS) and in peripheral tissues (Margetic 2002) suppressing food intake 
and stimulating energy expenditure (Webber J 2003).
In humans, circulating leptin levels are potentially regulated by fasting, feeding, 
and body weight changes (Pijl H, Toomvliet AC, Meinders AE, Considine RV and Caro 
JF 1996) where a 10% reduction in body weight led to a 50% reduction in leptin
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concentration, and rising to 70% of the initial value during maintenance of the reduced 
weight with an increased caloric intake. The apparent disproportionate decrease in leptin 
concentration suggests that leptin homeostasis depends on caloric restrictions, as well as 
the reduction in adipose tissue mass. On the other hand, a 10% weight gain resulted in 
three-fold increase in leptin levels, suggesting that leptin secretion may also be dependent 
on caloric intake (Klein S, Coppack SW, Mahamed-Ali V and Landt M 1996). In support 
of this, one day of over feeding (120 Kcal/kg over 12 hours) was sufficient to raise serum 
leptin concentration significantly in the absence of any weight gain (Cammisotto PG and 
Bukowiecki LJ 2004). Obese individuals often have increased leptin concentration (El- 
Haschimi K, Pierroz DD, Hileman SM, Bjorback C and Hier JS 2000), which is 
indicative of leptin resistance and likely the result of desensitization for the leptin 
intracellular signal via its receptor. This may occur on at least two distinct levels: 
saturable transport of leptin across the Blood Brain Barrier (BBB) and abnormalities in 
the extent of leptin receptor activation and/or signal transduction (El-Haschimi 2000).
In addition to its metabolic effects, leptin has been shown to have a strong 
influence on several endocrine axes, where it was shown recently that in humans the 
decrease in leptin concentrations in response to food deprivation is responsible for the 
starvation-induced suppression of the hypothalamic-pituitary-gonadal axes (Veniant MM 
and LeBel CP 2003) as well as several other neuroendocrine axes. Thus, it seems that 
leptin may act as the critical link between adipose tissue, hypothalamic centers regulating 
energy homeostasis, and the reproductive system, indicating whether adequate energy 
reserves are present for normal reproductive function. These actions may, at least be
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explained by the suppressive effect of leptin on neuropeptide Y (NPY) production and 
secretion by neurons in the arcuate nucleus (Magni P 2003), which has several centers 
that deal with satiety and regulation of food intake and metabolism. NPY is a strong 
stimulator of appetite (Sainsbury 2002), and is known to be involved in the suppression 
of growth hormone (GH) through stimulation of somatostatin suppression of 
gonadotropins or stimulation of the pituitary-adrenal axis (Rohner-Jeanrenaud F 2002).
The most important variable that determines circulating leptin concentrations is 
body fat mass (Speakman JR, Stubbs RJ and Mercer JG 2002). Obviously, under 
conditions of regular eating cycles, leptin reflects the proportion of adipose tissue (Frayn 
KN, Karpe F, Fielding BA, Macdonald lA and Coppack SW 2003), showing an 
exponential relationship where leptin production occurs after increases in plasma insulin, 
in response to feeding, while a decrease in leptin concentrations follows a does- 
dependent decrease in insulin during fasting.. This constitutive synthesis of leptin is 
modulated by several hormonal and non-hormonal variables. Stimulators of leptin 
secretion, in both rodents and humans, are overfeeding as indicated above, insulin, and 
glucocorticoids (Koutkia P, Canavan B, Johnson ML, DePaoli A and Giinspoon S 2003). 
Suppression has mainly been the result of fasting (Leibel RL 2002) and rise in cAMP 
(Slieker LJ, Sloop KW, Surface PL, Kriauciunas A, LaQuier F, Manetta J, Bue-Valleskey 
J and Stephens TW 1996). Early studies reported no acute effect of eating on leptin 
concentrations (Kolaczynski et al 1996a), but, on the contrary, later studies demonstrated 
that meals and insulin acutely affect leptin concentrations in humans (French S and 
Castiglione K 2002). It is worth noting that incubation of adipocytes in a medium
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containing glucose, but no calcium, markedly inhibited insulin-stimulated leptin secretion 
(ISLS) and synthesis, without affecting basal leptin secretion or lipolysis. However, when 
pyruvate was used as a substrate, ISLS was insensitive to the absence of calcium 
(Cammisotto and Bukowiecki 2004) which appears to have a permissive and indirect role 
on insulin-stimulated leptin secretion by regulating the early steps of glucose metabolism. 
This indicates that metabolites of glucose metabolism are crucial in the intracellular 
mechanisms involved in mobilizing GLUT-4 and thus leptin synthesis and secretion. It 
was suggested (Cammisotto and Bukowiecki 2004) that increasing cytosolic calcium 
entry from intracellular or extracellular stores has a potent inhibitory effect on insulin- 
stimulated leptin secretion. Thus, the role of calcium in the mechanism of stimulus- 
secretion coupling of leptin release in adipocytes is markedly different from that seen in 
the secretion of most peptide hormones from other systems.
Leptin treatment in insulin-deficient diabetic rats restored euglycemia, minimized 
body weight loss due to food restriction, substantially impaired glucose metabolic rates 
during post-absorptive states, and restored insulin sensitivities at the levels of the liver 
(Zhao AZ, Shinohara MM, Huang D, Shimizu M, Finkelman HE, Krebs EG, Beavo JA 
and Bomfeldt KE 2000; and Rossetti L, Massillon D, Barzilai N, Vuguin P, Chen W, 
Hawkins M, Wu J and Wang J 1997) and the peripheral tissues during glucose clamp 
(Chinookoswong 1999). The acute effect of insulin on leptin secretion precedes major 
changes in the biosynthesis of secreted proteins. This suggests that fat cells may possess 
regulatable pools of pre-synthesized leptin, which may be discharged by insulin. It was 
identified and characterized, in rat adipose cells by means of equilibrium density and
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velocity sucrose gradient centrifugation technique (Roh 2000). In addition, the adipose 
cells possess different pathways of intracellular protein trafficking (Kandror KV and 
Pilch PF 1996), which include the translocation of glucose transporter isoform 4 (GLUT- 
4) (Rea S and James DE 1997) and several other co-localized proteins from intracellular 
vesicles to the cell surface in a strictly insulin-dependent fashion (Czech and Corvera 
1999).
Glucose uptake via the GLUT-4 isoform of mammalian hexose transporters 
accounts for most of the stimulatory effects of insulin on this process in muscle and 
adipose cells where GLUT-4 rapidly recycles through the plasma membrane/endosomal 
membrane system in the presence of insulin (Wang ZW, Pan WT, Lee Y, Kakuma T, 
Zhou YT and Unger RH 2001). In the basal state, this transporter protein is directed to 
and retained within specific intracellular membranes through the action of distinct 
elements in the GLUT-4 structure. Insulin causes the movement of GLUT-4 out of this 
sequestered localization, leading to an increase in its steady state concentration on the cell 
surface membrane where it can promote glucose uptake (Roh 2000). Exocytosis of both 
leptin- and GLUT-4-containing vesicles can be induced by insulin; however, only leptin 
secretion is responsive to serum insulin stimulation. Hence, the regulated secretion of 
leptin and insulin-dependent translocation of GLUT-4 represent different pathways of 
membrane trafficking in rat adipose cells (Halaas JL, Gajiwala KS, Maffei M, Cohen SL, 
Chait BT, Rabinowitz D, Lallone RL, Burley SK and Friedman JM 1995).
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Leptin circulates both in the free and in the bound form (Sinha MK, Opentanova 
I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, 
Stephens TW and Caro JF 1996). The total leptin levels were significantly higher in the 
group of obese subjects (51.4ng/ml) compared with a group of lean subjects (12.2ng/ml). 
Total circulating leptin is found in significantly higher proportions in the bound form in 
lean (46%) compared to obese (21.4%) subjects. No significant changes were observed in 
bound leptin after 24 hr fasting in either lean or obese subjects, while significant rapid 
changes in free leptin were observed in lean and obese subjects as a result of fasting and 
refeeding. Affinity chromatography demonstrated that in human serum, leptin is bound to 
several proteins of which either 100 or 80 kDa protein is probably the soluble leptin 
receptor (Ob-Re) (Wallace AM 2000) depending upon whether it is in humans or mice.
^^^I-labelled leptin binds competitively to at least three serum macromolecules 
with molecular masses of -85, 176, and 240KDa in rodents and -176 and -240kDa in 
humans (Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI and 
Friedman JM 1996). The ability to bind appears to involve sulphhydryl/disulphide 
interactions because it is inhibited under reducing conditions. When serum is added to 
recombinant ^^^I-leptin, there is a shift in sedimentation of the ^^^I-leptin as analyzed by 
sucrose gradient centrifugation from approximately S 1.9 to approximately S 4.3. This 
shift is markedly attenuated in serum from obese mice {pb/ob, db/db) compared with that 
from endogenous controls. In lean mice with low circulating leptin (2.5-3.5ng/ml) the 
immunoreactive leptin is predominantly found in the bound state, while in obese serum
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leptin levels are elevated (13.5ng/ml) and a major proportion is found in the free form 
(Sinha et al 1996).
Changes in the serum leptin concentration could also result from alterations in 
production, hormone clearance or both (Pijl 1996). In humans, leptin clearance from 
circulation is dependent on kidney function (Cumin F, Baum HP and Levens N 1996), 
and there is no apparent difference in the calculated clearance rate between lean and 
obese subjects (Klein 1996). Circulating leptin concentration appears to be in direct 
proportion to the amount of oh mRNA in the adipose tissue. The amount of ob gene 
mRNA in adipocytes from obese individuals is greater than that in adipocytes from lean 
subjects (Pijl 1996). Ob gene mRNA decreases with weight loss in both humans, and 
rodents (Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, 
Lallone R and Ranganathan S 1995), and increases with weight gain (Hamilton 1995). 
Over feeding has been demonstrated to increase ob mRNA in the absence of significant 
weight gain in rats (Harris RBS, Ramsay TG, Smith SR and Bruch RC 1996) which 
suggests a direct relationship between ob mRNA expression and circulating leptin 
concentrations.
The p3-adrenergic receptor is expressed in white and brown adipose tissue (Gettys 
TW, Harkness PJ and Watson PM 1996). Specific agonists for this receptor stimulate 
energy expenditure, activate brown adipose tissue to increase thermogenesis and increase 
lipolysis in white adipose tissue (Lowell BB and Flier JS 1995). Exposure of isolated rat 
white adipocytes to the pg-agonist, ICI 210,651 reduced ob mRNA and leptin release into
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the culture medium. Other agents increasing intracellular cAMP such as isoproterenol 
and dibutyryl cAMP had similar effects (Slieker et al 1996; Mantzoros CS, Qu D, 
Frederick RC, Susulic VS, Lowell BB, Maratos-Flier E and Flier JS 1996). Insulin- 
stimulated leptin release could be detected as early as 30 min and a maximal 2-3 fold 
effect was produced by lOng/ml insulin. The effect of insulin was completely blocked by 
simultaneous activation of cAMP-dependent protein kinase. Using the activation of 
lipolysis as an index of cAMP-independent protein kinase activity, it was shown that 
inhibition of leptin release by norepinephrine or the selective Pg-adrenergic receptor 
agonist, CL316-213, occurred in parallel with activation of cAMP-dependent protein 
kinase. In-vivo administration of CL316-243 (1 mg/kg) reduced ob mRNA, and 
circulating leptin, by 20% of baseline within 12h in normal mice (Mantzoros et al 1996). 
No effect of the compound was noted in mice with knockout of the pg-adrenergic 
receptor gene (Lowell and Flier 1995). It appears that p-3 agonists suppress food intake 
by a mechanism either downstream of leptin or by a different mechanism altogether in 
mice. Both ob mRNA and leptin were reduced by chronic cold exposure (4°C for 21 
days), an effect believed to be mediated by the sympathetic nervous system (Hardie 
1996).
The increase in thermogenesis after feeding is likely to be due to an increase in 
sympathetic outflow that ultimately activates the release of norepinephrine from 
sympathetic nerve terminals. This in turn activates the p - 3  adrenergic receptors on brown 
fat cells; it raises their metabolic rate by increasing expression of the gene that encodes 
uncoupling protein UCPl. Recent evidence has implicated a similar mechanism in WAT
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via UCP-2 and in skeletal muscle via UCP-3. Other neurotransmitters and neuropeptides 
also function in this homeostatic system. Cholecystokinin (CCK) potentiates the 
anorectic effect of leptin (Schwartz 1996), and in addition CCK- 8  decreases stores of 
leptin in the stomach (Bado et al 1998) serving to add information to the loop of leptin’s 
action in the gut.
Leptin mRNA decreases with weight loss in both humans and rodents, and 
increases with weight gain in rodents. Therefore, fasting results in a substantial fall in 
leptin mRNA in humans and animals, but this is reversed upon refeeding (Kolaczynski et 
al 1996b). Overfeeding has been demonstrated to increase leptin mRNA in the absence of 
a significant weight gain in rats. These observations demonstrate the direct relationship 
between leptin mRNA expression and circulating concentrations of leptin.
1.5 Leptin Receptor
Leptin acts through its receptor, the product of the db gene. It has six isoforms 
identified from mouse choroid plexus using expression-cloning strategy (Tartaglia et al 
1995; Uotani S, Bjorbaek C, Tomoe J, Flier JS 1999). Differences in the receptor 
isoforms arise from alternative RNA splicing, at the most C-terminal coding exon, 
resulting in Ob-R intracellular domains with differing length and sequence composition 
showing several alternatively spliced variants (Lee et al 1996; Chen H, Charlat O,
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Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart 
RE, Duyk GM, Tepper RI and Morgenstem JP 1996).
OBR is a member of the class I cytokine receptor family (Tartaglia et al 1995), 
which includes the receptors of Interlukin IL-2, -3, -4, -6 , -7, Leukemia Inhibitory Factor 
(LIF), Granulocyte colony-stimulating factor (G-CSF), Growth hormone releasing 
hormone (GRH), prolactin, and erythropoietin (Bazan JF 1989). Members of this family 
have characteristic extracellular motifs of four cysteine residues and WSXWS amino acid 
motif, and they contain a different number of fibronectin type III domains (Heim MH 
1996). The receptor gene includes an extracellular Open Reading Frame (ORF) encoding 
a protein of 894 amino acids with a hydrophobic 22 amino acid secretory signal 
sequence, a predicted 23 amino acid transmembrane domain, and a short cytoplasmic 
domain of 34 amino acids (Tartaglia et al 1995). The extra-cellular domain of Ob-R was 
about 816 amino acids, while the predicted intracellular domain was around 34 amino 
acids suggesting that this protein might not have signal-transducing capability. The 
extracellular region of OBR consists of four fibronectin type III domains and two 
cytokine receptor domains (Heshka JT and Jones PJ 2001). It forms homo-dimers, even 
in the absence of leptin, and it is activated via ligand-induced conformational changes 
(Devos R, Guisez Y, Van der Heyden J, White DW, Kalai M, Fountoulakis M and Geert 
Plaetinck 1997). Like other cytokine receptors, OBR contains a highly conserved, 
proline-rich boxl (present at intracellular amino acid 6-17) (Bjorbaek C, Buchholz RM, 
Davis SM, Bates SH, Pierroz DD, Gu H Neel BG, Myers MG and Flier JS 2001) and two 
putative less conserved box2 motifs (intracellular amino acids 49-60 and 202-213) 
(Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS and Myers MG 2002).
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The intracellular domain of the long form (ObRb) contained motifs suggestive of 
intracellular signal-transducing capabilities. Boxl and box2 motifs are thought to recruit 
and bind Janus activated Kinases (Jaks), however, it was demonstrated that only boxl 
and the immediate surrounding amino acids are essential for Jak activation (Kloek et al 
2002; Bahrenberg G, Behrmann I, Barthel A, Hekerman P, Heinrich PC, Joost HG and 
Becker W 2002). Boxl and intracellular amino acids 31-36 are crucial for this 
interaction, whereas amino acids 37-48 appear to augment the signal, but can be 
substituted by other elements (Kloek et al 2002). Therefore, the receptors signal by 
activation of a receptor-associated Janus kinase, which results in tyrosine 
phosphorylation of a group of second messengers termed STATS (signal transducers and 
activators of transcription) (Morton 1999; Ghilardi N, Ziegler S, Wiestner A, Stoffel R, 
Heim MH, Skoda RC 1996; Haynes1997).
Members of the cytokine receptor family are generally internalized upon ligand 
binding via clathrin-coated vesicles into early endosomes with the receptor being 
processed for degradation or efficiently recycled back to the cell surface (Bazan JF 1990). 
Indeed, the dynamic process of receptor internalization and recycling or degradation is 
likely an important point of regulation for leptin signalling. Somewhat surprisingly, it has 
been estimated that, under resting conditions, only 5-25% of total cellular leptin receptor 
isoforms are located at the cell surface, with the majority residing in intracellular pools 
(Barr VA, Lane K and Taylor SI 1999). Analysis of receptor deletion mutants in CHO 
cells confirmed that both the short form of the receptor Ob-Ra and Ob-Rb mediate leptin
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internalization and degradation by lysosomes and showed that a domain between amino 
acids 8  and 29 of the intracellular domain determined this process (Barr 1999).
Genetic mapping of the gene encoding the Ob-R (leptin) receptor was localized 
to a narrow interval on mouse chromosome 4 through an expression cloning strategy 
(Tartaglia et al 1995). The isoforms included the long Ob-Rb receptor with an 
intracellular domain of 303 amino acids (Lee et al 1996), after confirming the cDNA 
using RT-PCR with an exact primer from the choroid plexus receptor and degenerate 
primers based on the human Ob-R long form (lida M, Murakami T, Ishida K, Mizuno A, 
Kuwajima, M and Shima K 1996). This splice variant is expressed at a high level in the 
hypothalamus followed by the pancreas indicating a strong evidence of potential direct 
action of leptin on those organs. The cDNA and amino acid sequence of the long receptor 
is identical to that of the short receptor up to lysine-889, after which the short receptor 
contains five additional carboxyl amino acids, while the long receptor contains an 
additional 275 amino acids or as depicted above, boxl, box-2, and box-3.
The soluble, form of the leptin receptor is not produced by alternative splicing, 
since an OB-Re transcript has not been discovered in humans (Chua SC, Koutrs IK, Han 
L, Liu SM, Kay J, Young SJ, Chung WK and Leibel RL 1997). Indeed, it can be 
generated by ectodomain shedding of membrane-spanned receptors (Ge 2002). The 
soluble leptin receptor circulates in the blood and can bind leptin with a high affinity 
(Kd= 0.75 ± 0.03 nmol/1) (Lammert A, Kiess W, Bottner A, Glasow A and Kratzsch J 
2001). Thus, it plays a role in regulating the plasma levels of free leptin, the biologically
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active form (Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J and Mantzoros 
CS 2002). In obese individuals, soluble receptor levels are reduced (Ogier V, Ziegler O, 
Mejean L, Nicolas JP and Stricker-Krongrad A 2002), whereas the receptor is up 
regulated in emaciation (Kratzsch J, Lammert A, Bottner A, Seidel B, Mueller G, Thiery 
J, Hebebrand J and Kiess W 2002).
The Jak proteins are associated constitutively with membrane-proximal sequences 
of the receptor intracellular domain (ICD) and phosphorylate the receptor intracellular 
domain upon ligand binding. The phosphorylated intracellular domain then provides a 
binding site for a STAT protein, which is activated upon binding to the phosphorylated 
receptor intracellular domain. The activated STAT proteins then translocate to the 
nucleus and stimulate transcription (Heim 1996). Cytoplasmic tyrosine kinases, members 
of the Jak family, recognize and associate with a specific membrane-proximal domain of 
the receptor upon ligand binding. OBR has been shown to recruit Jak2 and Jakl 
(Bjorbaek et al 2001), however, a recent study indicates that, under physiological 
conditions, only Jak2 is activated during OBR signalling (Kloek et al 2002). Activated 
Jaks transphosphorylate each other, as well as certain tyrosine residues of the receptor. In 
the case of ObRb, these residues are Tyr985 and Tyrll38 (Banks W, Niehoff M, Martin 
D and Pareil C 2002), thus providing a docking site for downstream molecules. 
Phosphorylated Tyrll38 serves as a binding site for STAT proteins. Replacement of this 
tyrosine residue with serine specifically disrupts STAT signalling (Bates SH, Steams 
WH, Dundon TA, Schubert M, Tso AW, Wang Y, Banks AS, Lavery HJ, Haq AK, 
Maratos-Flier E, Neel BG, Schwartz MW and Myers MG 2003). It is worth noting that
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SHP-2 is a tyrosine phosphatase that is activated by a conformational change induced 
upon interaction of one of its SH2 domains with a tyrosine phosphorylated ligand. Using 
phosphorylated fragments of Ob-Rb as bait, SHP-2 was found to bind to Tyr-985 (Neel 
BG, Tonks NK 1997) and as indicated in Figure 2. From these studies, a model was 
proposed whereby SHP-2 binds to phosphotyrosine 986, becomes activated and can thus 
down-regulate further tyrosine phosphorylation-dependent leptin signalling 
such as STATS activation (Carpenter LR, Farruggella TJ, Symes A, Karow ML, 
Yancopoulos GD and Stahl N 1998).
It has recently been discovered that STAT molecules are not recruited from a 
cytosolic monomeric pool, but from scaffolding/chaperone complexes, statosomes, of 
which even their inhibitors appear to be a part (Sehgal PB 2000). After recruited STATs 
become tyrosine-phosphorylated by Jaks, which leads to dissociation from the receptor 
and the formation of homo- or heterodimers they then translocate into the nucleus and act 
as transcription factors by binding specific response elements in the promoter of their 
target genes, such as sis-inducible-element (SIE), acute-phase-response element (APRE) 
and other gamma IFN-activated sequence (GAS)-like elements (Bendinelli P, Maroni P, 
Pecori K, Giraldi F and Piccoletti R 2000). A recently described specific molecule, 
(SOCS-3) a Suppressor Of Cytokine Signalling-3 (SOCS-3), which is a member of a 
small SH2 domain-containing protein family, and which appears to operate by binding to 
the phosphorylated tyrosine residues of signalling molecules and mediates either their 
degradation or inhibition (Hansen JA, Lindberg K, Hilton DJ, Nielsen JH and Billestrup 
N 1999) can inhibit this signalling pathway. SOCS-3 binds to Jak2 in a leptin-dependent
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fashion, inhibiting Jak-induced auto-phosphorylation and phosphorylation of the receptor. 
As a potent inhibitor of leptin signalling, it has been implicated in the leptin resistance 
seen in the obese rat (Bjorbaek et al 2001) because after induced hyperleptinaemia, 
expression of SOCS-3 was higher in the white adipose tissue of older rats. This suggests 
that the decline of leptin-induced anorexic actions with age is due to increased inhibition 
of the Jak/STAT signal transduction pathway, which is primarily used to exert leptin’s 
effect on body weight and energy balance (Wang J, Obici S, Morgan K, Barzilai N, Feng 
Z and Rossetti L 2001).
Another molecule has recently been implicated as a negative regulator of leptin’s 
effect through Jak/STAT signalling; protein tyrosine phosphatase-IB (FTPIB) (Cheng A, 
Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A, McGlade CJ Kennedy BP and 
Tremblay ML 2002). Jak2 has a consensus recognition motif and it was 
dephosphorylated by PTPIB in transfection studies (Zabolotny JM, Bence-Hanulec KK, 
Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y Kim YB, Elmquist JK, Tartaglia LA, 
Kahn BB and Neel BG 2002). However, it seems that some of leptin’s major effects do 
not require STATS signals. Disrupting STATS signalling by replacing tyrosine with 
serine at position 11S8 of the leptin receptor results in obesity, but reproduction, linear 
growth and control of NPY expression is not impaired, and glucose levels do not increase 
as much as in db/db mice (Bates et al 200S). This indicates the importance of other, 
STAT-independent, signalling pathways for leptin.
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In a study (Morton 1999), leptin treatment of RINmSF cells caused induction of a 
single STAT-3 DNA binding complex apparent after 15 min and continued to increase up 
to the 30 min time point. The time course of the study in pancreatic islets showed that 
induction of this single complex was observed by 2 min, peaked by 15 min and returned 
to basal levels by 30 min an important timing in the insulin secretion from B-cells which 
coincides with phase one insulin secretion. Other studies have demonstrated that STATS 
DNA binding activity in B-cells can be activated by leptin and other cytokines (Mathews 
CE, Langley SH and Leiter EH 2002; Mattson 2001) further implicating a direct effect of 
leptin on the B-cells. It is worth noting that STATS has been identified as one of the 
physiological mediators of leptin action because STATS is activated by leptin in a dose- 
dependent fashion in vivo (Vaisse C, Halaas JL, Horvath CM, Darnell Jr JE, Stoffel M 
and Friedman JM 1996).
The Ser/Thre MAPK (Erkl/Erk2) pathway can be stimulated by either the long or 
the short isoform of the leptin receptor, but to a lesser extent by the latter (Banks 2002). 
This observation supports the idea that the distal portion of the OBR is not essential to 
activate MAPK signalling, although to achieve maximal activation, an intact form of the 
long receptor is needed. As a result of leptin administration, Tyr985 becomes 
phosphorylated by the recruited Jaks, mainly Jak2 and Jakl, and provides a docking site 
for the SH2-domain containing protein tyrosine phosphatase, SHP-2 (Figure 2). After 
binding to that specific tyrosine residue, SHP-2 is phosphorylated at the C-terminus. This 
phosphorylated form, together with its adapter molecule Grb-2, activates downstream 
signalling effects (Banks 2002). OBR lacking Tyr985 is less able to induce Erk
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signalling, but is not completely inhibited. Downstream signalling in both pathways 
requires an intact catalytic domain of SHP-2. A lack of phosphatase activity causes a 
failure of Erk phosphorylation (Bjorbaek et al 2001). SHP-2 signalling may require 
stimulation by integiins to induce MEKl activation (Fujioka Y, Matozaki T, Noguchi T, 
Iwamatsu A, Yamao T, Takahashi N Tsuda M, Takada T and Kasuga M 1996). Activated 
MEKl phosphorylates Erk 1/2, and finally specific target genes are expressed, such as c- 
fos or egr-1 , a zinc-finger transcription factor that influences the initiation of growth and 
differentiation (Bjorbaek et al 2001). Activation of the MAPK signalling cascade has 
been demonstrated both in vitro (Banks 2002) and in vivo in the hypothalamus, liver and 
adipose tissue (Bjorbaek et al 2001; Machinal-Quelin F, Dieudonne MN, Leneveu MC, 
Pecquery R and Giudicelli Y 2002). In the human pancreatic p-cell line MIN6 , leptin- 
induced MAPK-activation has also been detected. Leptin also induced proliferation via 
this cascade. In addition, specific MAPK inhibitors blocked DNA synthesis and cell 
viability caused by leptin. This suggests that, at least in part, this mechanism is involved 
in obesity-induced pancreatic islet hypertrophy.
Northern blot, polymerase chain reaction or in situ analysis with probes generated 
from the extracellular domain of Ob-R forms shows expression in multiple tissues at 
varying amounts (Tartaglia et al 1995). In the mouse, the highest Ob-R mRNA levels are 
found in the choroid plexus, lung, and kidney, and somewhat lower levels of expression 
are detected in nearly all tissues. Subsequent analysis has shown that the vast majority of 
transcripts detected by these assays are transcripts encoding short intracellular domain 
forms. Using an RT-PCR protocol specific for the five different leptin receptors, both the
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long (Ob-Rb) and short form (Ob-Ra) leptin receptors were detected in the hypothalamus, 
testis, and adipose tissue, although the signal intensity varied between various tissues 
(Lee et al 1996). Of the 21 tissues examined by sensitivity RNase protection assay 
(procedure free of contaminating RNA), total (i.e. exocrine & endocrine) pancreas 
appears to have the most abundant proportion of Ob-Rb mRNA relative to Ob-Ra mRNA 
of all the peripheral tissues examined. It is only second in amount to the brain and 
hypothalamus overall (11% Ob-Rb vs. 18 and 36%, respectively) (Kieffer 1996). The 
distribution of leptin receptor within rat pancreatic islets was examined using anti-sera 
generated against an extracellular epitope of the leptin receptor. Although shorter 
isoforms of the leptin receptor may predominate, clearly Ob-Rb is expressed in 
pancreatic B-cells (Emilsson 1997 and Becker 1995). Leptin receptor immunoreactivity 
was observed on the majority of B-cells and A-cells, but not on glucagon-producing A- 
cells (Fehmann HC, Bode HP, Edert T, Karl A and Goke B 1997a).
Sequencing the gene encoding the leptin receptor from normal and db/db mice 
revealed that a mutation was present in Ob-Rb gene (Chen et al 1996). The mutation is a 
single nucleotide substitution (G-> T transversion) within an exon containing the extreme 
C terminus and 3’-untranslated region of the predominant short intracellular domain form 
of OB-R. This result in alternative splicing of the receptor-coding region and the addition 
of a 106 bp insert containing a premature termination signal. Thus, in db/db mice the 
cytoplasmic region of the receptor that interacts with the Jak/STAT pathway is missing 
(lida et al 1996). Genetic mapping in rats had shown that the fa/fa  mutation mapped to rat 
chromosome 5 (Masuzaki et al 1997), a region syntenic with the db region on mouse
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chromosome 4. A single-base substitution in the extracellular domain results in an amino 
acid change affecting dimerization of the receptor (Albaranji 1996). Although this 
mutation does not appear to affect binding affinity of the receptor, and there is some 
evidence that fa/fa rats are not totally insensitive, it strongly affects cell surface 
expression of the receptor, which makes it very resistant to leptin relative to control rats 
(Caro et al 1997).
Leptin can also act through some of the components of the insulin-signalling 
cascade, although reports disagree about its importance in modifying insulin-induced 
gene expression. Insulin itself acts through its receptor by recruiting different insulin 
receptor substrates (IRSs) that are tyrosine phosphorylated by the intrinsic kinase activity 
of the receptor. Phosphorylation of IRSs increases the affinity by which they bind other 
signalling molecules, and initiates further steps on the pathway. An important target of 
1RS molecules is phosphatidylinositol 3-kinase (PI 3-kinase) that generates 
inositoltiisphosphate (PIP3). IRSs exert PI 3-kinase activation through association with 
its regulatory subunit (p85), thus increasing the activity of the catalytic domain. Increased 
PIP3 levels lead to activation of PIP3-dependent serine/threonine kinases, such as PDK- 
1,2, which can activate Akt, another serine/threonine kinase that has several targets, such 
as glycogen synthase kinase-3 (GSK3). GSK3 is a serine kinase and plays a role in 
several actions, such as phosphorylation of glycogen synthase and C/EBPa (Kido Y, 
Nakae J and Accili D 2001). Insulin decreases GSK3 activity by serine phosphorylation 
(Szanto I and Kahn CR 2000).
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PB -kinase can further activate a signalling pathway through the activation of 
cyclic nucleotide phosphodiesterase-3B (PDE3B), a cAMP-degrading enzyme (Zhao AZ, 
Huan JN, Gupta S, Pal R and Sahu A 2002). In pancreatic B-cells, leptin diminishes 
cAMP levels and inhibits glucagon-like peptide-1-stimulated insulin secretion (Fehmann 
1997a). Leptin-mediated PDE3B induction and subsequent cAMP degradation has also 
been demonstrated in rat hepatocytes (Zhao et al 2000). Thus, in hepatocytes, insulin, like 
leptin, antagonises glucagon actions. Furthermore, this PDE3B pathway seems to interact 
with Jak/STAT signalling in the hypothalamus, as cilostamide, a PDE3 inhibitor, blocked 
the tyrosine phosphorylation of STAT3 and reversed the effects of leptin on food intake 
and body weight (Zhao 2002).
A signalling pathway divergent from activated PI3-kinase results in the induction 
of K(ATP) channels, which leads to hyperpolarisation of the B-cell (Harvey 2000a). This 
effect was described in the CRI-Gl rat insulinoma cell line (Harvey J and Ashford ML 
1998), isolated human pancreatic islets and glucose receptive hypothalamic neurons. 
Downstream signalling cascades stimulated by insulin, such as p70s6k, Akt or MAPK, do 
not seem to be utilized by leptin in this process, since blockade of them does not occlude 
leptin activation of K(ATP) channels (Harvey J, McKay NG, Walker KS, Van der Kaay 
J, Downes CP and Ashford ML 2000b). Phosphatidyl-inositol (3,4,5)-trisphosphate 
(PtdIn(3,4,5)P3) appears to be an attractive candidate downstream from PI3-kinase, as it 
mimics leptin’s effects. Surprisingly, leptin does not increase the total cellular Ptdin 
(3,4,5)P3 content, but it is possible that there is only a localized increase in it (Harvey et 
al 2000b). It is likely that PtdIn (3,4,5)P3 leads to disruption of actin filaments, the final
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known step in enhancing the activity of K(ATP) channels by leptin (Harvey 2000a). This 
is supported by the observation that phalloidin (an actin filament stabiliser) prevents 
activation of channels, both by leptin and Ptdin (3,4,5)P3 (Harvey et al 2000b).
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Figure 2: Signalling pathways affected by leptin. Small blue dots represent 
phosphorylation (Hegyia K, lopa KF, Kovacsb K, Totha S and Falusac A 
2004).
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Recently, it was suggested that a novel pathway that could be involved in leptin’s 
action in metabolism (Minokoshi Y, Kim Y-B, Peroni OD, Lee GD, Fryer LG, Muller C, 
Carling D Kahn BB 2002). Leptin has been shown to activate the oc2 subunit of 5-AMP- 
activated protein kinase (AMPK), which stimulates fatty-acid oxidation by blocking the 
effect of acetyl coenzyme A-carboxylase (ACC) in skeletal muscle. AMPK 
phosphorylates ACC-yff, the muscle isoform, which leads to its inhibition and increased 
fatty-acid oxidation by disinhibiting carnitine palmitoyl transferase (CPT) (Kahn BB and 
Flier JS 2000). Elevated cAMP levels activate AMPK 15 min after leptin treatment. This 
effect has been shown to be due to a direct effect of leptin on muscle. Leptin also acts 
through the a-adrenergic system, causing similar but delayed effects, because of its 
hypothalamic actions. It is not yet clear how leptin elevates AMP levels and activates 
AMPK when it directly targets muscle cells. Nevertheless, this is not the only way that 
leptin increases fatty acid oxidation. In normal non-adipocytes, e.g. pancreatic islets, 
PPAR-y is activated by STATS induction after leptin administration. Then, binding to its 
response element, it induces expression of acyl CoA oxidase and CPT-1, which leads to 
increased oxidation of fatty acids (Unger RH 2000). In cells lacking functional leptin 
receptor, this system does not function. Instead, high levels of fatty acids result in 
increased expression of PPAR-y and lipogenic enzymes, such as ACC or fatty acid 
synthase (Unger RH, Yhou Y-T and Orci L 1999).
Since insulin secretion followed by synthesis are regulated by different 
mechanisms, then leptin might deductively express its effect on insulin via probable 
different intracellular pathways. The presence of leptin receptor on the B-cells further
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supports the probable direct action of leptin on insulin secretion. Since leptin has 
suppressive effect on insulin secretion through the potassium channels, then suppression 
of phase one secretion could be associated with inhibition of components of this pathway. 
Furthermore, since leptin and insulin receptors share common intracellular components 
(PI-3 kinase) then leptin’s action on insulin synthesis could be mediated through this 
pathway. In addition, leptin seems to have a bimodal action where it shows stimulatory 
effects on some occasions, and inhibitory effects on others. The need to develop an index 
showing leptin’s effect on insulin secretion using ex vivo rat pancreas perfusion 
experiments over a wide range of concentrations will shed more light on the dose 
response of relations between insulin secretion rate and leptin. In addition, any variation 
in the leptin receptor will support a probable dynamic interaction between leptin and its 
receptor on the B-cell further reinforcing the direct effect of leptin on the production of 
insulin. So it is hypothesized from those facts that leptin has a negative feedback loop 
effect on the glucose-induced insulin secretion within physiological ranges of glucose, 
above which the loop will shift from being negative to a controversial positive feedback 
loop.
1.6 Insulin
The mammalian endocrine pancreas is composed of circumscribed clusters of 
more than a thousand endocrine organs (islets of Langerhans) embedded in the exocrine 
tissue of the pancreas. It is composed of at least four major phenotypically specific
48
hormone-producing cells: the A-cells, B-cells, D-cells and C-cells that produce glucagon, 
insulin, somatostatin, and pancreatic polypeptide respectively, and are arranged according 
to a precise topography (Pipeleers D, Veld I, Maes P and Van De Winkel M 1982). 
Within each islet, these various endocrine cells are thought to communicate with each 
other, either extracellularly via their secretory products, or intercellularly via cell gap 
junctions as demonstrated through fluorescence-activated cell sorting (FACS), by a 
significant increase in insulin secretion of B-cell aggregates as opposed to isolated B- 
cells stimulated with glucose (20mM). Insulin response comparison of the separated cell 
suspensions mentioned above with that of intact islets signified the dependency on 
paracrine and intercellular communication between islet cells ( 1 1  times more insulin 
production when combined as compared to isolated B-cells) (Pipeleers 1982). These 
results are compatible with the view that the peripheral rim of A-cells in the rat islets 
plays a role in glucose regulation of insulin release through a paracrine interaction with 
the more centrally located B-cells. In addition, a structural coupling between B-cells (gap 
junctions) was associated with an increased responsiveness to glucose. In conclusion, the 
capability of intact islets to counteract a glucose challenge by a rapid and appropriate 
insulin release may thus require both some degree of coupling between B-cells and 
optimal glucagon or secretin levels in the vicinity.
Furthermore, both hormonal and neuronal influences, within the islets, may 
modulate B-cell activity in vivo and in vitro and specifically by perifusion, which 
includes the existence of significant autocrine effects on the B-cells itself, a topic still 
controversial with studies providing conflicting evidence. B-cells express components of
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insulin signalling systems including insulin receptors, insulin receptor substrates 1 and 2, 
phosphatidylinositol 3-kinase (PI3-K), and protein kinase B (Stagner JI, Samols E and 
Weir GC 1980). In addition, dose-dependent activation of the insulin-signalling pathway 
in p-cells leads to initiation of insulin synthesis at both transcriptional and translational 
level, increasing the cellular content of releasable hormone (Xu GG, Gao Z, Borge DP 
and Wolf AB 1999) as measured by amperometry (Aspinwall CA, Qian WJ, Roper MG, 
Kulkami RN, Kahn RC and Kennedy RT 2000), which illustrate that insulin evokes 
insulin secretion mediated by the insulin receptor, and that such positive feedback occurs 
during dose-dependent glucose stimulation. In addition, insulin was shown to evoke an 
increase in intracellular free calcium concentration (Lundquist I, Fanska R and Grodsky 
GM 1976; Aspinwall et al 2000). The potential in vivo significance of positive autocrine 
feedback on insulin secretion and synthesis was revealed in experiments where the gene 
for the B-cell insulin receptor was inactivated, or in mice lacking the B-cell insulin 
receptor where they illustrated a significantly lower insulin response to glucose loading 
(Kulkami RN, Bmning JC, Winnay JN, Postic C, Magnuson MA and Kahn CR 1999b). 
In addition, it is worth noting that conventional PKC is inhibitory on depolarization- 
induced insulin secretion, while it augments glucose-induced insulin secretion, therefore, 
presenting PKC with a bi-modal role depending on glucose concentration (Zhang H, 
Nagazawa M, Yamada S, Mogami H, Suzuki Y and Kojima 1 2004).
The endocrine pancreas is subject to dynamic changes in response to variations in 
the demand for insulin. The B-cell population is kept in balance by B-cell formation 
(neogenesis and proliferation) and B-cell death and many of the factors that control this
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delicate balance have been described (Mora JF, Esteban LM, Burks DJ, Nunez A, Garces 
C, Garces-Barrado MJ, Iglesias-Osma MC, Moratinos J, Ward JM and Santos E 2003). 
However, the signalling pathways that govern these processes are poorly understood, 
although a new physiological role for Ras-GRF-1 signaling in p-cell proliferation and 
neogenesis was introduced (Mora et al 2003). GRF-1 is an imprinted gene regulated by 
promoter DNA méthylation (Yoon BJ, Herman H, Sikora A, Smith LT, Plass C and 
Solo way PD 2002) that is expressed after birth. Although GRF-1 is expressed 
preferentially in the CNS, pancreatic islets also express GRF-1, but not GRF-2, 
suggesting a direct role for Ras-GRF-1 physiology in islet function (George M, Ayuso E, 
Casellas A, Costa C, Devedjian JC and Bosch F 2002). Indeed, GRF-1-deficient mice 
display a 30% reduction in B-cell area due to impaired B-cell proliferation and 
neogenesis and are hypo-insulinemic and glucose intolerant, but not insulin resistant 
(Mora et al 2003). The hypo-insulinaemia correlates with an increased lipid catabolism in 
adipose tissue, which is rapidly used as fuel, but the insulin content and insulin secretion 
were unaltered by the absence of Ras-GRF-1 signaling (Mora et al 2003).
Insulin (human, bovine, porcine) consists of an A-chain (21 amino acids) and a B- 
chain (30 amino acids), with intramolecular disulphide bonds. The insulin gene is present 
in a single copy in most mammalian species with the exception of the rat and the mouse, 
where there are two non-allelic insulin genes. Insulin is synthesized initially as a single­
chain precursor, preproinsulin, which comprises of an N-terminal Signal sequence of 24 
amino acids, followed by the insulin B-chain, an Arg-Arg sequence, the connecting C-
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peptide of 31 amino acids, a Lys-Arg sequence, and the insulin A-chain (Briggs MS and 
Gierasch LM 1986).
Insulin secretion from the pancreatic B-cell can be initiated in minutes, vary as 
much as 50-100-fold dependent upon the degree of stimulation, and be sustained for 
several hours without need for changes in the rated insulin gene transcription. 
Remarkably, the cellular content of the hormone and its molecular composition do not 
vary appreciably in the face of changes of insulin granule exocytosis (Sando H and 
Grodsky GM 1973). Minimal morphological changes are apparent, further indicating that 
the movement of lipids and membrane proteins between the granule storage pool, the 
plasma membrane, and Golgi are likewise tightly controlled. Such homeostasis is 
achieved by an interplay of signaling pathways originating from the metabolism of 
glucose with downstream targets at the level of translation of dense-core granule proteins, 
granule biogenesis, and membrane trafficking as discussed below. The B-cell contains a 
large pool of cytoplasmic insulin mRNA (10-15% total mRNA), which is translationally 
quiescent at hypoglycemic (<3 mM) glucose concentrations (Goodge KA and Hutton JC 
(2000). Removal of the preproinsulin signal to generate proinsulin occurs during 
translation as the molecule is translocated into the lumen of the endoplasmic reticulum 
(E.R). The three dimensional structure of proinsulin, once the disulphide linkages have 
been established, resembles that of insulin, except for the presence of C-peptide (Ashcroft 
SJH, Bunce J, Lowry M, Hansen SE and Hedeskov, CJ 1978). Translation of 
preproinsulin mRNA begins in the cytosol with the binding of free ribosomes to the 
molecule. Transfer to the E.R. membrane occurs co-translationally and is initiated by the
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binding of the emerging signal sequence to the 54 KDa subunit of the signal recognition 
particle (SRP). Association of the complex with the E.R. membrane protein SRP receptor 
(docking protein) occurs when 70-80 amino acids of preproinsulin have been 
polymerized. SRP is then released from the complex and the signal sequence is 
transferred to the signal sequence receptor, a glycosylated, integral E.R. membrane 
protein (Goodge and Hutton 2000). Proinsulin is processed to insulin and C-peptide by 
the action of proconvertase PC-2 and PC 1/3, which are subjected to nutrient-induced 
translational control in B-cells (Herbert TP, Alarcon C, Skelly RH, Bollheimer LC, 
Schuppin GT, Rhodes CJ 1998). This implies a major role for those enzymes in providing 
translated insulin to the reserve pool of granules (Nesher R, Anteby E, Yedovizky M, 
Warwar N, Kaiser N, and Cerasi E 2002) during phase two secretion, at a rate faster than 
the B-cell could mobilize from the readily releasable pool out into the extracellular 
medium (Bratanova-Tochkova TK, Cheng H, Daniel S, Gunawardana S, Liu YJ, 
Mulvaney-Musa J, Schermerhom Th, Straub SG, Yajima H and Shapr GWG 2002; 
Daniel S, Noda M, Straub SG and Sharp GWG 1999).
The circulating factors that regulate insulin biosynthesis include glucose, some 
amino acids, neurotransmitters, and hormones including leptin, resistin, ghrelin, 
adiponectin and others (Pipeleers DG, Schuit EC, Veld PA, Maes E, Hooghe-Peters EL, 
Van de Winkel M and Gepts W 1985; Sekine N, Cirulli V, Regazzi R, Brown LJ, Gine E, 
Tamarit-Rodriguez J, Girotti M, Marie S, MacDonald MJ and Wollheim CB 1994; 
Ashcroft EM, Proks P, Smith PA, :Ammala C, Bokvist K and Rorsman P 1994; Meier U 
and Gressner AM (2000); Meier and Gressner 2004). Since islets display a characteristic
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topography of their four constituent cell types, communication with each other, either 
extracellularly via secretory products or intercellularly via gap junctions, has regulatory 
effects on the production of insulin (Ashcroft FM and Rorsman P 1989; Drucker DJ, 
Philippe J, Mojsov S, Chick WL and Habener JF 1987,; Holz GG and Habener JF 1992 ; 
Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B and Byrne MM 2001). The 
vast majority of investigators studying glucose-induced insulin release have dealt with 
the effect of hexose on acute initiation of hormone secretion (Cerasi E, Fick G and 
Rudemo M 1974; Marshak et al 1999). Glucose, however, could exert a second, time- 
dependent effect on the pancreatic B-cell, which results in potentiation of insulin release 
stimulated consecutively by two pulses of glucose (Chen and Romsos 1995). The insulin 
response of the pancreas to the second stimulation could be markedly enhanced under 
certain circumstances (Grodsky GM, Curry D, Landahl H and Bennett LL 1969). 
Approximately six minutes after the initial rise, the rate of insulin secretion would drop 
sharply, almost to its base line level. The second phase of the insulin secretory process 
would begin at approximately the eighth minute of the glucose infusion in a perfused 
pancreas (Curry DL, Bennett LL and Grodsky GM 1968; Grodsky GM and Fanska RE 
1975; Sussman KE, Vaughan GD and Timmer RF 1966). Therefore, in normal perfusion 
pancreas preparations, the release of insulin may coincide with insulinogenesis by 
approximately the 15*^  minute of glucose infusion, and that this effect becomes more 
pronounced as the duration of the glucose stimulus progresses. In addition, the fact 
should not be overlooked that a substantial portion of the insulin secreted during the 
second phase was largely from the storage pool. This was supported by introducing 
puromycin (protein synthesis inhibitor) to the total perfusate (80pg/ml) which resulted in.
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at least, a 95% inhibition of protein synthesis as determined by valine-14C incorporation 
into the TCA precipitable protein of total pancreatic protein, with the assumption that 
synthesis of insulin was inhibited at a similar rate to total pancreatic protein.
It is worth mentioning that when extracellular glucose concentration is elevated 
from basal level of 4.5mM and above, the B-cell plasma membrane undergoes a slow 
depolarization from the resting potential (-70mV) up to a threshold from which 
regenerative electrical activity is elicited (Rorsman P, Eliasson L, Renstrom E, Gromada 
J, Barg S and Gopel S 2000). Furthermore, this electrical activity consists of oscillations 
in the membrane potential between depolarized plateaus, from which calcium-dependent 
action potentials originate, which are separated by electrically silent intervals (Barbosa 
RM, Silva AM, Tome AR, Stamford JA, Santos RM and Rosario LM 1998). Two classes 
of ion channel are particularly important in the generation of B-cell electrical activity: 
ATP-regulated Channels and voltage-gated L-type Ca^ '  ^channels.
When extracellular glucose concentrations is elevated, the rapid uptake of glucose 
(via GLUT-2 transporters) and subsequent metabolic degradation of the sugar result in an 
elevated cytoplasmic ATP/ADP ratio. This entrains the closure of the K atp  channels, 
membrane depolarization, and consequent opening of voltage-gated calcium channels, an 
increase in cytoplasmic Ca^ '^  concentration and ultimately the exocytosis of the insulin- 
containing secretory granules (Barbosa et al 1998). Biochemical and electrophysiological 
experiments in endocrine cells have suggested that the secretory granules exist in 
different pools, which vary with regard to releasability (Parsons TD, Coorssen JR,
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Hortsmann H and Aimers W 1995). Most of the granules (>95%) belong to the reserve 
pool and need to be chemically modified and physically mobilized to become available 
for immediate release. The latter subset of granules is referred to as the readily releasable 
pool (RRP) and characteristically contains <5% of the total granule number.
Insulin biosynthesis and secretion are not obligatorily coupled. Glucose- 
stimulated insulin secretion, for example, is inhibited in a Ca^^-free medium, whereas 
under these conditions biosynthesis is still activated (Xu 1999). Furthermore, the 
threshold for the glucose-induced activation of insulin secretion (4.2-5.6 mM) is higher 
than that for insulin synthesis (2.5-3.9 mM) in normal rats. Thus, the initial stimulation of 
pro-insulin biosynthesis, which occurs within 20 minutes of exposure to glucose, must 
use pre-existing m-RNA and involve translational regulation. Exposure of islets to 
glucose concentrations above 3.3mM resulted in an increased rate of transfer of 
cytoplasmic preproinsulin mRNA to subcellular fractions containing ribosomes and 
larger polysomes. Similar effects have been observed for the distribution of total mRNA 
of islet, which suggests that altered rates of initiation of translation may be a general 
response to glucose and not specific to insulin (Curry 1986). This implicated that the 
insulin synthesis and secretion are controlled by different mechanisms at different 
timings, which might explain the various actions of leptin on the two phases of insulin 
secretion.
A full biphasic insulin response requires accelerated B-cell metabolism and the 
involvement of numerous proximal intermediates, as well a distal coupling intermediate.
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whereas this is not true for non-metabolizable secretagogues, which elicit only first-phase 
insulin response (Nesher et al 2002). The first phase of insulin secretion typically lasts for 
10 minutes and reaches a peak rate of secretion of 80pg/min/islet (Rorsman et al 2000). 
By approximating the first phase of insulin secretion to a triangle, then calculations 
correspond to a total of 400pg/islet, implying that the number of granules released can be 
estimated at 200,000 per islet, which corresponds to -100 granules per B-cell belonging 
to the RRP, in an islet containing 2000 cells (Rorsman et al 2000). This estimation is in 
concordance with the quantitative morphometric assessment of the total granule 
population in mouse B-cell reaching 13,000, assessed more than thirty years ago (Dean 
PM 1973). The docked pool of readily releasable granules was identified by immuno­
précipitation of the plasma membrane protein syntaxin with a specific antibody and by 
co-immunoprecipitation of soluble N-ethylmaleimide-sensitive factor attachment protein- 
25 (SNAP-25) and the granule proteins synaptobrevin and synaptotagmin (Daniel 1999). 
Thus, when the isolated perfused rat pancreas is used as a sensitive preparation to study 
the dynamics of insulin response to secretagogue, low-level metabolic stimulus 
(6.9mmol/l glucose) elicits almost only first-phase response (Nesher et al 2002). 
Stimulation by higher concentration of glucose (8.3mmol/l) produces a stronger first- 
phase insulin response, as well as a moderate second-phase response. It is only with 
stronger glucose stimuli (16.7mmol/l) that a full second-phase insulin response is 
observed indicating a dose-dependent response to glucose, implicating intracellular 
mechanisms controlling granule mobilization at different concentrations of glucose 
(Nesher R, Warwar N, Khan A, Efendic S, Cerasi E and Kaiser N 2001) in concordance 
with the bimodal role protein kinase C (Zhang et al 2004). It is worth noting that in the B-
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cell, the total number of insulin-containing granules is in large excess over the number 
required to control the glycaemia of a single meal (Bratanova-Tochkova TK, Cheng H, 
Daniel S, Gunawardana S, Liu YJ, Mulvaney-Musa J, Schermerhom Th, Straub SG, 
Yajima H and Sharp GWG 2002). Exocytosis requires the interaction between the v- 
SNARE, VAMP-2 and t-SNARE syntaxin and SNAP-25. These three proteins associate 
via coiled-coil interactions into an extremely stable complex before exocytosis (Sutton 
RB, Fasshauer D, Jahn R, Bmnger AT 1998). Calcium is thought to be required for 
several steps in docking, priming, and exocytosis, and candidate target proteins have been 
identified by their C2 Ca^^ binding domains. Among these are the above-mentioned 
synaptotagmin and the Ca^^-dependent activator protein for secretion (CAPS) which 
binds Ca^ "^ , allows phospholipids binding, and suggest a possible role in fusion 
(Elhamdani A, Martin TF, Kowalchyk JA, Artalejo CR 1999).
The normal rates of glucose-induced insulin release are maintained by at least two 
key mechanisms: acceleration of the metabolic flux, which is controlled at the level of 
glucose phosphorylation by the P-cell isoform of glucokinase, and c-AMP production, 
which is stimulated by glucagon, GLP-1, and Glucose Insulinotrpoic Peptide (GIP), 
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) (Holz IV, GG, Kuhtreiber, 
MW and Habener, FJ 1993; Bratanova-Tochkova et al 2002). Therefore, glucose 
regulation of second phase insulin release is mediated by metabolic signals. Activation of 
cAMP-dependent protein kinase-A (PKA) is regarded as an important pathway that 
amplifies stimulus-secretion signals in pancreatic B-cells with emphasis on the important 
role for ATP in promoting distal exocytotic steps via activation of PKA (Takahashi N,
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Kadowaki T, Yazaki Y, Ellis-Davies GC, Miyashita Y and Kasai H 1999). Thus, 
stimulation of the isolated perfused pancreas with glucagon for example (5.0 pg/ml, 
which activates adenylate cyclase and PKA pathways), without glucose or any other fuel 
produces no insulin response; a minimal first-phase insulin response may be observed 
when glucagon is applied together with 5.0 mmol/1 glucose, while the combination of 
glucagon and 7.0 mmol/1 glucose results in the appearance of moderate first- as well as 
second-phase insulin responses (Takahashi et al 1999). On the other hand, PKC signal 
pathways play a clear role in the potentiation of insulin response to glucose and incretins 
(Nesher et al 2001). Carbamyl-choline (carbachol 5.0 pmol/1, which activates p-cell 
phospholipase-C [PLC] and PKC and facilitates calcium mobilization) produces no 
insulin response in the absence of added fuel, but a moderate biphasic insulin response 
can be seen when applied in the presence of minimal fuel secretagogue (3.3 mmol/1 
glucose) (Nesher et al 2002). Mochly-Rosen and Kauvar (1998) developed and refined 
the PKC model of intracellular action by characterizing specific receptors for inactive C 
kinase (RICK)-anchoring proteins that bind the kinase in its folded form, thereby 
protecting it from degradation. Following its activation, each PKC isoenzyme 
translocates to a new site in order to colocalize in close proximity with its substrate by 
binding to a second highly specific anchoring protein termed RACK (receptor for 
activated C kinase). Thus, according to the RICK-RACK concept, compartmentalization 
and substrate specificity are achieved by translocation and binding of the PKC to a highly 
selective RACK protein that maintains the kinase juxtaposed with its effector substrate. 
Sim and Scott in 1999 developed a slightly modified model for isoforms of PKA, in 
which the inactive holoenzyme is bound to a scaffold protein termed AKAP (A kinase
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anchoring protein) via its regulatory (R) subunit, maintaining it in close proximity to the 
specific effector substrate. Activation by cAMP releases the catalytic (C) subunits to 
phosphorylate the adjacent substrate protein. Since there are only 4 R isoforms and three 
C isoforms in the PKA family, compartmental and functional diversity is achieved by the 
very large number of AKAPs (over 30 have been described thus far). While in the case of 
PKC, 12 isoforms have already been cloned (eight have been identified in pancreatic p- 
cells (Nesher et al 2001), and multiple isoforms are known to be present in any cell type. 
It was demonstrated by quantitative confocal histochemical imaging that glucose induced 
translocation of six PKC-isoforms to new sites within the p-cells of the isolated perfused 
rat pancreas (Nesher et al 2002). Employment of a short peptide analogue of RACKl 
binding site on aPKC to inhibit the translocation and function of aPKC was performed. 
The peptide specifically blocked translocation of activated aPKC and diminished the 
insulin response to glucose by -40%. The fact that the addition of mannoheptulose (an 
inhibitor of glycolysis) or omission of calcium also diminished the translocation of aPKC 
and its localization (in the activated form) in the vicinity of the cell membrane could 
suggest that the isoenzyme plays a role in the activation of the insulin granule SNARE 
(soluble A-ethylmaleimide-sensitive factor attachment protein receptor) complex and its 
membrane fusion. The intracellular mechanism by which nutrients could activate atypical 
PKC isoforms in islets is not completely uncovered, but candidate phosphatidylinositol 
3,4,5-triphosphate, which has been shown to activate Ç-PKC in vitro (Nakanishi H, 
Brewer KA and Exton JH 1993) and to be generated in islets by the activation of 
PI3Kinase in response to nutrients, a process coinciding with phase two of insulin 
secretion as supported above.
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It was apparent from a number of studies (Kowluru A 2003) that small molecular- 
mass G proteins play key regulatory roles in the stimulus-secretion coupling of the islet 
B-cell. These conclusions were reached on the basis of studies using mostly biochemical, 
physiological, and limited gene depletion approaches. Glucose-mediated, receptor- 
independent activation of these G proteins requires the intermediacy of protein histidine 
phosphorylation and subsequent relay of the high-energy phosphate to GDP bound to G 
proteins to yield their respective GTP-bound active conformation (Kowluru 2003). It also 
appears that alterations in the expression and/or functional activation of these proteins 
lead to impaired glucose-induced insulin secretion; a process that coincides with phase 
two of insulin secretion.
The pancreas B-cells express GLUT-2 glucose transporters, which permit rapid 
glucose uptake regardless of the extracellular sugar concentration (Thorens B, Sarkar 
HK, Kaback HR and Lodish HF 1988). In addition to being the main glucose transporter 
species of pancreatic B-cells in which it plays purely a permissive role in glucose sensing 
by allowing an unrestricted access of glucose to glucokinase, GLUT2 is present in 
intestine, liver, kidney, and hypothalamic and brain stem centers (Bratanova-Tochkova et 
al 2002). It role is very crucial as deduced from GLUT2-null mice which are 
hyperglycemic, hypo-insulinemic, hyper-glucagonemic, and glycosurie and die within the 
first 3 weeks of life (Bratanova-Tochkova et al 2002). At low glucose concentrations 
(<2.5mmol/L), phosphorylation is minimal probably due to the low expression of a high 
affinity hexokinase (HK), the B-cell isoform of glucokinase (GK) (Schuit CF, Moens K, 
Heimberg H and Pipeleers D 1999). In pancreatic B-cells, the absence or very low
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expression of hexokinase results in a low glycolytic flux and low ATP/ADP ratio at low 
glucose levels, levels essential for maintaining a low basal rate of insulin release (Schuit 
F, De Vos A, Farfari S, Moens K, Pipeleers D, Brun T and Prentki M 1997), and which 
supports the results of Takahashi et al. At glucose levels greater than 2.5mmol/L, P-cells 
phosphorylate glucose via high affinity glucokinase (hexokinase IV), which explains the 
high ATP/ADP ratio of lOmmol/L (lynedjian PB, Pilot PR, Nouspikel T, Milbum JL, 
Quaade C, Hughes S, Ucla C and Newgard CB 1982). The fact that glucokinase (GK) is 
not inhibited by G6P establishes the basis of a proportional change in cytoplasmic 
Glucose 6-phosphate (G6P) concentration when extra-cellular glucose concentrations 
increase (Wang H and lynedjan PB 1997; Sekine et al 1994). Moreover, the sigmoidal 
relationship between GK reaction velocity and glucose concentration renders B-cells 
maximally sensitive to changes in extracellular glucose around the physiological plasma 
levels. In B-cells, the GK upstream promoter region is not significantly influenced by 
acute changes in nutritional state. Although is it difficult to exclude that B-cells GK gene 
transcription is regulated to some extent via local islet hormone levels, it is unlikely that 
GK gene transcription in B-cells is regulated by glucagon or insulin (Wang and lynedjan 
1997) thus excluding negative feedback by insulin itself. Moreover, the glucagon-induced 
increase in B-cell cAMP formation synergizes with rather than antagonizes the glucose 
signals for insulin secretion. Direct effects of glucose are considered more likely, and 
could explain the loss of glucose-responsiveness in B-cells that have been exposed to 
prolonged periods of low glucose concentrations. Therefore, the low GK level in B-cells 
compared to liver parenchymal cells is probably the consequence of a weak promoter. 
This possibility may be functionally important: on the one hand, small changes in GK
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were shown to affect the glucose sensitivity of the cells; on the other hand, larger 
increases in GK expression severely disturbed the glucose-sensing properties by a 
process comprising G6P accumulation, ATP depletion, and cell death (Wang and 
lynedjan 1997). Whatever the underlying mechanisms, a rise of plasma glucose in the 
physiological range (between 3 and lOmmol/L) is known to cause a proportional flux of 
glucose phosphorylation via GK in the active subcellular pool. This leads to a 
proportional increase in overall glycolytic flux and mitochondrial glucose oxidation. 
Increased influx of glucose carbon into Kreb’s cycle leads to accelerated production of 
intermediates that leave the mitochondria and accumulate in the cytosol. Malate efflux 
from the mitochondria has been proposed to activate the malate/pyruvate shuttle and to 
promote electron transfer from cytosolic NADH to NADPH. Glucose metabolism, 
through glycolysis and mitochondrial oxidative phosphorylatin, drives stimulation of 
insulin secretion in pancreatic B-cells. According to low lactate dehydrogenase activity in 
B-cells, glycolysis-derived electrons carried by NADH^H^ are mostly transferred to 
mitochondria through the NADH shuttle system. Therefore, NADH shuttles couple 
glycolysis to activation of mitochondrial energy metabolism, leading to insulin secretion. 
Moreover, low activity of NADH shuttles in B-cells has been found in type-2 diabetes 
models and is the cause of impaired glucose-stimulated insulin secretion (GSIS) in foetal 
islets (Rubi B, Arco AD, Bartley C, Satrustegui J and Maechler P 2004).
Unlike most other mammalian cell-types, pancreatic B-cells express low lactate 
dehydrogenase levels and high pyruvate carboxylase activity (Schuit et al 1997). These 
two properties can explain why virtually all pyruvate that is formed from G6P enters the
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Krebs cycle and why B-cells produce little lactate (Sekine et al 1994). Tight coupling 
between glycolysis and mitochondrial oxidation has been considered to be crucial for 
more distal steps in the signal generation in B-cells (Prentki M, Tomheim K and Corkey 
BE 1997). The first and best-characterized signal proceeds via ATP-sensitive K^ ( K atp) 
channels. An acute rise in the extracellular glucose concentration from 1 to 10 mmol/L 
glucose induces a dose-dependent increase in the ATP/ADP ratio (Detimary P, Dejonghe 
S, Ling Z, Pipeleers D, Schuit F and Henquin JC 1998). This shift in adenine-nucleotide 
pool ratio is thought to stimulate insulin release via closure of K atp channels, which leads 
to membrane depolarization that leads to opening of L-type voltage-dependent calcium 
channels and induction of exocytosis (Ashcroft et al 1994). In addition, intracellular ATP 
is a negative allosteric regulator of the Kir6.2 pore-forming unit of these channels 
(Aguilar-Bryan L and Bryan J 1999). The second glucose-induced signaling pathway 
proceeds independently of K atp channels, but the exact nature of the produced signals is 
still unclear (Gembal 1993; Barg S, Eliasson L, Renstrom E, Rorsman P 2002).
It is noteworthy that a moderate increase in glucose concentration of the 
equilibration medium, in fasted perfused rat pancreas (from 4.4 to 8.3mM), amplified 
markedly both phases of the insulin response to subsequent glucose stimulation, and 
while no such effect was observed in fed rats (Efendic 1976). This is very similar to the 
findings in low insulin responders where the threshold for eliciting potentiation was 
around 7mM as against 15mM for control subjects. Thus, the sensitivity of the islets for 
the potentiation action of glucose seems to be enhanced in situations where acute insulin 
response to glucose is diminished.
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Another important factor that assists in enhancing the pancreatic B-cells glucose- 
competence in in vitro experiments is the insulinotropic hormone, glucagon-like peptide- 
1 (GLP-1) (Drucker 1987). GLP-1, an intestinally derived hormone, acts in vivo to 
increase the level of circulating insulin, and thus lower the concentration of blood glucose 
(Nathan DM, Schreiber E, Fogel H, Mojsov S and Habener JF 1992). In vivo, there is 
glucose dependency of the action of postprandial physiological levels of GLP-1 in 
healthy subjects over the glucose range of 5-15mM. Insulin Secretory Rate (ISR) was 
consistently increased at each ImM glucose interval. In contrast to in vitro, in in vivo 
experiments GLP-1 had no independent effect of insulin clearance beyond stimulating 
ISR to a greater level, and there was no priming effect of GLP-1 on subsequent insulin 
secretory response to glucose. Because all insulinotropic actions of GLP-1 are dependent 
on simultaneous exposure of p-cells to glucose (Fehmann HC and Habener JF 1992), 
GLP-1 may act as a hormonal regulator, or modulator, of the B-cell glucose signalling 
system, mediated by c-AMP signalling system. In addition, a subset of enteric neurons is 
glucoresponsive and expresses ATP-sensitive K1 (K atp)  channels (Lui MT, Seino S, 
Kirchgessner AL 1999). The immunoreactivities of the inwardly rectifying K1 channel 
6.2 (Kir6.2) and the sulfonylurea receptor (SUR), now renamed SURl and subunits of 
pancreatic B-cell KATP channels, were detected on cholinergic neurons in the guinea pig 
ileum. Glucoresponsive neurons were distinguished in the myenteric plexus because of 
the hyperpolarization and decrease in membrane input resistance that were observed in 
response to removal of extracellular glucose. These experiments demonstrate for the first 
time the presence of glucoresponsive neurons in the gut. Therefore, glucose-induced 
excitation of these neurons can be mediated by inhibition of K atp channels (Lui 1999).
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The results support the idea that enteric K atp channels play a role in glucose-evoked 
reflexes.
On the other hand, chronic exposure to high glucose levels (~12mmol/L) causes 
impairment of B-cell function in experimental systems, reducing glucose induced insulin 
release and depleting the B-cell insulin content (Leahy JL 1996). Furthermore, the 
amount of insulin mRNA, normalized for corresponding beta-actin m-RNA levels in 
isolated human pancreatic islets, was decreased by 40% on the 9* day, with a partial 
recovery observed after three additional days in normal glucose (Marshak et al 1999), 
indicating a reversible defect. In addition, it has been suggested that the increased 
secretory demand shortens the transit time from granule-packaging to insulin release in 
the B-cell, resulting in incomplete peptide processing, hence leading to 
hyperproinsulinaemia (Hosokawa YA and Leahy JL 1997). Chronic exposure to glucose 
is likely to down-regulate the convertase expression thus impairing prohormone 
conversion and leading to hyper-proinsulinaemia. A notable exception in this respect are 
free fatty acids (FFA), which acutely induce insulin release (Crespin SR, Greenough DB 
and Steinberg D 1969) without corresponding increase in translational regulation of 
proinsulin biosynthesis (Goodge and Hutton 2000), but chronic exposure to FFA may 
inhibit synthesis and proteolytic conversion of proinsulin, and may underlie the clinical 
diabesity syndrome (Shafrir E and Ziv E 1998). In addition, tissue triacyl glycerol (TAG) 
also seems to interfere with insulin mediated glucose metabolism and to stimulate insulin 
secretion acutely where non-esterified-fatty acid (NEFA) levels in vitro have been shown 
to induce, in normal islets, B-cell hyperplasia and increased insulin secretion at sub­
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stimulatory glucose level (Hirose H, Lee HY, Inman LR, Nagasawa Y, Johnson H and 
Unger RH 1996). Insulin production was greatest in obese groups, which had the highest 
fat content. Therefore, tiiacylglycerol content determines the level of insulin production 
and matches it to the level of insulin effectiveness, perhaps by providing an intra-cellular 
source of FFA retrieved from intra-cellular triacylglycerol storage sites of the B-cell.
Age-related changes in the p-cell sensitivity to glucose, as well as in its overall 
capacity to secrete insulin (Blahi D, Muller CD, Anderson KD, Tobin DJ and Andres R 
1985), was shown in isolated perfused pancreas preparation studying the effect of age and 
glucose (8.3, 11.1, 20mM for 50 minutes) on insulin secretion in the rat. In older rats, the 
first phase showed significant decrease as compared to younger ones. The second phase 
of insulin secretion was not statistically significantly different for the various glucose 
concentrations. Interestingly, it was observed that the islets of Langerhans from ageing 
rats have progressively higher basal insulin secretory rates than those of younger ones, 
which could be related to a possible increase in constitutive release at non-stimulating 
glucose concentrations in B-cells (Malaisse WJ, Sener A, Koser M, Ravazzola M and 
Malaisse Lagae 1977). In addition, in isolated islets the response to non-glucose 
secretagogues 3-isobutyl-1-methylxanthine (IBMX), and ketoisocaproate (2-KIC) is 
effective in the absence of glucose and seems relatively not impaired with ageing, which 
imply a possible deficiency related to changes in the levels of GLUT-2 protein 
production of which was found to progressively decrease with aging (Novelli M, De Tata 
V, Bombara M, Bergamini E, and Masiello P 2000). This reduction • seemed to be 
quantitatively and temporally related to the impairment in glucose-stimulated insulin
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secretion and c-AMP cascades seem to compensate for the decrease in insulin secretion 
as supported above with GLP-1 induction of insulin secretion (Brandt et al 2001).
Acute exposure of both rat and mouse isolated islets to concentration of leptin 
within physiological range (lOng/ml) does not alter basal insulin secretion nor insulin 
secretion stimulated by glucose alone, as in agreement with Leclerq-Meyer (Leclercq 
Meyer V and Malaisse WJ 1997; Leclercq-Meyer V and Malaisse WJ 1998). In contrast, 
an inhibitory effect of leptin was reported in islets from ob/ob mice (Bogan and Lodish 
1999; Baker 1996) and normal rat isolated islets (Pallett 1997) showing that the effect of 
leptin in islets from ob/ob mice is mediated through activation of the ATP-sensitive 
potassium channel of B-cell. Leptin specifically inhibits glucose + 
isobutylmethylxanthine (IBMX) stimulated insulin release, given the well known effect 
of IB MX which inhibits islet phophodiesterase; therefore, leading either to a decrease in 
the intracellular levels of cAMP or a down-stream effect on insulin secretion. These 
findings suggests that in normal rodents, leptin does not act on the main pathway of 
coupling between glucose and insulin release in B-cell, involving activation of ATP- 
sensitive channels, membrane depolarization, and calcium entry through voltage- 
sensitive Ca^ "^  channels. The results obtained in ob/ob mice islets led Kieffer et al (1997) 
to hypothesize that leptin acts as a tonic inhibitor of basal insulin release, and that this 
effect can be overcomed after a meal, when insulin secretion is potentiated by incretins. 
The inhibitory action of glucose on KAXp-channels, as observed in intact islets, is 
proposed to result from a glucose signaling system where uptake of glucose is mediated 
by a facilitative glucose transporter (GLUT-2). Reports from normal animals led to
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speculation that the small inhibitory effect of leptin on stimulated insulin secretion under 
conditions of increased c-AMP intracellular levels may represent a brake, avoiding 
insulin hypersecretion in response to meals (Fehmann 1997a). This effect would be 
enhanced in overweight individuals with increased plasma levels of leptin and therefore 
would participate in the physiological mechanisms preventing the development of 
obesity, before the occurrence of confounding alterations, such as a putative resistance to 
leptin (Uwaifo and Arioglu 2000).
1.7 The insulin receptor
Insulin receptors are widely distributed in mammalian tissues, varying in number 
expressed per cell from approximately 10  ^ on hepatocytes and adipocytes to 10  ^ on 
fibroblasts and recently identified on B-cells (Rothenberg PL, Willison LD, Simon J and 
Wolf BA 1995) with evidence of the intracellular cascade of molecules to conduct its 
relevant effects (Harbeck MC, Louie DC, Howland RJ, Wolf BA and Rothenberg PL 
1996).
The receptor contains two distinct subunits, termed A and B, which are derived 
from a common polypeptide precursor by proteolysis, and are therefore the product of a 
single gene (Kahn and White 1988). The A-subunit is wholly extracellular and contains 
the insulin-binding site. The B-subunit is a transmembrane protein, the intracellular 
portion being a tyrosine-specific protein kinase as shown in Figure 3 overleaf. The insulin 
receptor (IR) exists in two isoforms, as a result of alternative mRNA splicing, that either
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lack (type A, Exl 1-) or contain (type B, Ex 11+) the 12 amino acids encoded by exon 11, 
which are located at the COOH terminus of the a-chain of the receptor (Uhles S, Moede 
T, Leibiger B, Berggren PO, and Leibiger IB 2003).
It was recently reported that in insulin-producing pancreatic B-cells, selective 
insulin signaling could be gained by using the two isoforms of the insulin receptor 
(Leibiger B, Moede T, Kemper S, Kulkami RN, Kahn CR, de Vargas LM, and Berggren 
PO 2001). While insulin, secreted upon glucose stimulation, activates the transcription of 
its own gene by signaling via IR-A/PI3K Ia/P70 S6 kinase and CaM kinase II (Leibiger 
B, Moede T, Schwarz T, Brown GR, Kohler M, Leibiger IB, and Berggren PO 1998), it 
requires signaling via IR-B/PI3KC2 a-like activity/PKB to activate p-cell glucokinase (p- 
GK) gene transcription (Leibiger et al 2001). In addition, it was shown that activation of 
the insulin promoter (via A-type IR) and of the p-GK promoter (via B-type IR) is not 
dependent on IR isoform-specific differences in receptor internalization, but is dependent 
on the 12 amino acids encoded by exon 11, which determine the localization and 
function of the receptor isoforms in the plasma membrane (Uhles 2003). Taken together, 
it implies that IR isoform-dependent activation of the insulin and B-GK promoters results 
from IR-mediated signaling from different plasma membrane microdomains (Uhles 
2003). This may mechanistically explain the access to different adaptor proteins and the 
subsequent activation of selective signaling pathways.
Insulin initiates its metabolic and growth-promoting effects by binding to the A- 
subunit of its tetrameric receptor, thereby activating the kinase in the B-subunit. This in
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turn catalyzes the intermolecular autophosphorylation of specific tyrosine residues of the 
p-subunit, further enhancing the tyrosine kinase activity of the receptor toward other 
protein substrates (Kasuga M, Karisson FA and Kahn CR 1982).
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Figure 3: A model of the insulin receptor showing its various structural and 
functional domains (Brady MJ 2004).
Considerable evidence demonstrates that insulin receptor’s tyrosine kinase 
activity is essential for many, if not all, of the biological effects of insulin (Chou CK, 
Dull TJ and Gherzi DR 1987). In most cells, insulin stimulates tyrosine phosphorylation 
of a cytoplasmic protein with a relative molecular mass between 165 and 185 KD, 
collectively called ppl85 (Momomura K, Tobe K, Seyama Y, Takaku F, Akanuma Y and
71
Kasuga M 1987), from which later was cloned the Insulin Receptor Substrate-1 (IRS-1) 
(Xiao JS, Rothenberg P, Kahn RC, Backer JM, Araki E, Wilden PA, Cahill DA, 
Goldstein BJ and White ME 1991). The resulting auto-phosphorylation (P) of the insulin 
receptor on tyrosine (Tyr) residues increases the association of various signaling 
molecules, which also includes IRS-2. Insulin receptor directly phosphorylates IRS-2 on 
multiple tyrosine residues, which, in turn, initiates a variety of second messenger 
cascades. Recent work has demonstrated a critical role for IRS-2 in the maintenance of 
peripheral insulin sensitivity, central leptin sensitivity, and proper p cell development in 
the islets of Langerhans (Lin X, Taguchi A, Park S, Kushner JA, Li F, Li Y and White 
MF 2004; Kubota N, Terauchi Y, Tobe K, Yano W, Suzuki R, Ueki K, Takamoto I, 
Satoh H, Maki T, Kubota T, Moroi M, Okada-Iwabu M, Ezaki O, Nagai R, Ueta Y, 
Kadowaki T, and Noda T 2004). Thus, IRS-2 plays a central role in preserving insulin 
action in multiple cell types, while reduction of 1RS expression and/or function may be a 
fundamental cause of the development of insulin resistance, obesity, B-cell failure, and 
type-2 diabetes (Brady 2004).
PI3-Kinase is a heterodimeric enzyme composed of regulatory (p85) and catalytic 
(pi 10) subunits, which catalyzes the phosphorylation of phosphor-inositol-4-phosphate 
(PI-4-P) and phosphatidylinositol-4-5-diphosphate (PI-4-5-P2) to produce 
phosphatidylinositol 3-phosphate (PI-3-P), phosphatidylinositol 3-4 diphosphate (PI-3-4 
P2) and phosphatidylinositol 3-4-5-triphosphate (PI-3-4-5-Ps). This implies that IRS-1, in 
its phosphorylated form regulates insulin signal transmission by acting as a docking 
protein binding to and regulating intracellular enzymes containing SH-2 domains. It is
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worth noting that type lA  and type IB PISKinases have different functions in the p-cell. 
The catalytic subunit of type lA  PI3 kinases, which are regulated by tyrosine kinase 
receptors, is one of three pllO  isoforms (a, p, and 5). These associate with one of five 
regulatory subunits; p50-a, p55-a, and p85-a, resulting from alternative splicing of a 
single gene; and p55-y and p85-p. The only type IB isoform of PI3 kinase, called pllO-y, 
associates with the plOl regulatory subunit and is activated directly by G-protein coupled 
receptors (GPCRs) through an interaction with G-py. Like other PI3 kinases, pllO-y 
phosphorylates phosphatidylinositol 4, 5-bisphosphate [PtdIns(4,5)P] to generate 
PtdIns(3,4,5)P in vivo and subsequently activates numerous downstream targets including 
3-phosphoinositide-dependent kinase-1, Akt, protein kinase C-Ç and p70S6 kinase 
(Macdonald PE, Joseph WJ, Yau D, Diao J, Asghar Z, Dai F, Gudit GY, Patel MM, 
Backx PH and Wheeler MB 2004).
Inactivation of IRS-1 {IRS-1-/-) leads to mild insulin resistance, 
hyperinsulinaemia, and P-cell hyperplasia with no overt diabetes syndrome (Kahn 1998). 
In contrast, inactivation of IRS-2 {IRS-2-/-) results in B-cell failure and causes type 2 
diabetes (Kulkami RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D, Kahn 
CR 1999a; Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Prévis S, Zhang Y, 
Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF 1998). In B-cells stably 
overexpressing twofold IRS-1, Ca '^^  homeostasis was perturbed, with an increase in 
cytosolic Ca^ "^  and increased insulin secretion (Xu 1999). Further investigation revealed 
that the increase in cytosolic Ca^^ was due to inhibition of sarco-(endo)-plasmic 
reticulum Ca^^-ATPase (SERCA), a protein responsible for Ca^ "^  uptake into the
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endoplasmic reticulum (ER) lumen. In isolated mouse islets, insulin treatment of islets 
caused an increase in intracellular Ca^ "^  within minutes, with concomitant insulin 
exocytosis (Aspinwall et al 2000). In addition, studies with a B-cell-specific insulin- 
receptor knockout mouse and 1RS-1-deficient B-cell lines show that glucose-induced 
insulin secretion is lost under those conditions (Kulkami et al 1999a). Abnormal 
intracellular concentration of calcium ([Ca^^i) is a common defect in both type 1 and 
type 2 diabetes (Prentki 1997; Aspinwall et al 2000; Xu 1999). It was shown that IRS-1 
regulates B-cell Ca^^ homeostasis, insulin biosynthesis, and B-cell proliferation, and that 
elevated expression of IRS-1 induces abnormal Ca^ "^  homeostasis and B-cell dysfunction 
(Mattson MP 2001). This was further supported by immuno-electromicroscopic and 
coimmunostaining experiments, which presented a strong case for the presence of IRS-1 
on endoplasmic reticulum membrane of B-cell lines. Considering the dynamic nature of 
insulin receptor signaling, it is possible that 1RS proteins translocate to several locations 
in the cell in response to upstream signals. However, the majority of both phosphorylated 
and non-phosphorylated 1RS proteins are maintained in intracellular membranes. 1RS 
proteins in this pool can interact with other proteins in the same location and potentially 
form large protein complexes that are insoluble in detergents. An example of this comes 
from one study reporting that IRS-1 can bind to the a-3A subunit of the AP-3 adaptor 
protein complex, resulting in intracellular membrane localization (VanRenterghem B, 
Morin M, Czech MP and Heller-Harrison RA 1998). The localization of 1RS proteins to 
the ER increases the likelihood of a direct interaction with SERCA isoforms in P-cells. 
Therefore, the existence of a novel positive-feedback pathway in which insulin can 
regulate insulin secretion in pancreatic B-cells seems to play major role in the events of
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glucose homeostasis. A key component of this pathway is interaction between IRS-1 and 
SERCA, which regulates intracellular Ca^ "^ . IRS-1 is present in the ER and can directly 
bind to the p-cell isoforms of SERCA, specifically SERCASb. Insulin stimulation results 
in increased binding of IRS-1 to SERCASb, which inhibits the Ca^^-ATPase, increases 
cytosolic Ca^^, and augments fractional insulin secretion. Importantly, this positive- 
feedback loop on insulin secretion is dependent on the presence of glucose. In addition, 
PI3Kinase combines with other intracellular second messenger for a broad array of 
effects, which includes the Ras effector molecule. Known effectors of Ras signaling 
pathways include the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, Raf-MEK-Erk 
kinase cascade, some protein kinase C isoforms, Ral-GDS family members, and AF-6, 
Norel, Mekkl and Rinl (Boettner B and Van Aelst L 2002).
1.8 Action of leptin on B-cells
 -The pancreatic islets (B-cells) of m ice have been used to investigate the
effect of leptin on insulin secretion, as up-regulation of leptin receptor numbers in this 
model leads to greater sensitivity to exogenous leptin. Treatment of lean animals with 
leptin leads to a reduction in serum glucose usage during euglycaemic clamp 
(Chinookoswong 1999). These effects are also seen after acute intracerebroventricular 
(i.c.v) infusion of leptin into laboratory animals, which leads to a significant increase in 
glucose turnover without altering the plasma insulin concentration (Weigle DS, 
Bukowski TR, Foster DC, Holderman S, Kramer JM, Lasser G, Lofton-Day CE, 
Prunkard DE, Raymond C and Kuijper JL 1995; Elias et al 1998) by increasing insulin
75
sensitivity; this appears to be mediated partly by the central nervous system (Kamohara 
S, Burcelin R, Halaas JL, Freidman JM and Charron MJ (1997). Since the B-cells of 
normal rodents are chronically exposed to leptin, they may be relatively less responsive 
under acute experimental conditions (Sivitz WI, Walsh SA, Morgan DA, Thomas MJ and 
Haynes WG 1997).
Patch-clamp electrophysiological analyses on both normal and ob/ob mouse B- 
cells show that the application of leptin to single mouse B-cells results in 
hyperpolarization, consistent with the opening (activation) of ATP-sensitive K-channels 
(K -atp channels) (Ashcroft and Rorsman 1989) to produce an inhibitory action on insulin 
secretion (Harvey and Ashford 1998). A leptin-induced increase in membrane 
conductance and hence hyperpolarization as a result of K - atp channel activation is further 
supported by the observations that the leptin response is sensitive to the application of the 
sulphonylureas, tolbutamide and glibenclamide, selective blockers of K - atp channels 
(Harvey and Ashford 1998). Leptin increases the K - atp open-channel probability with no
significant effect on open times. These observations suggest that leptin suppresses insulin 
secretion during fasting, when ambient insulin levels are low. However, during feeding, 
the resultant increase in intracellular insulin concentration inhibits the opening of K - atp  
channels by leptin, thus reversing the inhibition of insulin secretion. Such a model could 
explain in part the apparent resistance to leptin actions observed in obese individuals who 
are typically hyperinsulinaemic even during fasting (Fournier LA, Begin-Heick N, 
Whitfield JF and Schwartz JL 1992).
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Culture of isolated islets with leptin depletes the TAG content and increases the 
oxidation of NEFA (Branstrom R, Corkey BE, Berggren PO and Larsson O 1997). The 
latter may be related to the induction of UCP-2 and UCP-3 in WAT and skeletal muscle 
by leptin. This action seems to be dependent on the formation of fatty acyl-CoA. 
Remarkably, long-chain acyl-CoA esters (LC-CoA), the metabolically active form of 
NEFA, binds to and may open K - atp channels in pancreatic B-cells. Therefore, it is 
possible that elevations in LC-CoA within B-cells after exposure to leptin result in 
activation of K -atp channels and thereby inhibition of insulin secretion.
Leptin significantly reduced insulin release from the perfused pancreas of ob/ob 
mice, a standard, reliable model to assess islet function (Fehmann et al 1997b). In 
addition, leptin inhibits basal insulin secretion in perfused pancreas studies, in 
hyperinsulinaemic ob/ob mice but not Zucker fa/fa  rats (Rohner-Jeanrenaud 1998). In 
addition, leptin inhibits glucose-induced insulin secretion in isolated islets from ob/ob 
and wild-type mice but not in those from db/db mice (Fehmann et al 1997b). Notably, on 
ob/ob islets, the suppressive effect of leptin may be reduced at higher glucose levels, and 
is absent in the presence of the incretin hormone GLP-1 (Drucker 1987). One explanation 
for this observation is that leptin acts primarily during fasting to dampen insulin secretion 
and that this tonic inhibition is overcome by the nutrient and incretin signals (GLP-1) that 
accompany feeding.
Both feeding and administration of CCK-8 (the biologically active carboxy- 
terminal polypeptide of cholecystokinin) results in rapid and large decrease in both
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intracellular leptin immunoreactivity and the leptin content of the fundic epithelium 
(Bado et al 1998), with a concomitant increase in the concentration of leptin in the 
plasma (Matson 1997). These results indicate that gastric leptin may be involved in early 
CCK-mediated effects activated by food intake, possibly including satiety.
Leptin attenuates insulin release from ob/ob islets stimulated by acetylcholine or 
phorbol ester, both activators of Protein Kinase C (PKC) (Chen 1997). The finding that 
leptin curtails acetylcholine-induced insulin secretion may in part explain why islets from 
leptin-deficient ob/ob mice have enhanced sensitivity to PKC-stimulated insulin secretion 
(Kieffer 1997). In contrast to B-cells of leptin-deficient ob/ob mice, the B-cells in normal 
rodents are continuously exposed to leptin and therefore may be expected to be less 
sensitive. Overall, the reports regarding the effect of leptin on insulin secretion in normal 
rodents are conflicting. However in the majority of the studies, leptin significantly 
reduced insulin release from perfused mouse pancreas and isolated rat or mouse islets in 
the presence of low, normal, or high glucose concentrations (Morton 1999; Ahren B and 
Havel PJ 1999; Poitout 1998, Cases et al 2001).
Insulin secretion stimulated by agents that elevate cellular concentrations of 
cAMP, such as glucose + IB MX, a phoshodiesterase inhibitor, or forskolin and GLP-1, is 
inhibited by leptin during both static incubations and perifusion of mouse or rat islets 
(Ahren and Havel 1999). These observations suggest that in normal rodents, leptin 
antagonizes cAMP signalling. On the other hand, leptin within the physiological range 
{ca. lOng/ml) was introduced to isolated islets from normal Wistar rats, incubated with
78
16.7mM glucose, and showed no alteration of the basal insulin nor the insulin secretion 
stimulated by glucose alone (Ceddia 1999). Although Kieffer et a l (2000) showed that 
the effect of leptin in islets from ob/ob mice is mediated through activation of ATP- 
sensitive potassium channels in B-cells, leptin (20ng/ml) had no effect on insulin 
secretion stimulated by glucose (16.7mM). This does not support the K^ channel 
mechanism of action. Leptin also suppresses the elevations of cellular c-AMP levels that 
occur in response to exposure of B-cells to GLP-1 or to forskolin (Ahren and Havel 
1999). A mechanism proposed to explain this action of leptin on c-AMP levels is 
phosphoinositide-3-kinase-dependent activation of phosphodiesterase-3B, and subsequent 
reduction of the intracellular cAMP. Notably, leptin restrains insulin secretion from both 
mouse ob/ob islets, and rat islets induced by phorpbol Myiistate acetate (PMA), a PKC 
activator. Therefore, it appears that leptin may antagonize insulin secretion from p-cells 
by interacting with both cAMP-dependent Protein Kinase-A (PKA) and PKC signaling 
pathways (Fehmann 1997a).
Leptin stimulates sympathetic activity when given by intraperitoneal, intravenous, 
or intracerebro ventricular injection (Mizuno 1998). Rasing the sympathetic tone reduces 
both basal and glucose-stimulated insulin secretion (Howland RJ, Baroody GM 1982), 
suggesting that leptin may modulate pancreatic endocrine functions through activity of 
the sympathetic nerve endings around the pancreatic endocrine cells.
The effect of leptin on insulin secretion has also been investigated in various B- 
cell lines derived from islet cell tumor (insulinomas) (Harvey and Ashford 1998). The
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results obtained in different insulinoma cell-lines have been contradictory and less 
consistent than those of cultured islets and the perfused pancreas. In the rat insulinoma 
cell-line INS-1, leptin significantly reduced insulin secretion stimulated by agents that 
increase intracellular content of cAMP, but not insulin secretion stimulated by activators 
of PKC (Ahren and Havel 1999). These latter observations suggested that, in the INS-1 
cell-line, the cAMP-PKA signal transduction pathway is a target by which leptin may 
inhibit insulin secretion.
Protein phosphorylation of tyrosine residues underlies actions of leptin in CRI-Gl 
cells. Furthermore, inhibition of tyrosine kinase activity by application of genistein, 
tyrphostin, or herbimycin mimics leptin-induced hyperpolarization and increase in K^ 
conductance (Harvey 1997). Therefore, the mechanism underlying the opening of K -a tp  
channels by leptin may involve inhibition of tyrosine kinase or activation of tyrosine 
phosphates and subsequent tyrosine dephosphorylation. Because the opening of K -a tp  
channels by leptin is blocked by wortmannin, an inhibitor of PI-3 kinase, the mechanism 
underlying leptin activation of K -a tp  channels appears to involve dephosphorylation of 
cytosolic proteins before activation of PI- 3 Kinase (Scherer PE, Bickel PE, Kotler M and 
Lodish HE 1998). These findings suggest that the inhibitory actions of leptin on insulin 
secretion are primarily mediated through the PI-3 Kinase-dependent activation of 
phosphodiesterase-3B (PDE3B) and a subsequent reduction of the intracellular cAMP. 
Because cAMP potentiates insulin secretion in part by closing (inactivating) K - a t p  
channels, a reduction of cAMP by leptin is consistent with the activation of K - a t p  
channels by leptin.
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1.9 Study objectives
In order to fulfill the objectives of this study, the perfused rat pancreas, using the 
ex-vivo technique, was used. Leptin, as a potential modulator of insulin, was prepared in 
the laboratory by the batch culture method with amendments of the technique originally 
developed by Qiagen (Qiagen 1997). Various concentrations of leptin were introduced 
with variable concentrations of glucose covering the spectrum from fasting to 
hyperglycemia, and its effects on insulin secretion was assessed using insulin 
radioimmunoassay. This would give a clear idea of how leptin might modulate insulin 
secretion at the glucose concentrations covering fasting up to hyperglycemia. 
Furthermore, in view of the uncertainty regarding the existence vascular connections 
existing between the duodenum and the pancreas, a subsidiary experiment was carried 
out to investigate the potential direct connection between these organs.
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2. Materials and Methods
2.1 Introduction
The purpose of the experiments reported here was to derive an index whereby the 
effect of leptin on the production of insulin in the ex vivo perfused rat pancreas could be 
investigated. The primary step was to obtain relatively pure fresh recombinant leptin in 
sufficient amounts to cover all the different experimental designs. A perfusion apparatus 
previously obtained from the University of Surrey, Guilford, U.K., which consisted of a 
water bath, two oxygenators each with a motor fitted to provide continual rotation of a 
nylon mesh oxygenation screen inside. The apparatus was redesigned by adding a locally 
assembled surgery platform fitted onto the setup, for ex-vivo perfusion experiments. A 
control set of experiments was performed to establish a base line for insulin secretion rate 
of various glucose concentrations, after which similar experimental series were 
conducted with the combination of four different concentrations each of glucose and 
leptin. In order to check the fasting glucose concentration blood was routinely obtained 
from a tail vein before each perfusion.
2.2 Expression and isolation of leptin in E.coli
Leptin, the hormone product of the ob-gene produced mainly from the adipose 
tissue, was recombinantly expressed in E. coli using a p u d  9-rat ob plasmid and a stab 
culture of E. coli SG13009 [pREP4] [pQE30-rat ob] expressing histidine-tagged rat leptin 
(his-tag rat leptin), the generous gift of Dr Takashi Murakami, Department of Cellular
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and Molecular Function Analysis , Graduate School of Medicine, Kanazawa University, 
Takaramachi 13-chome, Kanazawa-city 920-8640, Japan. The E. coli strain mentioned 
above, hosted the pQE vector, which included the p-lactamase gene conferring resistance 
to ampicillin. The pREP4 plasmid conferred resistance to kanamycin and constitutively 
expressed the lac repressor protein encoded by the lad  gene. Multiple copies of pREP4 
were present in the host cells and ensured the production of high levels of the lac 
repressor protein, which binds to the operator sequences and tightly regulates 
recombinant protein expression. Expression of recombinant proteins encoded by the pQE 
vectors was rapidly induced by the addition of isopropyl-P-D-thiogalactoside (IPTG), 
which bound to the lac repressor protein and inactivated it. Once the lac repressor is 
inactivated, the host cell’s RNA polymerase could transcribe the sequences down stream 
from the promoter. The transcripts produced were then translated into the recombinant 
protein. The special double operator system in the pQE expression vectors, in 
combination with the high levels of the lac repressor protein generated by the pREP4, 
ensured tight control at the transcriptional level. The general procedures employed here 
were modifications of the protocol given in the QIA-Expressionist Handbook (Qiagen 
1997).
Small-scale (250ml) expressions and purifications were performed before 
proceeding with the large-scale (6-litres) preparation. The eukaryotic protein expressed 
intracellularly in E. coli is believed to be sequestered into insoluble inclusion bodies due 
to the high transcriptional rate of the promoters involved in the plasmid hosted by the 
bacteria. In addition, the intracellular association of hydrophobic domains during folding
83
is believed to play a critical role in the formation of inclusion bodies. The 6-His tagged 
proteins in insoluble inclusion bodies could be easily solubilized with dénaturants such as 
6M guanidine-HCl or 8M urea and thus purified on Ni-NTA agarose, which ionically 
binds to the histidine tag.
Nitrilotriacetic acid (NTA), exclusively available from QIAGEN, was a 
tetradendate chelating absorbent. NTA occupies four of the six-ligand binding sites in the 
coordination sphere of the nickel ion, leaving two sites free to interact with the 6xHis tag 
as shown in the computer generated Figure 4 below.
6xEüs lag îesin
Figure 4: Interaction between Ni-NTA and 6xHis tagged protein (from 
The Expressionist (Qiagen 1997)
Reagents used in the production, isolation and purification of rat leptin are shown in
Table 1 overleaf.
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Reagent Composition
Luria broth: • lOg/L bacto-tryptone in water
• 5mg/L bacto-yeast extract
• 5mg/L NaCl
Lysis buffer: 
pH 8.0
• 50mM NaH2? 0 4 , pH=8 ,
• 300mM NaCl;
• lOmM imidazole
Elution buffer:
pH 6 . 8
• 50mM NaH2? 0 4 , pH=8 ;
• 300mM NaCl;
• 250mM imidazole
5 X SDS-PAGE sample buffer: 
pH 7.4
• 15% P-mercaptoethanol,
• 15% Sodium dodecyl sulphate,
• 1.5% bromophenol blue,
• 50% glycerol.
Kanamycin Stock Solution: • 25mg/ml in water, sterile filter, 
store in aliquots at -20°C.
Ampicillin Stock Solution: • lOOmg/ml in water, sterile filter, 
store in aliquots -20°C.
IPTG (IM): • 238 g/ml in water, sterile filter, 
store in aliquots at -20°C.
Buffer A 
pH 8.0
• 6 M guanidine-HCl,
• 0.1MNaH2?O4,
• 0.01 M Tris-HCl, pH8
• 0.5% Tween 20,
• lOmM P-mercaptoethanol.
Buffer B 
pH 8.0
• 8 M urea,
• 0.1MNaH2?O4,
• 0.01 M Tris-HCl,
• 0.5% Tween 20 (v/v)
• lOmM P-mercaptoethanol.
Sonication Buffer 
pH 7.8
• 50mM NaHP0 4 , pH=7.8.
• 0.3M NaCl.
Regeneration buffer
pH 7.4
• 6 M guanidine-HCl in 0.2M acetic 
acid
Phosphate Buffer Saline 
pH 7.4
• 8 g NaCl
• 0 .2 g K2HPO4
• 1.15g NaH2P04
• 0 .2 g sodium azide
Table 1: Reagents used in the expression and purification of leptin
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The culture was incubated, overnight, in autoclaved Luria Broth medium (12ml) 
enriched with glucose (2% w/v), to which ampicillin (lOOpg/ml) and kanamycin 
(25pg/ml) at 37°C were added. Luria broth (500ml) medium with the same concentration 
of antibiotics was inoculated with 12ml of the first culture. The culture was incubated 
with vigorous shaking (300rpm), until the O.Dgoo was between 0.8-1.0. A 1ml sample, 
the non-induced control, was taken immediately before induction, centrifuged and the 
cell pellet suspended in 50pl 5XSDS-PAGE sample buffer and frozen at -20°C until 
needed for SDS-PAGE analysis.
Isopropyl-p thiogalactopyranoside (IPTG) was added to a final concentration of
O.lmM to activate the plasmid holding the ob gene, by binding to the intracellular lac 
repressor protein and inactivating it. It was left to shake for 5 hours after which a second 
1ml sample (induced control) was collected, cells pelleted, and suspended in 50pl 
5XSDS-PAGE sample buffers and frozen at -20°C until use.
The cells were centrifuged for 10 min at 8000 x g (4°C) after the activation phase 
with IPTG. The pellet was washed with phosphate buffer saline (pH 8.0) and stored at - 
20°C overnight. The cells were thawed and re-suspended in sonication buffer (50mM 
NaHP0 4 , 0.3M NaCl, pH 7.8) at 2-5ml per gram-wet weight (wet volume of bacteria X 
3). The sonication buffer contained lOmM imidazole to minimize the binding of 
untagged, contaminating proteins to the Ni-NTA and increased the purity with fewer 
steps of sonication. Lyzozyme was added at a concentration of lOpg/ml and the
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preparation was incubated on ice for 60 min, after which Tween 20 was added (0.02%) to 
aid in removing background proteins and nucleic acids.
Three 6-pulse sonication steps using a microtip probe (200W) were made with 
each pulse lasting for 10s. The lysates were kept on ice at all times in order to prevent 
over heating and risk of degeneration of the lysed out leptin.
After the first sonication step, the lysates were centrifuged at 10000 x g for 30 
min to separate the soluble proteins (saved on ice) from the inclusion bodies. 5pl 2X 
SDS-PAGE sample buffer were added to 5pi supernatant and stored at -20°C for SDS- 
PAGE analysis.
The remaining sonication steps were to concentrate the inclusion bodies by 
centrifugation at 10000 x g for 20 min and to lyse any cells left intact. To the wet volume 
obtained, 6 volumes of buffer-A (6M guanidine-HCl, O.IM NaH2P0 4 , 0.01 M Tris-HCl, 
pH 8, 0.5% Tween 20, lOmM p-mercaptoethanol) were added, and mixed well on a 
rotating plate (40 rev/min) at 4°C. The lysates were centrifuged with at 9000 x g at 4°C 
for 20 min. The supernatant was added to 50% Ni-NTA agarose slurry pre-washed with 
buffer A and mixed by rotating (200rpm) at 4°C for 20 min.
The 6 consecutive histidine residues (6xHis tag) found on the expressed hormone 
leptin show a remarkable selectivity and affinity for the patented nickel-nitrilotriacetic 
acid (Ni-NTA) metal-affinity chromatography matrices. The 6x His tag had a
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conformation independent interaction with Ni-NTA matrices, uncharged at physiological 
pH, and poorly immunogenic. Hence the tag did not interfere with the structure of the 
recombinant protein leptin, and could be potentially purified in a one-step procedure with 
mild elution conditions.
The mixture was added to a Ni-NTA column with the bottom outlet capped. The 
cap was removed and the flow was collected and saved for SDS-PAGE analysis. Three 
washing steps were performed consisting of 300ml buffer A (pH 8), 200ml buffer B (pH 
8) (8M urea, O.IM NaH2P0 4 , 0.01 M Tris-HCl, 0.5% Tween 20,10mM P- 
mercaptoethanol), and 200ml buffer B (pH 7.1). Imidazole (O.IM) was added to buffer B 
(pH=8) to elute the column after which p-mercaptoethanol (lOOmM) was added and the 
column closed for one hour.
Leptin was refolded by sequential dialyses, using 12-14K MYCE dialysis bags, 
against urea in four stages, each of three hours, from 3M to 0.5M urea with 10% glycerol 
in PBS in the following sequence: 3M urea to 2M urea, to 1.5M urea, to IM, to 0.5M 
urea, and finaly to OM urea. This was followed with dialysis against PBS in four stages 
each for three hours. The lysates were centrifuged at 10000 x g at 4°C for 20 min. Buffer 
A and p-mercaptoethanol (lOOmM) were added and kept for one hour, after which the 
same dialysis procedure was repeated.
Since the yield of the leptin was relatively low to the amount required in the 
experiments designed, graded centrifugation of the lysate was carried out with
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incremental speeds, in steps of 1000 rpm, to reach 10000 rpm, to concentrate the 
inclusion bodies and subject them to the sequential refolding cycles.
Leptin yields and purity were assessed using Lowry method and polyacrylamide 
gel electrophoresis respectively as described below.
2.3 Sodium-dodecylsulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE)
Sodium-dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
low cost, reproducible, and rapid method for quantifying, comparing, and characterizing 
proteins. The method separates proteins based primarily on their molecular weights. SDS 
binds to the hydrophobic portion of the protein, disrupting its folded structure and 
allowing it to exist stably in solution in an extended conformation. As a result, the length 
of the SDS-protein complex is proportional to its molecular weight thus showing a linear 
relationship between the migration speed and the charge density.
There are two types of buffer systems in electrophoresis, continuous and 
discontinuous. A continuous system has only a single separating gel and uses the same 
buffer in the tanks and the gel. In a discontinuous system, a non-restrictive large pore gel, 
called a stacking gel, is layered on top of a separating gel called a resolving gel. Each gel 
is made with a different buffer, and the tank buffers are different from the gel buffers.
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The resolution obtained in a discontinuous system is much greater than that obtained with 
a continuous system.
In polyacrylamide gels, the higher the concentration of acrylamide, the smaller 
the pore size. As a result, in a gradient polyacrylamide gel, acrylamide concentration 
increases as the proteins migrate from the origin resulting in the more accurate and 
sharper separation of a wide range of protein sizes than usually is possible with a single 
concentration gel.
Following SDS-PAGE separation, the protein bands were visualized directly on 
the polyacrylamide gel using Coomassie Blue staining. The stain was made up of 
Coomassie Brilliant blue consisting of variable ratios of: methanol : water : acetic acid. 
The gel was covered with staining solution, sealed in a special container and left 
overnight on an automated shaker after which it was destained with 25%:65%:10% 
methanol: water: acetic acid solution with agitation. Usually 0.2-0.5pg of any protein can 
be detected in a sharp band and staining is quantitative up to 15-20pg for at least some 
proteins.
2.3.1 Materials: S tock Solutions
a. Sample buffer (Two-fold Concentration). 20ml glycerol was added to 
1.5g Tris dissolved in 35ml of distilled water and pH adjusted to 6.75 with 
12M HCl following with 10ml of 2-mercaptoethanol, 4g of SDS and 2mg
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of bromophenol blue were added and diluted with distilled water to a final 
volume of 100ml.
b. 3M Tris buffer (pH8.8). 36.3g Tris was dissolved in about 80ml distilled 
water; the pH was adjusted to 8.8 with 12M HCl. Distilled water was 
added to a final volume of 100ml. This solution was stable for several 
weeks at 4°C.
c. 0.5M Tris buffer (pH 6.8). 6.02g Tris was dissolved in approximately 
90ml distilled water. The pH was adjusted to 6.8 with 12 M HCl and the 
final volume was made up to 100ml with distilled water. This solution was 
stable for several weeks at 4°C.
d. Urea/SDS/dithiothreitol Solution. 38.4g urea, 24.6mg dithiothreitol and
0.16g SDS were dissolved in 50ml of distilled water and the final volume 
was made up to 80ml.
e. 1.5% ammonium persulphate solution. 0.15g of ammonium persulphate 
was dissolved in 10ml of distilled water.
f. Electrode buffer (pH 8.3). 42.6g glycine, 9.18g Tris and 3g SDS were 
dissolved in 3L distilled water.
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g. Protogel. 30g acrylamide and 0.8g N,N’-bisacrylamide were dissolved in 
approximately 70 ml of distilled water; final volume was adjusted to 
100ml.
2.3.2 Gel preparation
Linear gradient (5-20%) polyacrylamide gels were prepared as previously 
modified (Daher 1998) where 5% acrylamide resolving gel and 20% acrylamide 
resolving gel were prepared as shown in Table 2 overleaf. The formulations presented 
provided final gel concentrations as shown in Table 3 overleaf.
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Material
Resolving gel
Stacking Gel
5% 20%
Sucrose ---- 6.75g
Tris-HCI 5.55ml 5.55ml 3.75ml
Protogel 7.50ml 30.0ml 1.85ml
Urea/SDS/dithiothreitol 4.50ml 0.45ml 0.30ml
1.5% Ammonium persulfate 1.05 ml 1.05ml 1.15ml
Water 30.30ml 4.05ml 7.50ml
Table 2: Reagent volumes of gel mixtures for the 5-20% gradient gel for protein 
electrophoresis
Material
Resolving gel
Stacking Gel
5% 20%
Sucrose ---- 0.438M
Tris-HCI 0.340MpH8.8 0.370MpH8.8 0.123MpH6.8
Dithiothreitol 0.149mM 0.016mM ImM
Urea 0.588M 63.3mM 4mM
SDS 0.52mM 0.055mM 3.5mM
Ammonium persulfate 1.4mM 1.5mM 4.4mM
Table 3: Final compositions of resolving (5%-20%) and stacking gels used here in SDS- 
PAGE
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To initiate polymerization, immediately before pouring the resolving gels, 34.5pl 
tetramethylethylenediamine (TEMED) was added. The 20% and the 5% solution were 
placed in two mixing elemnyer flasks with a magnetic stirrers to prevent the gels from 
solidifying. Using a micro-pipette, 3.5ml volumes of 5% gel were manually poured into 
the 20% gel flask, mixed gently, and the same volume of taken from the 20% gel flask 
and poured into the setup’s gel container. This task was repeated until all the gel finished. 
This procedure resulted in forming a 5-20% concentration gradient in the gel container, 
with an ascending graduation of gel concentrations from start point to end point of the 
container. The gel was then over-layered with water-saturated butanol and left for 45min 
to allow polymerization to take place. After 45 min the water-saturated butanol was 
discarded and the gel top rinsed several times with distilled water. Remaining water 
droplets were removed with a filter paper.
Just before pouring the stacking gel, 11.25pl TEMED was added. The stacking 
gel was placed on top of the resolving gel. Immediately, a ten-well comb was inserted 
and the gel left to polymerize. After 30 min, the upper and lower electrode chambers 
were filled with electrode buffer and the comb carefully removed.
2.3.3 Preparation of sam p les for electrophoresis:
One volume of sample was mixed with three volumes of sample buffer in an 
Eppendorf tube and heated at 95°C for 5 minutes to denature the proteins. The tubes were
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centrifuged at 16000 x g for 4 minutes to separate any insoluble material. Molecular 
weight markers (Sigma Chemical Co. Ltd.) were dissolved in sample buffer according to 
the supplier’s instructions, aliquoted and stored at -80°C. Just before use, the molecular 
weight aliquots were thawed and treated as for samples described above. 20pl of 
molecular weight marker solution was loaded into the middle gel lane with a gel loading 
tip.
2.3.4 E lectrophoresis
After loading the samples, the lid of the upper chamber was fitted and the water 
cooling system switched on. The power supply (Amersham Pharmacia Biotech) was 
turned on and electrophoresis was carried out at 30mA until the bromophenol blue 
marker reached the resolving gel after which the current was raised to 60 mA. Four hours 
later, the power was switched off, the gel removed and the automated staining procedure 
with Coomassie Blue commenced. The protein staining solution was prepared by 
dissolving Coomassie Blue R-250 (0.1% w/v) in water: methanol: glacial acetic acid 
(5:5:2 by volume). The solution was filtered (Whatman No. 1 filter paper) to remove any 
insoluble material before use.
The gel was rinsed for a few seconds in distilled water to remove excess SDS and 
placed in an automated stainer/destainer (Amersham Pharmacia Biotech, Processor Plus 
80-6444-04) at room temperature, over night supplied with a shaker that kept the fluids
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equally distributed around the gel in the container. The program consisted of rinsing with 
distilled water, followed by staining for 6 h, rinsing with distilled water, and destaining 
(10% alcohol, 30% methanol, and 60% distilled water) over four steps for 10 h.
2.4 Experimental Animals
The animals used were Wistar albino rats (Rattus norvegicus). Animals were 
maintained according to, and experimental protocols complied with, the Guide for the 
Care and Use of Laboratory Animals (National Research Council of the United States 
1985). The rats were all males because of their less variable endocrine physiology 
through their life span as compared to female rats. The average age of the rats was three 
months at the time they were selected for experimentation, and their mean weight was 
200 ± 3.6g (SEM). The rats were separated into two principal categories:
a) Control rats.
b) Experimental Rats.
The control rats were used to establish the base line insulin production. Rats, with 
average weight of 200 ± 3.2g were kept in cages (20cm x 40cm x 60cm) in the animal 
house, with a constant room temperature of 21°C, and with regular twelve hour light/ 
dark cycles starting at 6:00am. They were given standard rat chow (Hawa Chicken, Jbeil, 
Lebanon) consisting of 64% carbohydrate, 30% protein, and 6% fat with an energy 
density of 4.3 kcal/g, and water ad libitum. Before perfusion, the rats were put on a 
twenty four hour fast in separate clean cages with water ad libitum. Thirty two rats, 8 rats 
per group, were sacrificed to establish the base-line insulin secretion profiles for the four
96
concentrations of glucose used (4, 8, 12, and 16mM). Body weights of fasted rats were 
significantly lower than fed rats, showing a mean weight loss of ca 10% to 180 ± 6.5g 
(SEM) after fasting. In all the rats used, the fasting blood glucose, taken by tail vein 
puncture (see below) ranged between 4 and 4.4 mM as tested by SGM-Italia kit.
The experimental group of rats was prepared under the same conditions as the control 
group for the experiments. In total, 76 rats were sacrificed for the experimental section 
where four rats were used for each experimental design which consisted of principal 
variables, the concentration of D-glucose and the concentration of leptin administered. 
The different combinations of glucose and leptin concentrations are displayed in Table 4 
below.
5ng/ml Leptin lOng/ml leptin 15ng/ml leptin 20ng/ml leptin
4mM glucose 4mM-5ng/ml 4mM-10ng/ml 4mM-15ng/ml 4mM-20ng/ml
8mM glucose 8mM-5ng/ml 8mM-10ng/ml 8mM-15ng/ml 8mM-20ng/ml
12mM glucose 12mM-5ng/ml 12mM-10ng/ml 12mM-15ng/ml 12mM-20ng/ml
16mM glucose 16mM-5ng/ml 16mM-10ng/ml 16mM-15ng/ml 16mM-20ng/ml
Table 4: Overall design of the perfusion experiments showing the concentrations of 
leptin (ng/ml) and glucose (mM) perfused in 24 hour fasted rats.
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2.4.1 Tail vein blood sam pling
Tail bleeding provided easy and fast access to blood in order to assess and 
evaluate the level of glucose after a 24-hour fasting period and before the perfusion was 
carried out. The rat was removed and placed in a restraining device prepared for this 
purpose on a waist-high bench with its tail draped over the edge into a beaker of hot 
water (60°C) until the lateral veins appeared under the skin of the tail. The tail was gently 
twisted to expose the lateral vein and then pressure was put on the base of the tail to act 
as a tourniquet. The lateral tail veins were usually Clearly visible, but occasionally it was 
helpful to clean the tail with a damp swab. A butterfly needle was gently introduced 
(0.6mm) into the vein parallel to the skin surface at a shallow angle, while holding the tail 
with the left hand, and about two-thirds the distance down the tail. The tourniquet was 
released allowing blood to flow freely once the needle was in the vein.
Successful entry in the vein was accompanied by a flow of blood. During 
collection, the cut end of the butterfly needle was allowed to touch the collecting vessel 
as adhesive forces with the wall of the container promoted blood flow. Removal of the 
needle and light finger pressure prevented further bleeding. Repeated samples of blood 
could be obtained by repeating the procedure while using a slightly more anterior portion 
of the vein, or using the contralateral vein.
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2.4.2 Preparation of the pancreas for ex-vivo perfusion
2.4.2.1 General principles of pancreas organ perfusion
The perfusion technique was originally designed by Anderson and Long 
(Anderson E and Long JA 1947) for the rat pancreas and later modified by Sussman, 
Grodsky and Baroody and Howland. Sussman et al presented a preparation that consisted 
only of the pancreas or of the pancreas together with the duodenum, the latter 
corresponding to the preparation used by Lundquist et al. A similar procedure was 
developed by Baroody and Howland, with modifications to fit the diversity of the 
experimental requirements designed. Principally two different types of pancreas 
preparations have been used with both their advantages and disadvantages. The 
preparation frequently used was the pancreas isolated together with stomach, duodenum, 
and spleen and adopted for rat as well as mouse pancreas perfusions. This preparation has 
advantages compared with the completely isolated pancreas.
a) The isolation procedure is less time consuming, implying reduced harm to the 
preparation.
b) Catheterization of the portal vein is more easily performed. It is worth noting 
that a portal venous catheter is of utmost importance because venous effluent 
containing pancreatic hormones can be kept completely separated from 
exocrine tissue and secretion, therefore preventing enzymatic degradation of
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endocrine products. A portal venous catheter is also a prerequisite for accurate 
sampling of venous effluent at short intervals (Lenzen 1978).
Maintenance of organ viability, when the rest of the animal is sacrificed is the key 
factor for the success of the perfusion experiment. It is the period between cessation of 
blood flow into the organ and its replacement by the perfusate that is critical. It was 
essential to maintain the pancreas viable, under stable physiological conditions, ready for 
perfusion.
Several considerations were taken into account to ensure that the perfusion system 
complied as far as possible with the following criteria:
i. The operator of the perfusion set up had total control of the perfusion 
medium’s flow, temperature, and pressure.
ii. The concentrations of the basal perfusate and various stimulatory substances 
in the perfusion medium were under experimental control.
iii. Calcium was present to ensure the normal production of insulin in a biphasic 
pattern.
iv. The perfusion set up was easily maintained, cleaned and controlled, allowing 
opportunity for early intervention when failures appeared possible.
From these criteria, and in order to maintain absolute control over perfusate 
compositions, the required volumes of perfusate were prepared and continuously pumped
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through the test organ without recirculation and with additions of factors as programmed 
by the experimental schedule and design.
The advantages of the ex-vivo perfused pancreas preparation over other 
techniques used as in vitro, such as isolated perfused pancreas, isolated islets, slices or 
tissue fragments are as follows:
• The normal topography of the pancreas and its interrelations with the 
neighboring organs, nerves (intrinsic and extrinsic) and blood vessels was 
preserved during the procedure.
• Monitoring of organ viability through out the experiment was made possible 
through measurements of perfusate flow and pressure, dissolved oxygen 
concentrations and nutrient uptake.
• The delivery of nutrients and secretagogues was by the vascular route as 
opposed to the diffusional delivery as in isolated isles. Hence sequential 
perfusion of the islets was maintrained as in the in vivo states.
Using isolated islet preparations for assessing the insulin secretion rate has some 
disadvantages as compared to the preparations used in this study. Collagenase, used 
during islet preparation, may cause cellular injury, which may include the islets 
themselves. Isolated islet cells or whole islets are rendered non-physiological, in that the 
normal vascular delivery of substrates is not maintained. Hence, there will always be 
potential for divergence from the physiologically typical insulin response to D-glucose. 
This is supported by the observation that insulin secretion patterns differ between islet
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and perfused pancreas preparations which demonstrates a biphasic pattern, with a large, 
transient, first phase followed by a, slowly rising phase of secretion.
The height of the first peak of insulin release seems to always be equal to or 
greater than the height of the peak of the second phase of release (Petrusez and 
Merchenthaler 1992, Leclercq-Meyer 1999, and Lenzen 1979). In perifused islets, the 
first phase is invariably low or even absent, and the peak of the second phase release 
significantly exceeds that of the first phase (Sando and Grodsky 1973). This may reflect 
the “reveerse” delivery sequence of incretins and secretagogues through A- and C-cells 
and then to B-cells as opposed to the physiological delivery route of B-cells and then to 
A- and C-cells.
2.4.2.2 The ex vivo pancreas
The schematic diagram presented in Figure-5, highlighting the preparation of the 
pancreas for in vitro perfusion, was used as a guide for the distribution of the ligatures 
and vascular cannulation in the current study. Major variations in the structure of the 
setup and in the technique were introduced to change the context of the experiment from 
in vitro to ex vivo. To ensure the flow of the entire volume of perfusate into the pancreas, 
ligatures and cannulation were made directing the flow of the perfusion medium into the 
pancreas from the dorsal aorta through the coeliac and superior mesenteric arteries 
(Figures 5 overleaf and 6), and out through the portal vein (Figure 7 and 8).
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Hepatic Artery
Right Gastric Artery -,
Left Gastric Artery
— Dorsal Aorta
Gastroduodenal Artery
Lineal Artery
Superior Mesenteric. Artery 
Right Renal Artery
Adrenal Artery
1 Left Renal Artery
Aortic Cannula.
Figure 5: Schematic diagram of the rat dorsal aorta and ligatures before the aortic 
cannula was introduced, showing ligatures of the adrenal, left gastric, 
hepatic, right gastric arteries, and the dorsal aorta (after Baroody 1979).
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A bdom inal A orta
Figure 6: The dorsal aorta separated from the inferior vena cava in preparation for
cannulation and connective tissues rostrally for a short distance (1cm) with a 
clamp being placed as indicated in Figure 5 point 1.
10 :
S pleen
Stom ach
Figure 7: Schematic diagram of the hepatic portal vein with the portal cannula 
inserted indicating the outflow of the perfusate (after Baroody 1979).
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In this context, the perfusion experiment was done in an ex vivo context, 
developed and standardized from previous in vitro work performed on the same perfusion 
setup (Baroody and Howland 1980). The entire pancreas and organs of the digestive 
system remained in the rat while perfusion was carried out. This approach constituted a 
closer to normal physiological arrangement and a less invasive procedure, which also 
proved to be more direct and easier to perform. The ex vivo experiment’s main aim is to 
mimic the physiologically diverse regulatory parameters involved in the production of 
insulin at baseline and when leptin and other potential secretoagogues were introduced. 
In order to master the technique, a 3-month training period was dedicated for various 
trials leading to a standardization of the procedure. Experience obtained from the trials, 
was used to update the perfusion setup previously used to be used for this new system of 
work, the ex vivo perfusion.
Animals were weighed and anesthetized by intrapeiitoneal injection with sodium 
pentobarbitone (Nesdonal) at a dose of 5.5mg/100gm body weight. The rat was 
positioned supine and limbs extended and fixed on the surgery platform. A midline 
incision was made through the skin and the abdominal wall from the suprapubic region to 
the manubrium stemi along the linea alba. A second incision extended at right angles to 
the initial midline incision in the mid lumbar region. The abdominal wall was retracted 
laterally exposing the internal abdominal organs. A cotton wool swab soaked with warm 
(37°C) 0.9% (w/v) saline was placed over the abdominal organs during the dissection to 
avoid drying of the exposed organs. As shown in Figure 5, the dorsal aorta, located in the 
lumbar region anterior to the renal artery, was separated from the inferior vena cava and
105
connective tissues rostrally, for a short distance (1cm) where a loose ligature was placed 
around the aorta to fixate the cannula when introduced.
The stomach, intestine, and the spleen were gently displaced to the right side, 
exposing the dorsal aorta rostral to the left renal artery [Figure 5; point 1], where the 
superior mesenteric artery and the coeliac axis branch. The area was cleaned of fat, and a 
loose ligature placed posterior to the superior mesenteric artery [Figure 5; point 2]. The 
superior adrenal artery was located and clamped [Figure 5; point 3]. The three branches 
of the coeliac axis, the left gastric artery [Figure 5; point 6], the right gastric artery 
[Figure 5; point 4], and the hepatic artery [Figure 5; point 5] were located and clamped. 
The three splenic vessels [Figure 7; points 7, 8, and 9] were collected and ligated.
The abdominal contents were moved to the left of the animal and the hepatic 
portal vein and the gastro-hepatic ligament located (Figures 7 and 8). A clamp was placed 
around the aorta anterior to the coeliac axis in the vicinity of the crura of the diaphragm 
(Figure 5; point 13). A small incision was made in the wall of the aorta posterior to the 
first ligature, where the cannula was introduced through until its tip reached the origin of 
the superior mesenteric artery [Figure 5; point 2], and the ligature tightened. 0.1ml of 
heparin (5000 lU/ml) was immediately introduced into the cannula; after which it was 
immediately connected to the basal perfusate flow.
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Portal Vein Cannula
Figure 8: The portal vein cannulated between the portal ligature and entry of the 
hepatic portal vein into the liver, and protruding 5mm inside the portal 
vein. The abdominal aortic cannula is shown on the lower right.
The hepatic portal vein was then cannulated at a point between the portal ligature 
and entry of the hepatic portal vein into the liver extending 5mm within the portal vein 
[Figure 7; point 14 and Figure 8], and the ligatures firmly tied. The entire operation took 
less than 10 min with a maximum of 30 seconds of anoxia during the arterial cannulation. 
The average perfusion flow rate was 1.48 ± 0.02 ml/2min; perfusion pressures ranged 
between 45 and 65mm Hg, The comparison of the arterial and venous oxygen tension 
provides an estimate magnitude of oxygen extracted by the perfused pancreas. However, 
it must be noted that while the islets constitute a small {ca 2%) proportion of the total 
tissue mass being perfused, they receive some 30% of the total pancreatic blood flow.
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Hence, data comparing arterial and venous oxygen tensions may need to be treated with 
caution when used as indicators of islet cell viability.
2.4.3 Perfusion Media
The perfusion medium used here, Krebs-Henseleit bicarbonate buffered medium, 
acts as a replacement for blood in order to achieve the requirements of the normal 
functioning of the organ perfused. The medium meets the following requirements:
1. Adequate oxygen delivery.
2. A buffered physiological pH of 7.4, equivalent to the arterial pH.
3. Physiological concentrations of the principal ions.
4. A sufficient oncotic (colloid osmotic) pressure to maintain normal capillary 
haemodynamics.
In the present study, the buffer composition was as shown in the Table overleaf. 
Oncotic pressure was maintained using dextran T80 that has a molar mass sufficient to 
ensure its retention within the capillary volume, thus enabling it to substitute for plasma 
protein in the maintenance of capillary haemodynamics. Plasma protein was avoided in 
this preparation as insulin adsorbs onto plasma albumin and is extremely difficult to 
remove in its entirety. Hence, dextran was used to ensure that the perfusion medium was 
not contaminated with exogenous insulin from added plasma albumin.
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Substance M olar Concentration Mass g/L
NaCl (from lOX stock) 119 mM 3.47
KCl (from lOX stock) 4.7 mM 0.175
CaClz 2.5 mM 0.275
KH2 PO4  (from lOX stock) 1.2 mM 0.081
MgS0 4 .7 H2 0  (from lOX stock) 1.1 mM 0.105
NaHCOg 25 mM 2.075
Dextran 5g/100mls 25
Adenosine 1.5 mM/L 0.4
Glucose 4 mM 0.72
8  mM 1.44
12 mM 2.16
16 mM 2.88
Trypsin Inhibitor 10 mM 0.05
pH 7.4
Table 5: Krebs Henseleit bicarbonate buffered medium used as the basal perfusion 
medium.
A stock solution was prepared containing; NaCl, KCl, KH2PO4 , MgS04.7H20 at 
concentrations 10 times those of the final concentration, and stored at 4°C for up to only 
one month (Table 6). A 1:10 dilution was done on the day of use with the requisite 
quantities of calcium chloride and sodium hydrogen carbonate added immediately prior 
to making up the solution to volume with distilled water (TableS). The calcium chloride 
is a contributing molecule for the biphasic insulin secretion pattern from the perfused 
pancreas when stimulated by D-glucose (Lenzen 1979). In addition, the
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calcium/magnesium ratio of 2.3 closely resembles the physiological plasma ratio (2.4) of 
non-protein bound calcium to magnesium. Below such a ratio, insulin secretion might be 
in a relatively inhibited state due to magnesium’s vital role in enzymatic reactions 
catalyzed by ATP and its role in increasing hormone-receptor affinity (Curry 1977).
M aterial Concentration (mM) Mass (g/L)
NaCl 1190 34.2
KCl 47 1.75
KH2PO4 12 0.81
MgS04.7H20 12 1.47
Table 6: Composition of the lOX stock solution used to prepare the basal perfusion 
medium. This solution was kept at 4°C for a maximum of one month
To the basal perfusion medium the following reagents were added:
Dextran T80 (Sigma-Aldrich) to 5 g/100 ml for maintenance of the colloid 
oncotic (osmotic) pressure, and because, unlike albumin, it does not bind 
either calcium or magnesium, two cations normally needed for the normal 
secretion pattern of insulin.
Adenosine (Himedia Laboratories, India). Final concentration 1.5 mM/L, to 
maintain the integrity of the vascular endothelial cells and to act as a 
vasodilator (Baroody 1979).
110
D-Glucose (Sigma-Aldrich G8270) to a final concentration 0.072 g/100ml (4 
mM) in the basal medium. The glucose concentrations of the stimulatory 
media were 8, 12, and 16 mM.
Soybean trypsin inhibitor (Sigma-Aldrich T9128). Final concentration 0.1 g/L 
to prevent proteolytic breakdown of insulin.
The basal and the appropriate stimulatory perfusion media were put separately 
into the two rotating screen oxygenators and left to oxygenate with a gas mixture (O2 : 
CO2 , 95%:5%) for 30 minutes prior to start of perfusion. At the time of perfusion the 
medium was maintained at 38.1°C, the pH was regularly checked and confirmed at 7.4; 
both solutions were saturated with the gas mixture thus maintaining both pH and 
adequate oxygen delivery. The perfusion medium containing 4mM glucose without leptin 
is referred to as the basal perfusion medium in this study.
2.4.4 G lucose and leptin concentrations used
In order to obtain a broad view of the physiological effects of leptin on the 
production of insulin, the ex vivo perfusion experiments were designed to simulate leptin 
and glucose physiological concentrations in rats with average weight of 201 ± 7.2g. Four 
concentrations of glucose (4, 8, 12, 16mM) were used. 4mM approximating the human 
fasting blood glucose concentration. Normal human postprandial blood glucose
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concentration was assumed to be represented by 8 mM glucose in the perfusate. Blood 
glucose concentration in obese human pre-diabetic subjects with impaired glucose 
tolerance was represented by the 12 mM glucose concentration while 16 mM glucose was 
considered representative of the blood glucose concentration in frank diabetes. It is 
appreciated that in diabetes, blood glucose concentrations may be well in excess of 16 
mM but this level may be considered representative of the typical diagnosed diabetic 
subject with reasonable glycaemic control. Less information is available upon leptin 
concentrations in blood but typically within this range of 4 -  20 ng/ml. Hence, four leptin 
concentrations (5, 10, 15, 20 ng/ml) were used in combination with the aforementioned 
glucose concentrations. For each combination, a set of four perfusion experiments was 
carried out using a normal Wistar strain of Rattus norvegicus rats that had been fasted for 
24 hours before perfusion.
2.4.5 Operation and m odifications of the perfusion apparatus
The perfusion setup used in this study was obtained from the University of 
Surrey, School of Biomedical and Molecular Sciences (SBMS), Guilford, U.K., as a 
generous support by Dr. Roger Howland, Senior lecturer in Physiology and University 
supervisor of this study. All modifications were done at the Lebanese American 
University, Biology Department, Byblos Campus, Lebanon with the constructive help 
and guidance of Dr. George Baroody, Associate Professor of Physiology and local 
supervisor of this study. The outline design of the apparatus for perfusion of the rat
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pancreas is shown in Figure 9 and the schematic diagrams are presented in the 
Appendices.
The perfusion setup consisted of the water bath, with the motor-driven 
oxygenators fitted inside, the fraction collector, oxygen meter, peristaltic pump, surgery 
platform, with access to oxygen and carbon dioxide supply from separate gas cylinders as 
shown in Figure 9. The main water bath of dimensions 40cm by 30cm by 30cm, was 
made up of 1cm thick acrylic sheets in which the two rotary screen oxygenators (based 
upon an oxygenator manufactured by Ambec, Beck Industries Inc, U.S.A.) were fitted, at 
least half immersed in the water. The oxygenators (Figure 9; B) were made of a 
watertight Perspex jacket in which a nylon mesh fitted to a stainless steel axis revolved at 
an average of 50 rev/min. This was connected via a belt drive to a synchronous electric 
motor (Figure 9; A) within a compartment above the oxygenators.
A 700W heater element and thermostat (S.R.I Ltd, Edenbridge, Kent, UK) fitted 
in the water bath maintained the water temperature at 39°C during the course of an 
experiment. A magnetic stirrer situated at the base of the water bath ensured even 
distribution of heat throughout the chamber. A thermometer was immersed in the water 
bath to monitor any changes in the temperature.
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A multi-channel peristaltic pump (miniplus 2, Gilson Gambetta, Villiers, Bel, 
France) (Figure 10; C), was used to drive the perfusate at a rate of 140 strokes/1 minute 
(1.5ml/min). Perfusate passed either from the oxygenator’s outlet to the arterial cannula, 
or back to the oxygenators for re-circulation and oxygenation purposes depending upon 
the two-way tap settings fitted to the surgery platform.
The two-way taps (Figure 9; E, Figure 10; E) situated on the surgery platform 
facing the operator (Figure 9; D, Figure 10; D), direct and redirect the perfusate from the 
oxygenators. The perfusate passes either back for recirculation purposes, or through the 
arterial cannula, into the abdominal aorta of the rat being perfused as indicated in Figure 
11 below.
Figure ll:T he  surgery platform with the two-way taps. A: entry of the perfusate 
from the basal oxygenator. B: return route back to basal oxygenator. 
C: entry point from the stimulant oxygenator. D: the route back to 
stimulant oxygenator. Points E and F indicate the paths to the aortic 
cannula.
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The surgery platform was designed and assembled as in Figure 12 (Architect B, 
Haddad). It was composed of 1cm thick acrylic sheets with a flat surface over which the 
rat was laid, under which grids were included to permit leaking fluids from the rat’s body 
to empty in a collection container. The grid outlet was designed with two protruding 
wings and situated over the perfusion main water bath allowing the water vapour to be 
directed into the outlet through the same grids to the rat for humidification purposes. 
This prevented drying of the organs during preparative surgery and during the actual 
perfusion.
The platform was affixed on the main water bath by two 15cm suspension handles 
designed tightly to fit the walls of the main bath, as shown in Figure 12 below. A lid 
fitted with movable connections closed to cover the rat during perfusion preserving the 
heat and vapour entering from the grids beneath.
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GridsRat Laid Supine
Multichannel taps
____ _
Suspension handles
Figure 12: The surgery platform schematic drawing with the different parts 
labelled, including the lid, grids, handles, and the area where the 
perfusate flow control taps (Multi-channel taps) are situated.
Fitted to the surgery platform, the perfusate flow control taps served to direct the 
perfusates according to the need of the experiment. Figure 14-A, shows the entry of the 
perfusate from the basal oxygenator. Figure 14-B shows the route back to basal 
oxygenator for recirculation purposes. Figure 14-C shows the entry point from the 
stimulant oxygenator, while Figure 14-D shows the route back to stimulant oxygenator.
The cannula from the portal vein was connected to the collection outlet (0.6mm 
internal diameter) into which a dissolved oxygen probe was inserted (Dissolved Oxygen 
Meter, Jenway Ltd, Felsted, Dunmow, Essex, U.K.) to monitor the oxygen content of the 
effluent perfusate as shown in Figure 13. This section of the assembly was held by a
movable handle allowing free movement of the collection outlet to accept the portal 
cannula of the rat on the surgery platform (Figure 12; collection outlet). The perfusate 
was collected at a rate of 0.75ml/min into micro-centrifuge tubes in an automated 
fraction collector (Spectra/Chrom CFl Fraction Collector). The samples were collected 
into chilled Eppendorf tubes and preserved on ice in order to reduce any proteolytic 
breakdown of insulin secreted into the perfusate, before being stored at -20°C for 
quantitative analysis by insulin radioimmunoassay (RIA).
Oxygen, m eter probe | [ C ollection o u tle t | | Sm ^ery Platform |
Figure 13: The collection outlet is connected to the portal vein cannula, collecting 
the perfusates into Eppendorf tubes in the fraction collector. The oxygen 
probe is fitted into an opening so that the tip is in the perfusate effluent. 
The dissolved oxygen concentration was presented as mg O2/ ml 
perfusate.
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Two rotameters were connected to gas cylinders to provide the two oxygenators 
with the required concentrations of oxygen and carbon dioxide. The oxygenators were 
connected in series with the flow meters, delivering 95% O2 : 5% CO2 to the screen 
oxygenators at a rate of 200ml/min.
The two oxygenators were filled with normal (0.9%; 154 mM) saline solution 
before pumping started. The saline solution was allowed to circulate within each of the 
two oxygenator systems before being pumped out. In addition, 3Omis of basal and 
stimulatory perfusion media were flushed through the tubing of the perfusion set-up, after 
which 200mls of the basal and the stimulatory medium were added to oxygenator 1 and 2 
respectively. These volumes covered the lower half of the nylon mesh screens of the 
oxygenators which were heated by conduction in the water bath.
The peristaltic pump was activated and re-circulation allowed for about 30 
minutes ensuring homogeneous aeration and constant temperature distribution (39°C) in 
any section of the tubing. This is indicated by the blue arrow of A->B, and red arrow of 
C->D of Figure 14. The (E) and (F) taps indicate the route that the perfusate followed to 
reach the abdominal aorta of the perfused rat through a further two-way tap. Perfusion 
pressures were measured using a mercury manometer at the junction with the arterial 
cannula. The perfusion pressure ranged between 55 and 75mmHg throughout each of the 
perfusion experiment.
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Figure 14: The flow control taps and the different paths the perfusate can follow. A 
and C are inlets of the perfusates coming from the oxygenators, while B 
and D are the return paths to the oxygenators respectively for 
recirculation purposes. E and F indicate the path taken to reach the rat 
passing through the exchange key. K: the connection to the mercury 
manometer for perfusion pressure recording.
The perfusions commenced with the basal medium from the oxygenator 
containing the 4mM perfusates for at least eighteen minutes to establish the pre­
stimulatory equilibration phase. Then, the stimulant perfusates were introduced through 
the three-way valve. The venous effluent was collected in chilled Eppendorf tubes in a 
fraction collector, after a single passage through the pancreas preparation, at 2-minute 
intervals with a volume around 1.5ml/min. The perfusion medium was never recycled 
after passage through the preparation.
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As indicated in figure 14, the basal perfusate was channelled through path E for 
about 18 minutes, after which stimulatory perfusates were directed through path F until 
the end of the experiment (60min). The stimulant medium consisted of one of the three 
glucose concentrations (8, 12 and 16mM), either alone or with one of the four leptin 
concentrations (5, 10, 15 and 20nM) used in this study.
When the cannulation of the rat was complete on the surgery platform, the arterial 
cannula was connected to the multiple exchange key (MEK) from which the perfusate 
flowed into the abdominal aorta of the rat. The hepatic portal vein cannula was connected 
to the collection outlet from where the flow was directed through a drop counter to the 
fraction-collector. The internal diameter (0.6mm) of all the polyethylene tubings was 
consistent to ensure uniformity of flow of the perfusates.
During the dissection procedure, great care was taken to keep the animal’s 
exposed organs warm and moist. A warm 0.9% saline moistened cotton swabs was used 
for this purpose and to avoid traumatizing the tissues by the instruments. An electric 
cauterizer was used to seal all vessels severed during the dissection operation of the 
perfusion. The pancreata were constantly monitored for signs of failure, such as oedema 
and increased vascular resistance as indicated by increased perfusion pressures.
The input dead space of the perfusion system was 0.5ml, comprising the line 
between the media switchover tap and the abdomiiial aorta representing a delay of 40 
seconds at 0.75 ml/min perfusion rate. In addition, the vascular transit time of the
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perfused pancreas, measured by using the effluent perfusate glucose concentration as an 
indicator, was about 30 seconds. This was the average time needed for glucose in the 
effluent to reach the final stimulating concentration of 8, 12, or 16mM, completely 
replacing the pre-stimulatory medium used in the first six minutes of the perfusion. Thus, 
complete changeover from basal to stimulatory media was achieved in no more than 1 
min 10s, which is approximately half the time needed to fill one Eppendorf tube.
Throughout every experiment, the mean perfusion pressure was between 50 ± 4 
and 70 ± 8 mmHg (SEM), depending on the flow resistance of each preparation. Arterio­
venous oxygen concentration difference ranged between 10 and 14mg 0 2 /ml. The 
perfusate “arterial” input oxygen concentration after equilibration with 02:C02 (95%:5%) 
ranged between 30 and 35mg 0 2 /ml, while the venous output oxygen concentration was 
16 to 20mg 0 2 /ml, representing an uptake of approximately 225 to 325 p,mole 0 2 /min, 
signifying adequate tissue viability . Further confirmation of tissue viability was provided 
from measurement of glucose uptake by the preparation at all concentrations of glucose.
Samples were removed from the fraction collector and kept stored at -10°C until 
the end of the experiment. They were then transferred to and maintained at -80°C until 
assayed for insulin by radioimmunoassay. At the end of each perfusion, the pancreatic 
tissue that showed distention because of perfusates flowing through it, and which was 
within the duodenal mesentery and along the hepatic portal vein was dissected out. It was
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deep-freezed with liquid nitrogen, and the tissue preserved at -80°C for potential later 
quantification of Ob-Rb mRNA of the long form leptin receptor.
In order to prevent bacterial growth within the tubing of the perfusion setup, it 
was essential to clean the apparatus thoroughly after each group of perfusions. Therefore 
the apparatus was disassembled, put overnight in detergent and rinsed thoroughly with 
tap water after which its was rinsed with distilled water before being left to dry.
2.4.6 Demonstration of a pancreatic-duodenal humoral connection
To investigate any potential direct humoral or other form of connection between 
the digestive system and the pancreas, 10 ml of 1% filtered methylene blue was 
introduced into the superior mesenteric artery and its route of progression through the 
tissue preparation was followed visually to demonstrate the uniformity of flow and the 
sequence of colouration of organs were documented by serial viode images.
2.5 Glucose assay
Glucose in plasma and perfusate was assayed by the method of Sharp (1972), a 
glucose oxidase/peroxidase technique using 4-aminophenazone as the chromogen. 
Glucose concentrations were determined in 10 p,l of undiluted sample from blank- 
corrected absorbance of the coloured adduct at À = 520 nm.
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2.6 Insulin assay
2.6.1 Insulin radioiodination
The incorporation of radioiodine into protein molecules involves the covalent 
linkage of radioiodine in the tyrosyl and to a lesser extent in the histidyl residues of the
protein molecule. The basic steps of the modified method were based upon the following
points:
a) Dissolving low concentrations of porcine insulin (free of reducing substances) in 
phosphate buffered saline (pH 7.4) to be radiolabelled followed by addition of
This pH enhanced the efficiency of radioiodination as observed in our 
laboratory trials.
b) Adding freshly prepared chloramine-T to initiate the reaction. Mix well and 
permit to proceed up to 45 seconds.
c) Stopping the radioiodination by adding sodium meta-bisulphite at the same molar 
concentration as chloramine-T.
d) Immediate removal of unbound iodine by ion-exchange chromatography on a 
Sephadex G15 column.
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The iodination of insulin was carried in the radioisotope laboratory at the Syrian 
Atomic Energy Commission Center, with the kind support and collaboration of Ibrahim 
Ousman, Ph.D. (Surrey), General Secretary of the Syrian Atomic Energy Commission, 
Damascus. Since the amount did not meet the requirements of the present study, 
radiolabelled iodine ^^ I^ was further supplied by the Syrian Arab Republic Atomic 
Energy Commission, imported from the Izotop (Institute of Isotopes, H 1121 Budapest, 
Konkoly-Thege Miklos str. 20-33, Hungary). Porcine insulin was used for the 
radiolabelling as cross reactivity with rat insulin antibody was demonstrated (Baroody 
1979). 0.5M phosphate buffer (pH 7.4) was used to dissolve the reagents. Chloramine T 
(Sigma, UK) was used to start the radiolabelling reaction at a concentration of 40mg/ml 
in 0.05M phosphate buffer (pH 7.4). Sodium metabisulphite (Sigma, UK) was used to 
stop the radiolabelling reaction at a concentration of 2.5mg/ml dissolved in 0.05M 
phosphate buffer (pH 7.4).
To remove free iodine, potassium iodide (Sigma, UK) was added at a 
concentration of 20mg/ml dissolved in 0.05M phosphate buffer pH 7.4. G15 Sephadex 
was used for separation of radiolabelled insulin from free radioactive iodine, in a 1cm by 
12cm chromatography column (Amersham Pharmacia Biotech, UK). In order to increase 
the yield of radiolabelled insulin, pre-washing the column with 0.05M phosphate buffer 
(pH 7.4) containing 0.05% insulin-free bovine serum albumin (BSA) (Sigma, UK) was 
done.
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2.6.2 Method
The following procedures were carried out in a fume cupboard. Ready-made 
Sephadex G-15 columns obtained from Pharmacia Biotech (in Sephadex, disposable PD- 
10 desalting columns) were washed with protein elution buffer containing sodium acetate 
and BSA. In a small conical reaction vial, 5pg of porcine insulin was added and diluted in 
25 pi 0.5M phosphate buffer pH 7.4. All steps of iodination were carried out in a fume 
cupboard with the window down as much as possible, while wearing three pairs of 
disposable latex gloves. 5 pi (18.5MBq) Iodine ^^ I^ was added in an auto-analyzer cup 
and 5pi chloramine T (40mg/ml) added over it to start the radiolabelling reaction. The 
reagents were allowed to react for 45 seconds after which the reaction was stopped with 
200 pi sodium metabisulphite.
50 pi potassium iodide was added to remove any free iodine. The content of the 
reaction vial was applied to the top of the Sephadex G15 column using a disposable 
pipette, and allowed to flow into its bed. Once this has had been absorbed, 15 ml of 
elution buffer (0.05M phosphate buffer pH 7.4, 0.5% B.S.A) was added.
20 tubes were collected each containing 0.5ml eluant. As shown in Figure 15, 
radiolabelled insulin appeared in tubes 5 to 8. The contents of these tubes were pooled 
and counted in a p counter to determine the specific activity. All the tubes were disposed 
except those aliquots containing iodinated insulin. lodinated insulin was stored at 4°C for 
one week after which it was used for radioimmunoassay.
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Figure 15: Tube number (x-axis) vj. cpm of the 0.5ml tubes from the 
elution (y-axis) showing separation of radiolabelled insulin 
(tubes 5 to 8) from free radioiodine (tubes 11 to 16).
To ensure that the radiolabelling yield was sufficient to cover the number of 
samples to be tested, and to ensure that the first peak was that of iodinated insulin, 
electrophoresis on Whatman papers was done with insulin on one paper and a 
combination of insulin with potassium iodide on the other. After running the 
electrophoresis for 1.5 hours at llOV the Whatman paper was cut at 1cm interval and 
read in a gamma counter to determine the counts per minute upon each 1 cm strip. A 
proportion of the iodine did not bind to the insulin and remained free. This was clearly 
demonstrated in figure 15, which indicates two peaks; the first represents radiolabelled 
insulin and the other free iodine, which migrated further on electrophoresis. In order to 
confirm that the second peak was indeed free iodine, potassium iodide was added, acting
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as an iodine ion carrier, and was added to the load. It migrated further towards the 
cathode than the iodinated insulin and showed again a second peak. Thus, good 
separation of radioiodinated insulin from free iodine by the Sephadex column was 
confirmed.
2.6.3. R adioim m unoassay of insulin
2.6.3.1 Introduction
Since radioimmunoassay (RIA) technology, using radioisotopes as labels, was 
first developed by Yalow and Berson (1960), it has been improved dramatically in 
sensitivity and precision. The technique is based on antibody recognition of the substance 
to be quantified (analyte). There are two main RIA techniques, competitive and 
noncompetitive heterogeneous formats, which require washing steps to separate bound 
and free labels (conjugates). The competitive assay follows the law of mass action, which 
specifies the reaction between analytes and their binding protein, the antibody. The key 
factor in assay optimization is the binding affinity of the antibody.
In radioimmunoassay, a fixed concentration of labelled insulin is incubated with a 
constant dilution of anti-serum such that the concentration of antigen binding sites on the 
antibody is limited to approximately 50% of the total insulin concentration to be bound to 
antibody. When unlabelled insulin is added to this system, there is competition between
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labelled insulin and unlabelled insulin for the limited and constant number of binding 
sites on the antibody. Thus, the amount of labeled insulin bound to antibody will decrease 
as the concentration of unlabeled antigen increases (law of mass action). After the 
immune reaction reaches equilibrium, the mixture is washed to remove unreacted 
conjugates (radiolabelled insulin); antigens and the immune complex are trapped on the 
solid phase or plastic tube.
Applying the competitive principle, the plot of antigen-bound percentage against 
logarithmic concentration of analyte provides the standard curve. This can be measured 
after separating antibody-bound from free labeled and counting one or the other, or both 
fractions. A standard curve was setup with increasing concentrations of standard rat 
insulin (Novo Laboratories, Copenhagen, Denmark) and from this curve the amount of 
antigen in experimental samples can be determined.
2.6.3.2 R eagents
2.6.3.2.1 Assay buffer:
•  0.05 M Phosphate buffered saline (PBS) pH 7.4.
• 0.025M EDTA.
• 0.08% Sodium azide.
• 1% Bovine serum albumin.
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2.6.3.2.2 Antiserum
• Lyophilized guinea pig anti bovine insulin serum with goat anti-guinea pig 
IgG (Guildhay, Guildford, Surrey UK).
2.6.3.2.3 Labelled Insulin
I labelled -insulin, freshly iodinated, containing <35pCi (1295kBq), in 7.5 
ml PBS.
2.6.3.2.4 Insulin standards
• Purified rat insulin in assay buffer at the following concentrations: 0.1, 0.2,
0.5, 1.0, 2.0, 5.0, and 10 ng/ml.
2.6.3.2.5 Quality control standard
• Purified rat insulin in assay buffer (2 ng/ml).
2.6.3.2.6 Precipitating reagent
• 3% Polyethyleneglycol (PEG)
• 0.05% Triton X-100
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• 0.05M PBS
• 0.025M EDTA
• 0.08% Sodium azide
All reagents were kept refrigerated between 2 and 8°C for short-term storage. For 
prolonged storage (>2 weeks) reagents were frozen at -20°C.
The assay protocol is presented in Table 7 overleaf.
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2.6.3.2.7 Apparatus
1. Polystyrene tubes (donated by the Syrian Nuclear Center for 
Research) 12 x 75 mm.
2. 100 j L i l  pipette with disposable tips.
3. 100 pi & 1.0ml repeating dispenser.
4. Refrigerated swing bucket centrifuge capable of developing 2000 -  
3000 X g. (Sigma Laborzentrifugen, Germany).
5. Absorbent paper.
6. Vortex mixer.
7. Refrigerator.
8. Gamma counter (Quick-Count Bioscan).
Conversion o frp m  to x  g:
Calculated as below:
g= (1.12x10'^) (r) (rpmf.
Where r  = radial distance in cm (from axis of rotation to the bottom of the tube)
rpm = rotational velocity of the rotor.
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2.6.3.2,8. Calculations
1. The duplicate counts were averaged for total count tubes (1-2), non-specific 
binding (NSB) tubes (3-4), total binding tubes (reference. Bo) (5, 6), and all 
duplicate tubes for standards and samples to the end of assay.
2. The average NSB counts were subtracted from each average count (except for 
Total Counts). These counts are used in the following calculations.
3. The percentage of tracer bound was calculated [(Total binding counts/Total 
counts)] X 100%. (This was between 35-50%).
4. The percentage of total binding was calculated as (%B/Bq) for each standard and 
sample [% B/Bq = (Sample or Standard/Total Binding) x 100].
5. The %B/Bo was plotted for each standard on the y-axis and the unknown 
concentration of the standard on the x-axis of semilogarithmic graph paper.
6. The standard curve was constructed by joining the points with a smooth curve.
7. Concentrations (ng/ml) of rat insulin in the unknown samples was determined 
(unknowns and controls) by interpolation of unknown counts onto the standard 
curve.
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Within-assay variation was calculated as the coefficient of variation (SD/mean x 
100) of the Quality Control standards included within each assay. Between-assay 
variation was calculated as the coefficient of variation derived from pooled Quality 
Control values.
2.7 Lowry method
The Lowry method relies on two different reactions. The first is the formation of 
a copper ion complex with amide bonds, forming reduced copper in alkaline solutions. 
This is called a "Biuret" chromophore. The second is the reduction of Folin-Ciocalteu 
reagent (phosphomolybdate and phosphotungstate) by tyrosine and tryptophan residues. 
The reduced Folin-Ciocalteu reagent is blue and thus detectable with a spectrophotometer 
in the range of 500-750 nm. The Biuret reaction itself is not all that sensitive. Using the 
Folin-Ciocalteu reagent to detect reduced copper makes the assay nearly 100 times more 
sensitive than the Biuret reaction alone.
The assay is relatively sensitive, but takes more time than other assays and is 
susceptible to many interfering compounds. The following substances are known to 
interfere with the Lowry assay: detergents, carbohydrates, glycerol, Tricine, EDTA, Tris, 
potassium compounds, sulfhydryl compounds, disulfide compounds, magnesium and 
calcium. Most of these interfering substances are commonly used in buffers for 
preparing proteins. This is one of the major limitations of the assay. The Lowry assay is
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sensitive to variations in the content of tyrosine and tryptophan residues. If the protein 
you are assaying has an unusual content of these residues, an appropriate substitute 
standard is required. The standard curve is linear in the 1 to 100 ug protein region. The 
absorbance can be read in the region of 500 to 750 nm. Most researchers use 660 nm, but 
other wavelengths also work and may reduce the effects of contamination (e.g. 
chlorophyll in plant samples interferes at 660 nm, but not at 750 nm).
2.7.1 P roced u re
Alkaline Reagent
0.1 M NaOH 
29b Na2(:()3
0.5% Na Tartrate (used of potassium salt will cause SDS to be insoluble)
0.5% Na Dodecylsulfate 
Copper Reagent 
1% C uS 04*5H 20
Assay Mix (MADE FRESH EACH TIME)
50 mL alkaline reagent and 0.5 mL copper reagent 
Folin-Ciocalteu Reagent
Dilute with an equal volume of water to prepare the desired volume
2 .7 .2  P roced ure:
• Add samples containing up to 100 pg of protein
• Bring all tubes to 1 mL total volume with water. Two tubes containing only water 
as blanks were used.
• The Assay Mix and diluted Folin-Ciocalteu reagent were prepared.
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5 mL of assay mix were added to each tube and thoroughly vortexed.
Tubes were incubate at room temperature for 10 min.
0.5 mL of diluted Folin-Ciocalteu reagent was added and vortexed immediately. 
Incubation at room temperature for 30 min.
Tubes were vortexed; spectrophotometer with the blank and measure absorbance 
at 660 nm was prepared (or other appropriate wavelength).
2.8 Data handling and statistical methods
All individual data sets were examined using the Kolgomirov-Smirnov goodness 
of fit test (Dawson-Saunders and Trapp 1994) to confirm normal distributions and to 
validate the use of parametric statistical analyses.
Outputs from the perfused pancreata were expressed as pmoles insulin/2min by 
conversion from the output concentration (ng/ml) in a volume of 1.5 ml/2 min. Perfusion 
profiles (output vs time) were examined a priori by a repeated measures design of 
analysis of variance using glucose concentration and leptin concentration as the within- 
subjects factors. Variance heterogeneity was assessed using the Mauchly sphericity test 
(Dawson-Saunders and Trapp 1994). Where significant heteroscedasity was found, 
degrees of freedom used in the analysis of variance were reduced by the Greenhouse- 
Geissler 8 factor (Dawson-Saunders and Trapp 1994) to compensate for lack of variance
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homogeneity. These analyses provided information upon the parallelity or otherwise of 
the response profiles of insulin output with time.
To quantify differences in amounts of insulin produced under the various glucose 
and leptin perfusion regimes, areas under the response curves were calculated, using the 
trapezoidal rule as total areas. Areas under the response curves above the baseline were 
calculated as incremental areas by subtracting the mean basal insulin output from the 
outputs seen during glucose stimulation. Data for areas under the response curves were 
assessed using the Kolgomirov-Smimov goodness of fit test to confirm normal 
distributions. Once normal data distributions were confirmed, areas were examined with 
respect to the effects of both glucose and leptin concentrations using one way analysis of 
variance followed by Scheffé’s multiple range test (Dawson-Saunders and Trapp 1994) to 
localize specific differences. Homogeneity of variances was examined using Levene’s 
test (Dawson-Saunders and Trapp 1994); where significant heteroscedasity was found, 
logarithmic data transformations were applied to reduce variance heterogeneities.
Sensitivities of Phase 1 and Phase 2 insulin secretion with respect to the effects of 
leptin at varying glucose concentrations were assessed using linear regression analyses. 
Slopes of the regression lines were compared using the two-tailed Student’s V’ test 
(Dawson-Saunders and Trapp 1994) for unpaired samples.
Statistical significance was assumed in all cases at p < 0.05
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3. Results
3.1. Recombinant leptin production
Leptin was recombinantly expressed in E. coli using a puc 19-rat ob plasmid and a 
stab culture of E. coli SGI3009 [pREP4] [pQE30-rat ob] expressing “His-tag rat leptin”. 
The first attempt to produce leptin, (Figure 16 overleaf), indicated leptin in Lane 1 at 16 
kDa compared to the low molecular weight marker (LMWM). In the scan of the 
electrophoresis gel, leptin purity at peak 10 is 15.63%. 5 mmoles of leptin, as determined 
by the Lowry protein quantification technique (Lowry 1951), were added.
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LI L2 LM W M
10 < “
Leptin
16000Da
lOOOODa
Pk Pos Ht Area
1 12 1033 4192 4 .9 2
2 24 671 7516 8 .8 3
3 38 776 9250 1 0 .8 6
4 63 1028 12393 1 4 .5 6
5 86 1363 9180 1 0 .7 8
6 100 765 6097 7 .1 6
7 108 751 3880 4 .5 6
8 143 735 8577 1 0 .0 7
9 162 552 10741 1 2 .6 2
10 227 1130 13310 1 5 .63
m m
Figure 16: SDS-PAGE gel showing recombinant leptin during two steps, LI 
and L2, of purification as compared to a low molecular weight 
marker (LMW). The table on the right indicates leptin as 15.63% 
of the total protein in peak 10.
In an attempt to increase the yield, another culture was done, but with a 
systematic analysis procedure to detect where the defect in the technique leading to a low 
yield lay. The electrophoresis scan showed that leptin was being produced in high 
amounts after the first sonication step but with significant amounts of impurities (Figure 
17, Lysate 2). Samples (1ml), from the various steps of the procedure, were run on SDS- 
PAGE, focusing on the samples from the purification procedure with Ni-NTA column.
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Figure 17: SDS-PAGE of the samples collected through out the expression and 
purification of the leptin protein. Lanel: Lysate 2, Lane2: Lysate 3, 
Lane 3: Lysate 4, Lane 4: LMWM, Low molecular weight marker.
According to the technique adopted from Dr Murakami, a modification of the 
technique recommended in Qiagen’s “The Expressionist” booklet (third edition, March 
1997), the expected leptin concentration of the equivalent step should be low, and the 
leptin would be soluble. The reason for this was that eukaryotic proteins expressed in 
bacteria form inclusion bodies due to their high expression rate and resultant high 
concentrations. Hence the major leptin concentration was expected to be highly expressed 
and in the form of inclusion bodies. As a result, the focus was set on refolding the 
inclusion bodies believing them to be produced because of the high promoter activity of
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the plasmid holding the leptin gene in the E.coli strain. A series of dialysis steps using 
guanidine-HCl to refold the inclusion bodies of leptin against a decreasing concentration 
of urea was carried (3hours/step), but revealed nothing on the gel of the SDS-PAGE, 
suggesting an error in the procedure which preceded the dialysis step.
Samples from the different lysate steps were taken, and then mixed with sample 
buffer to be run on SDS-PAGE. The three lysates showed a decreasing yield as displayed 
by the opacity of the band at 16kDa (Figure 17), but also showed an increasing purity 
disclosed by the background purity of the lane in which each band ran (Figure 17, Lanes
2 and 3). Lysate 2 showed significant protein impurities of larger molecular weight than 
leptin, while lysate 3 and 4 showed a relatively clearer electrophoresis bed.
Taking this into account, centrifugation of lysates at 10000 x g for 20 min seemed 
to play a major role in the purification of impurities displayed on the electrophoresis bed 
with leptin. In order to focus more on detecting the source of the error, samples from all 
the steps of purification were taken and run on SDS-PAGE. Samples from before and 
after Ni-NTA chromatography were taken and showed no difference in their 
electrophoresis pattern (Figure 18 lanes 2 and 3). In addition, samples from lysates 2 and
3 (Figure 17) were also run on Ni-NTA columns and the eluate was run on SDS-PAGE. 
No difference was observed in the electrophoresis pattern as shown in Figure 18, lanes 4, 
5, 6 and 7. In conclusion, the elution through Ni-NTA column did not prove to purify the 
leptin from the impurities as shown in lanes 2 and 3, 6 and 7 as compared with lanes L2, 
L3, and L4 of Figure 18.
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LMWM *
9 10 H |L 2  L3
LMWM
Figure 18: SDS-PAGE showing the variation in the protein purity, before and after 
Ni-NTA chromatography. Lane 1 and 11 : Low molecular marker. Lane 
2 and 3: lysate 4 before and after Ni-NTA respectively. Lane 4 and 5: 
Lysate 3 before and after Ni-NTA respectively. Lane 6 and 7: Lysate 2 
before and after Ni-NTA respectively. Lane L2: lysate 2. Lane L3: 
lysate 3. Lane L4: lysate 4.
Two possible reasons were considered; either the 6-His Tag was located internally 
in the three dimensional structure of leptin in a way not accessible to the imidazole ring 
of the Ni-NTA resins, or the resin solution was expired and needed recharging. The 
second reason was not considered further since the colour of the resins remained blue 
indicating that the resins were charged with nickel, the element crucial for the binding of 
the 6-His Tag to the resins, and hence still valid for use.
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The three lysates were mixed together and centrifuged at 12000xg in an attempt to 
decrease the impurities. The leptin was then run by SDS-PAGE and in addition, 
compared to trypsin inhibitor (Fluka) with a molecular mass of 20KDa. The purity of 
leptin showed above 80% as compared to the purity of trypsin inhibitor which was less 
than 25% (Figure 19).
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5•
g-
20000Pa
16000Da
LMWM XI
T.I.
Lepdn 1 ' Leptin 2 +
Leptin
Figure 19: SDS-PAGE showing the purity of the expressed and purified leptin 
using gradient centrifugations as compared to trypsin inhibitor 
protein (Fluka). Lane 1: Low molecular weight marker. Lane 2: 
Trypsin inhibitor [20KDa] (Fluka), Lane 3: leptin [16000Da] during 
purification procedure. Lane 4: Leptin [16KDa] used for perfusion 
experiments. Lane 5: Leptin mixed with trypsin inhibitor to show 
separation.
In addition, the leptin and trypsin inhibitor were mixed together and run in the 
same lane. This showed clearly leptin at 16kDa as compared to 20KDa for trypsin
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inhibitor. This indicated that the centrifugation step after sonication was crucial, time 
saving and could replace the rest of the steps involving the sonication. Large-scale (5 
liters) preparations were made, checked for soluble leptin in lysates and purified by the 
above mentioned protocol. Following protein concentration determination by the Lowry 
method, using bovine serum albumin standards and assuming all protein to be leptin, 
separate volumes, to provide the required concentrations when made up in 1 liter of 
Krebs-Henseleit medium were dispensed, lyophilized and stored at -80°C. Serial dialysis 
steps as indicated above were done to ensure recoomfirmation of the leptin protein 
allowing disulfide bonding to occur.
3.2. Viability of the perfused pancreas
Tissue viability was assessed using oxygen uptake and glucose utilization. It was 
reported in the previous section that oxygen uptake of the preparations ranged between 
approximately 225 and 325 jimole Oi/min. Glucose uptakes of the perfused pancreas at 
the stimulatory glucose concentrations used, i.e. 5, 10, 15, and 20 mM are shown in 
Figure 20 overleaf.
Initial high glucose uptake due to surgical anoxia associated with anaerobic 
respiration and glucose depletion was maintained for up to five minutes as indicated in 
Figure 20 after which the glucose level uptake stabilized at around 2 to 3pmole/2min for 
the rest of the perfusion experiments. Glucose uptake in the perfusion experiments with 
16 and 12mM was relatively higher than the 8mM. This is to indicate that, not
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surprisingly with higher glucose concentration around the pancreatic cells, there is a 
higher efficiency in glucose uptake by its transporters.
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Figure 20: Glucose uptake by the perfused pancreas at perfusate glucose
concentrations of 8 mmol/L (•), 12 mmol/L (■) and 16 mmol/L (^). Means 
± SEM; N = 4 at each glucose concentration
3.3 Insulin assay
Porcine insulin standard curves, concentration versus percentage bound (B/F) 
were plotted on semilog graph paper and were of the form shown in Figure 21 overleaf. 
Insulin at lOng/ml showed 10 ± 1.5 (Mean ± SEM.) % of total radioactivity bound (B/F) 
O.lng/ml showed 82 ± 1.5 (Mean ± SEM) % of the total radioactivity bound. None of the
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experimental samples fell outside the range of the insulin standard curve mentioned. 
Within- and between-assay variations were 4.2% and 5.4% respectively.
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3.4 Insulin secretion by the perfused pancreas
3.4.1 Insulin secretion  profiles in the a b sen ce  of leptin
It is worth noting that the flow rate was influenced by the concentration of 
glucose in the perfusing medium. During the first 18 minutes when the perfusate glucose 
was in the range of 4mM, the flow rate ranged between 0.5 and 1.0 ml/2 min. The flow 
rate increased to 1.48 ± 0.02ml/2 min when the switch to the stimulatory medium was 
made although the pump maintained a constant rotational speed providing a perfusion 
pressure of about 50mm Hg implying vasodilation and hence reduced vascular resistance 
at glucose concentrations above basal.
All data are presented as mean ± SEM, normal distributions of all data sets having 
been confirmed (Kolmogorov-Smimov goodness-of-fit tests). A repeated measures 
design of analysis of variance of the data presented in Figure 21 overleaf indicated, as 
anticipated, significant effects of glucose concentration upon insulin output, (Fj [9,2] = 
4848.1; p <  001).
The basal insulin secretion rate (at zero to 6 minutes perfusion time) ranged 
between 8.48 ± 0.34 pmol/g/2min and 9.31± 0.03 pmol/g/2min, i.e. the first 3 samples in 
the time span of six minutes of the basal perfusion. On shifting from basal (4mM 
glucose) to stimulation medium (8, 12 or 16mM glucose), insulin output increased and 
perfusion with the stimulation medium was maintained for 36 minutes. The pancreas was
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collected, as described above, weighed and snap-frozen in liquid nitrogen for storage and 
potential Ob-Rb mRNA analysis.
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Figure 22: Insulin outputs in response to glucose at 8 mmol/L (•), 12 mmol/L (■) and 
16 mmol/L (♦)
The biphasic secretion pattern of insulin (Elahi 1985; Lenzen 1979) was evident 
after a glucose load of 8mM glucose or more was applied. Specifically for the 8mM, a 
peak pulse of 26.38 ± 1.09 pmole/2min was achieved after 4 minutes following 
stimulation medium reaching the pancreas. The primary peak was followed by a drop in 
the rate of release to 12.05 ± 0.54 pmoles/2min, after which the second phase
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commenced and with a progressive increase remained within the range 15.15 ± 0.9 
pmoles/2min to 21.87 ± 1.18 pmoles/2min during the period of experimentation. This 
was in concordance with Elahi et al, where introduction of glucose (8.3mM) into the 
perfused rat pancreas resulted in an early spike reaehing 46.5pmoles/min, a value 
comparable to the peak achieved during the present perfusion (25pmoles/2 min).
Similarly, a perfusing glucose concentration of 12mM, basal insulin secretion (at 
zero to 6 minutes perfusion time) ranged between 7.39 ± 0.36 and 8.81 ± 0.2 
pmoles/2min. Stimulation with 12mM glucose resulted in a biphasic insulin secretion 
profile (Figure 22) as reported by Curry, where glucose in the perfusate was at 200 mg/dl 
(11.1 mM) during the entire 60-min perfusion period. In the present study, the first phase 
showed a peak pulse of 49.90 ± 1.13 pmoles/2min, achieved within 2-minutes of 
stimulation, and maintained for about 6 minutes. A drop to 22.39±0.36 pmoles/2min 
followed, after which a progressive increase in secretion remained throughout the 
remaining perfusion with the stimulation medium. The second phase secretion range was 
between 24.72± 0.98 and 38.01 ± 1.03pmoles/2min.
In the third perfusion (16mM), the basal insulin secretion rate ranged between 
7.44 ± 0.49 and 9.93 ± 0.46 pmoles/2min. The biphasic pattern of insulin response 
remained evident (Figure 22), with the first phase peak reaching 79.72 ± 0.90 
pmoles/2min achieved after 4 minutes of stimulation signal, which maintained for 6 
minutes, after which a decrease to 23.09 ± 0.38 pmoles/2min reached on the tenth minute 
after stimulation. The response to the stimulation medium was observed forty seconds
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after shifting, as reported by Lenzen, where 5.5mM glucose was used as the pre­
stimulatory medium and a response to stimulation attained in the above-mentioned latent 
period. The second phase showed a progressive increase through out the remaining 
perfusion rising from 30.33 ± 0.85 pmoles/2min to 61.70 ± 0.85 pmoles/2min thirty four 
minutes after stimulation (Figure 22).
The insulin secretion rate of both phases in all baseline sets perfused with 
stimulatory media was significantly greater than that seen during perfusion with the basal 
medium. In response to glucose stimulation (8mM), insulin released in the first phase, 
which lasted six minutes, was about 31.2% of that released during the following forty 
minutes of the second phase. While in the second set of the base line experiments 
(12mM), glucose-stimulated insulin released in the first phase of secretion, which lasted 
for six minutes, reached 38% of that released in phase two, which was terminated at 34 
minutes. As for the third set of glucose (16mM) stimulated insulin secretion control 
groups, insulin released in the first phase, which lasted for ten minutes, consisted of 35% 
of that released in the second phase of insulin secretion, and which followed for the 
remaining 26 minutes of the perfusion. Hence, a dose-dependency of insulin output upon 
perfusing glucose concentration was evident.
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3.4.2 Effects of leptin upon insulin secretion  profiles
3.4.2.1 Insulin secretion at 4mM glucose
Results of the ex vivo perfusion experiments with 4mM glucose and four leptin 
concentrations are presented in Figure 23. Repeated measures analysis of variance of the 
data indicated significant effects of time (F  ^ [240,20) = 41.9; p < .001) and significant 
glucose-leptin interaction (F  ^ [3, 18] = 23.5; p < .001) showing modulation of the 
response to glucose by leptin. There were no significant variance inhomogeneities among 
the data.
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Figure 23: Effects of leptin at 0 (o), 5 (a ), 10 (♦), 15 (□) and 20 ng/ml (•)  upon insulin 
output of the ex vivo pancreas perfused with 4 mM glucose. N=4 for each 
leptin concentration.
The basal insulin secretion rate from the four different experimental groups (4mM 
glucose v.y. 5, 10, 15, 20ng/ml leptin) ranged between 5.17 ± 0.2 pmoles/2min and 8.86 ± 
0.25 pmoles/2min covering the first 6 minutes of the perfusion. Following the change 
from basal to stimulation medium, a drop in insulin secretion rate, in three minutes, 
below the minimum value of the basal insulin secretion rate was observed in the 5 and 
20ng/ml leptin groups. This was not the case in the 10 and 15ng/ml leptin groups where 
an increase above the maximum level of the basal insulin secretion rate was observed 
reaching 38.49 ± 1.24 and 16.78 ± 0.02 pmoles/2min respectively.
The secretion rate in the 5ng/ml group showed an insulin output ranging between
2.17 ± 0.56 and 6.05 ± 1.24 pmoles/2min, which represented 3 ± 1% of basal secretion 
rate and with 76% of the insulin released during the stimulation period of the perfusion 
experiment below 5.17 pmoles/2min. On the other hand, the secretion rate of the lOng/ml 
leptin group ranged between 8.84 ± 0.02 and 37.23 ± 2.43 pmoles/2min with 95% of the 
insulin secretion rate above basal level. A biphasic secretion pattern was evident, 
reaching 19.8 ± 0.98 in phase one and 37.23 ± 2.4 pmoles/2min in phase two representing 
a rise of 238± 19% relative to the pre-stimulatory period with a mean value of 8.71 ± 
0.02 pmoles/2min. The first peak was reached in four minutes after shifting to stimulation 
medium while peak two appeared 30 minutes after stimulation.
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Insulin secretion in the 15ng/ml leptin perfusion showed an irregular biphasic 
secretion pattern with phase one ranging between 7.60 ± 0.02 and 10.93 ± 0.12 
pmoles/2min. Following peak one, a drop to 1.00 ± 0.05 pmoles/2min was observed 
followed by a rise in insulin production, which ranged between 9.10 ± 0.10 and 16.42 ± 
0.41 pmoles/2min, which represented a 35 ± 4% of basal secretion rate. The second peak 
was reached 30 minutes after shifting to stimulation medium.
There was no rise in insulin secretion rate for fourteen minutes after shifting to 
stimulation medium in the 20ng/ml leptin group, after which a rise from 5.79 ± 1.29 to 
15.85 ± 0.64 pmoles/2min was reached in 20 minutes. Insulin secretion showed a mono- 
phasic secretion pattern with only one peak showing 35 minutes after shifting to 
stimulation medium and which represented 40.7 ± 5% of basal secretion rate.
The patterns of insulin release disclosed regular oscillations as previously 
reported for basal (1.5mM) and stimulatory (8.5mM) concentrations of glucose (Petrusez 
and Merchenthaler 1992). Here the first peak at 18 minutes was followed by another 
secretory cycle of 5.5 ± 0.4min each, identified at 26 minutes after shifting to stimulation 
medium.
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3A.2.2 Insulin secretion at 8 mM glucose
The purpose of this set of ex vivo perfusion experiments is to study the effect of 
leptin on glucose (8mM)-stimulated insulin secretion. 8mM glucose is a stimulant 
concentration for insulin (Elahi 1985), and in response the insulin secretion shows a 
biphasic pattern. Four rats were used in order to show the biphasic insulin secretion 
pattern when stimulated with 8mM D-glucose in combination with the four leptin 
concentrations used here. The average perfusion flow rate was 1.45 ± 0.2 ml/ 2min and 
the perfusion pressure ranged between 50 and TOmmHg.
Results of the ex vivo dose response perfusion experiments with 8mM glucose 
versus four leptin concentrations (5, 10, 15, and 20 ng/ml) are presented in Figure 24.
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Figure 24: Effects of leptin at 0 (o), 5 ( a ), 10 (♦), 15 (■) and 20 ng/ml (•)  upon insulin 
output of the ex vivo pancreas perfused with 8mM glucose. Mean ± SEM for 
N=4 for each leptin concentration
Repeated measures design analysis of variance of the data in Figure 24 indicated 
significant effects of leptin upon the secretion profiles (F  ^ [4, 18] =598.5: p<0.001). 
Apparent maximum suppression was seen 15ng/ml leptin while the highest dose of leptin 
(20ng/ml) showed least apparent suppression. The suppression seen at leptin 
concentrations of 5 and 10 ng/ml of leptin appeared intermediate between that seen at 
zero and 20 ng/ ml leptin thereby suggesting a U-shaped dose response relationship.
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The basal insulin secretion rate from the four different leptin treatment groups (5,- 
20ng/ml) ranged between 5.04 ± 0.43 pmoles/2min and 10.05 ± 0.62 pmoles/2min 
covering the pre-stimulatory period of the perfusion.
Introduction of glucose at 8mM with 5ng/ml leptin clearly led to suppression in 
insulin secretion rate below the mean value of the basal insulin secretion rate for sixteen 
minutes. The secretion rate ranged between 2.76 ± 0.49 and 12.87 ± 0.87 pmoles/2min 
during the time span mentioned and which timing coincided with the first peak and the 
first stage of the second peak pulse of insulin secretion. This indicated suppression, 
disclosed as a 51 ± 4% decrease from the rate of secretion observed in the first peak and 
second peak pulses of the control group during the same timing. At 28 minutes, a steady 
rise in secretion rate with a regular secretory oscillations pattern resembling the control 
was seen.
This was not the case in the dose response perfusion experiment 8mM glucose 
with 10 ng/ml leptin. The basal pre-stimulatory insulin secretion rate ranged between
4.18 ± 0.1 and 5.17 ± 0.1 pmoles/2min. After introducing the stimulatory medium, a 
biphasic secretory pattern was disclosed. The first phase of insulin secretion spanned 
fourteen minutes with a peak pulse of 5.05 ± 0.62 pmoles/2min reached six minutes after 
introducing the stimulatory medium and amounting to only 48.1% above the pre­
stimulatory level. The secretion rate dropped to 3.68 ± 0.12 pmoles/2min after which it 
was followed by a progressive rise in secretion displaying again a pattern of release with 
regular oscillations to reach 8.3 ± 0.67 pmoles/2min. There was an increased time span
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difference between the two phases (15min later) and with a significant delay of phase two 
only (26 min after commencement of perfusion with stimulatory glucose). The secretion 
rate after stimulation showed a suppression of 50.4% in the insulin level, with no 
decrease in phase two secretion.
Insulin secretion profiles from the 8mM glucose with leptin at 15ng/ml showed an 
irregular pattern of insulin secretion. A biphasic response profile was not evident and the 
insulin secretion rate ranged between 4.34 ± 0.2 and 13.24 ± 0.28 pmoles/2min with over 
ninety percent of secretion rate below or equal to basal pre-stimulatory secretion rate.
After introducing the stimulation medium in the perfusion experiment 8mM with 
20 ng/ml leptin, the first phase spanned eight minutes with a peak of 20.3 ± 0.85 
pmoles/2min a value representing a 65.2% rise above the pre-stimulatory level and 23% 
below control group peak pulse. A drop to 11.27 ± 0.12 followed phase one. The 
secretion rate of phase two ranged between 11.27 ± 0.12 and 26.1 ± 0.23 pmoles/2min. 
After minute 18, a steady rise in secretion rate with a regular well-marked secretory 
oscillation pattern was evident, starting 18minutes after shifting to the stimulatory 
medium and ranging between 15.51 ± 0.41 and 26.17 ± 0.23 pmoles/2min.
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3A.2.3 Insulin secretion at 12 mM glucose
In the same context of relating the glucose response of insulin to a variety of 
leptin concentrations, another set of ex vivo perfusion experiments was performed to 
study the effect of leptin on glucose (12mM)-stimulated insulin secretion. The 12mM 
glucose perfusion stimulates a biphasic insulin secretion pattern, as demonstrated here 
and elsewhere (Elahi 1985), with an initial pulse followed by a gradually increasing trend 
of insulin secretion.
The results of this component of the study are presented below in Figure 25. The 
average perfusion flow rate was -1.48 ± 0.3 ml/ 2min and the perfusion pressure 
maintained between 45 and 65mmHg.
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Figure 25: Effects of leptin at 0 (o), 5 ( a ), 10 (♦), 15 (■) and 20 ng/ml (•)  upon insulin 
output of the ex vivo pancreas perfused with 12mM glucose. N=4 for each 
leptin concentration.
Following confirmation of homogeneity of variances using Mauchly’s sphericity 
test, statistical analysis of the data presented in Figure 25, using a repeated measures 
design of analysis of variance, showed significant effects of leptin upon the insulin 
secretion pattern at 12 mM glucose (Fv[4,18] = 3168.9;/? <.001).
In the absence of leptin, basal insulin secretion rate over the first six minutes of 
the perfusion ranged between 7.39 ± 0.36 and 8.81 ± 0.20 pmoles/2min. A shift from 
basal to stimulation medium resulted in the biphasic secretion pattern disclosed with the
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first peak pulse reaching 50.06 ±1.13 pmoles/2min at 8 min. This fell to a nadir at 12 
minutes followed by the second phase showing a progressive increase from 22.3 ± 0.36 
pmoles/2min to 39.64 ± 0.87 pmoles/2min by the end of the experiment. The two phases 
of insulin secretion were separated by a fall to 22.39 ± 0.36 pmoles/2min. In both phases, 
the secretion rates increased by 82.38 ± 2% in phase one and 77.79 ± 3.0% as compared 
to the pre-stimulatory rates. The pattern of release in the absence of leptin disclosed 
regular secretory oscillations after the first phase and with seeretory cycles of 5.5± 
0.4min each, shown at the following times: 18 to 22 min, 24 to 30 min and 32 to 37 min.
The basal insulin seeretion rate from the four different leptin concentrations (5- 
20ng/ml) ranged between 5.32 ± 0.18 pmoles/2min and 6.51 ± 0.33 pmoles/2min 
covering the first six minutes of the perfusion experiment (N.B. no leptin was introduced 
during this period of perfusion in all experiments).
In the previous experiment using glucose at 12 mM, in the pancreata subjected to 
5ng/ml leptin, there was a complete suppression of insulin secretion rate to the average 
level of the mean value of the basal insulin secretion rate during the whole period of the 
experiment. The secretion rate ranged between 6.87 ± 0.54 and 8.11 ± 0.54 pmoles/2min. 
This indicated a decrease of 79 ± 4% from the rate of secretion observed in the first peak 
of the control group during the same timing, and an 82.6 ± 3% decrease from the 
maximum level attained in the control group during the same timing of phase two. 
Following time 20min, regular secretory oscillations patterns were observed with 
secretory cycles of 5.5± 0.4min each.
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This was not the case in the dose response perfusion experiment 12mM glucose 
with 15 ng/ml leptin. Following stimulation with 12mM glucose with 15 ng/ml leptin, a 
decrease in insulin secretion rate to 0.78 ± 0.02 pmole/2 min was observed in 2 minutes, 
after which a rise to 6.56 ± 0.28 pmole/2 min was reached after further six minutes. It 
could be inferred from overlapping this result on the control group, that a decrease in 
insulin secretion of 66.1 ± 3.0% was achieved. Phase two of the secretion ranged between
2.70 ± 0.30 and 4.20 ± 0.21 pmole/2 min, a level 35.0 ± 3.0% above insulin secretion in 
the pre-stimulatory period of the same experiment, but 68% lower when compared to the 
control ex vivo perfusion experiment with glucose at 12mM.
The first phase of stimulated insulin secretion in the ex vivo perfusion experiment 
at 12mM glucose with leptin concentration of 20 ng/ml spanned twelve minutes with a 
peak pulse of 6.67 ± 0.12 pmoles/2 min reached ten minutes after introducing the 
stimulatory medium. Although these results represented an increase above pre­
stimulatory secretion rate, they show a 68.7 ± 3.2% decrease in phase one, as compared 
to absence of leptin, with a delay of 10 minutes to reach the peak pulse (which occurred 
16 min after introduction of the stimulatory medium). Phase one was followed by a 
steady secretion rate ranging between 5.49 ±0.12 and 7.40 ± 0.43 pmoles/2 min in phase 
two until minute 38. After this point, a surge to 9.81 ± 1.57 pmoles/2min in less than 
three minutes presented another peak 40.0 ± 2% lower than the preparation in the absence 
of leptin. The presence of the typical secretory oscillations pattern up to 26 min 
demonstrates absence of the progressive increase in the insulin secretory rate in phase 
two, but with preservation of the basal cyclical pulsatile pattern of secretion.
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3.4.2A Insulin secretion at 16 mM glucose
This group of experiments was performed to investigate the effects of leptin on 
16mM glucose stimulated insulin secretion. Data from this experiment are displayed in 
Figure 26 overleaf. Statistical analysis of the data presented in Figure 26 confirmed that 
the data exhibited no significant departure from variance homogeneity. Repeated 
measures design of analysis of variance disclosed significant effects of leptin 
concentration (Fs [4, 18] = 3899.4; p < .001) during perfusion with glucose at 16 mM. 
The greatest degree of suppression of output appeared to occur at 15 ng/ml leptin, 
followed by a lesser degree of inhibition at 10 ng/ml leptin. At the highest leptin 
concentration of 20 ng/ml, the degree of inhibition appeared substantially smaller, insulin 
output being significantly less than in the absence of insulin but substantially greater than 
at the other three concentrations of leptin.
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Figure 26: Effects of leptin at 0 (o), 5 ( a ), 10 (♦), 15 (■) and 20 ng/ml (•)  upon insulin 
output of the ex vivo pancreas perfused with 16mM glucose. N=4 for each 
leptin concentration.
The 16mM glucose concentration in the perfusion medium stimulated a biphasic 
insulin secretion pattern (Elahi 1985), with an initial pulse followed by a gradually 
increasing secretion rate.
The basal pre-stimulatory insulin secretion rate of the perfusion at 16mM glucose 
ranged between 7.44 ± 0.49 and 9.93 ± 0.46 pmoles/2min. A shift from basal to 
stimulation medium resulted in the biphasic secretion pattern with the first peak pulse 
reaching 79.72 ± 0.90 pmoles/2min at eight minutes. This was followed by the second 
phase, showing a progressive increase ranging between 23.09 ± 0.38 pmoles/2 min and
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61.70 ± 0.85 pmoles/2 min 36 min later. The two phases were separated by a fall in 
insulin secretion rate to 23.09 ± 0.38 pmoles/2min. The secretion rates increased in phase 
one by 87.5 ± 2.0% and 83.9 ± 3.0% as compared to the pre-stimulatory secretion rates. 
The pattern of release disclosed regular secretory oscillations after the first phase, with 
seeretory cycles of 5.5± 0.4min eaeh.
The mean pre-stimulatory basal insulin secretion rate from the four groups 
(16mM glucose with leptin from 5 to 20ng/ml) ranged between 7.31 ± 0.02 pmoles/2min 
and 11.68 ± 0.12 pmoles/2min covering the first six minutes of the experiment. In this 
experiment, the insulin secretion rate in phase one reached 25.44 ± 0.28 pmoles/2min a 
decrease of 68.1 ± 3.0 % when compared to 16mM glucose without leptin. The phase one 
secretion lasted for only 4 minutes as opposed to 8 minutes in the control group meaning 
a deereased duration of insulin secretion in the first phase. The secretion rate that 
followed in phase two ranged between 17.5 ± 0.43 and 37.52 ± 1.83 pmoles/2 min. These 
results showed a decrease of 29.6 ± 2.0% at its highest level up to 40 min. A regular 
secretory oscillation pattern was again observed. This was followed by a surge in insulin 
secretion rate reaching 50.97 ± 1.16 pmoles/2min within 4 min, representing another 
peak 80.2 ± 3.2% above basal pre-stimulatory level, and 17.4 ± 2.8 % decreases from the 
same time point of perfusion in the absence of leptin.
With 10 ng/ml leptin, a rise in insulin secretion rate to 41.91 ± 0.02 pmoles/2min 
was observed at 6 minutes, a two-minute delay from that seen in the absence of leptin and 
a 46.1 ± 2.0 % decrease in the phase one peak pulse. A further decrease in secretion to
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6.90 ±0.15 pmoles/2 min as opposed to a trend of rising insulin secretion in the absence 
of leptin, showing an 80.8 ± 2% decrease at the beginning of phase two. This was 
followed by a gradual rise reaching 41.01 ± 0.72 pmoles/2min, a 74.8 ± 2.0 % rise above 
pre-stimulatory basal insulin secretion, and a 33.52 ± 3% decrease as compared to that 
seen in the absence of leptin.
At a leptin concentration of 15 ng/ml, there is a relatively complete suppression of 
insulin secretion as the expected biphasie pattern was absent. The secretion pattern 
through out the experiment was between 6.49 ± 0.33 and 24.38 ± 2.4 pmoles/2 min. With 
leptin at 15 ng/ml, the secretion point coinciding with phase one in the absence of leptin 
showed a reduction of 85.0 ± 2.0 %, and a decrease of 54.34 ± 2% from the highest point 
of insulin secretion in phase two.
3.4.3 Quantification of insulin release during perfusion: effects  of both  
g lu co se  and leptin concentrations
Insulin release was quantified using areas under the response profile. The areas 
estimated by the trapezoidal rule are initially expressed as pmole/2 min.min, which 
simplifies to pmole/2, .i.e. the total amount of insulin released under each experimental 
condition. The data are presented as an overall assessment of the effects of both glucose 
and leptin concentration upon insulin release, followed by examination of the effects of 
leptin concentration at each glucose concentration.
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3.4.4 Quantification of insulin release -  all com binations of g lu co se  and 
leptin.
Two-way analysis of variance (leptin and glucose) of total insulin secretion 
estimated as areas under the response profiles by the trapezoidal rule was performed. 
Homogeneity of variances was confirmed by the Levene test thereby validating the use of 
parametric analyses.
Significant effects of both glucose (F  ^ [3, 57] = 5244.5; p < 0.001) and leptin (F  ^
[4, 57] = 5317.4; p < 0.001) were disclosed. Further, a significant interaction between 
glucose and leptin concentrations (F  ^ [11, 57] = 1118.9; p < 0.001) indicated modulation 
of the insulin secretion response at differing perfusate concentrations of glucose by 
leptin. In view of this, it was considered necessary to examine separately the effects of 
leptin upon insulin secreted at each glucose concentration.
In all cases, a one-way analysis of variance was carried out of the effects of leptin 
upon total insulin secretion at each glucose eoncentrations. All such analyses showed 
significant effects of leptin (p always <0.001). Differences in insulin secretion between 
individual leptin doses were localized using Duncan’s multiple range test with a=0.05.
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3.4.4.1 Glucose at 4 mM
Quantification of total insulin secretion at 4 mM glucose, in the presence of leptin 
at 5, 10, 15 and 20 ng/ml, as total secretion and basal, phase 1 and phase 2 secretions are 
illustrated in Figure 27 below. It is evident that leptin has a reduced inhibitory effect on 
insulin secretion at lOng/ml of leptin. It inhibits output at any concentration as compared 
to the basal glucose (without leptin).
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Figure 27: Mean total areas (± S.F.M.) under the insulin response curve with glucose at 
4 mM and leptin at the concentrations indicated. Statistically similar (p > 
0.05) bars are indicated by the same letter.
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3.4A.2 Glucose at 8 mM
Levene’s test indicated no significant lack of homogeneity between the variances 
of the groups shown, and thus one way analysis of variance of the data was carried out 
with respeet to leptin concentrations followed by Duncan’s multiple range test with 
a=0.05. The data presented in Figure 28 below indicate that, at 8mM glucose, a U-shaped 
dose response relationship exists between insulin output and leptin concentration.
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Figure 28: Mean total areas (± S.F.M.) under the insulin response curve with 
glucose at 8 mM and leptin at the concentrations indicated. Statistically 
similar (p > 0.05) bars are indicated by the same letter.
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3.4A.3 Glucose at 12mM
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Figure 29:.Mean total areas (± S.E.M.) under the insulin response curve with 
glucose at 12mM and leptin at the concentrations indicated. 
Statistically similar (p> 0.05) bars are indicated by the same letter.
At 12mM glucose, leptin clearly has a suppressive effect, but the degree of 
suppression at the highest dose (20 ng/ml) is less than that seen in the presence of 8 mM 
glucose. Hence there is attenuation of the U-shaped dose response relationship with 
increasing glucose concentration, as demonstrated in Figure 29 above.
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3.4A.3 Glucose at 16mM
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Figure 30: Mean total area (± S.E.M.) under the insulin response curve with 
glucose at 16 mM and leptin at the eoncentrations illustrated. 
Statistically similar bars are (p > 0.05) indicated by the same letter.
At perfused glucose concentration of 16 mM, a similar pattern of U-shaped dose 
response relationship was observed (Figure 30 above). The suppressive effect of leptin is 
notably less than at glucose 12mM, suggesting that the stimulatory effect of the higher 
glucose concentration glucose over-rides the inhibitory effect of leptin.
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3.4.5 Quantification of the effects  of leptin on ph ase 1 and p h ase  2 insulin  
secretion .
The foregoing refers to the effects of leptin upon total insulin produetion over the 
entire perfusion period but gives no information as to the relative sensitivities to leptin of 
the individual phases of insulin secretion. Therefore, the effects of leptin upon each of 
phase one and phase two insulin seeretion were examined. Phase 1 secretion was taken as 
the duration of the first peak of secretion in non leptin-treated pancreata (6 -  14 min) and 
phase 2 was taken as the phase subsequent to the nadir of secretion seen at 16 min. These 
phases are evident in Figure 22 above.
Total insulin production in each phase under all conditions of glucose and leptin 
was estimated by the trapezoidal rule, as before. Normality of distributions of total 
insulin production having been confirmed (Kolmogorov-Smirnov p  always > 0.05), the 
effects of leptin at each glucose concentration were assessed by one-way analysis of 
variance and differences localized using Duncan’s multiple range analysis (a  = 0.05).
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3.4.5.1 Phase one insulin production
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Figure 31: Total area under the phase one insulin response curve (Mean ± 
S.E.M.) with glucose at 4 mM and leptin at the concentrations 
illustrated. Statistically similar bars {p > 0.05) are indicated by the 
same letter.
Hence at 4mM glucose, leptin appears to suppresses insulin secretion over the 
period of phase 1 secretion while glucose-stimulated pancreas with the least suppression 
at lOng/ml.
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3.4.5.1.2 Glucose at 8mM
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Figure 32: Total area under the phase one insulin response curve (Mean ± 
S.E.M.) with glucose at 8 mM and leptin at the concentrations 
illustrated. Statistically similar bars (p > 0.05) are indicated by the 
same letter.
The data in Figure 32 indicate that, while leptin at 5 and 10 ng/ml inhibited 
insulin output to similar degrees, a greater suppression was observed at 15ng/mlm but the
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suppressive effect was partially reversed at 20ng/ml. Once again a U-shape dose response 
relationship is indicated.
3.4.5.1.3 Glucose at 12mM
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Figure 33: Total area under the phase one insulin response curve (Mean ± 
S.E.M.) with glucose at 12 mM and leptin at the concentrations 
illustrated. Statistically similar bars {p > 0.05) are indicated by the 
same letter
Figure 33 interestingly reveals that the suppression at all doses of leptin is 
comparable indicating that, in the early postprandial state, leptin exerts an inhibitory 
effect on phase one insulin secretion.
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3.4.5.1.4 Glucose at 16mM
400
300
w^
 200 O
E
S
2
0)cO0>
V)
(0
JZa.
100
G lu c o se  = 16 mM 
Phase One 
A
Leptin Concetration
u Leptin = 0 ng/ml
■ Leptin = 5 ng/ml
■ Leptin = 10 ng/ml
■ Leptin = 15 ng/ml
■ Leptin = 20 ng/ml
B B
I
L eptin
Figure 34: Total area under the phase one insulin response curve (Mean ± 
S.E.M.) with glucose at 16 mM and leptin at the concentrations 
illustrated. Statistically similar bars (p > 0.05) are indicated by the 
same letter.
Figure 34 shows that the differences localized by Duncan’s multiple range 
analysis showed 5 and lOng/ml to have similar inhibitory effects, while a greater 
inhibitory effect to be seen at 15ng/ml. However, leptin at 20ng/ml showed substantially 
less inhibitory effect than the other leptin doses.
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3A.5.2 Phase two insulin production
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Figure 35: Areas under the phase two insulin response curve (Mean ± S.E.M.)
with glucose at 4 mM and leptin at the concentrations illustrated. 
Statistically similar bars (p < 0.05) are indicated by the same letter.
The differences localized by Duncan’s multiple range test are shown in Figure 35. 
Minimal suppression of insulin output by leptin was seen at leptin concentration of 10 
ng/ml.
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Figure 36: Area beneath the phase two insulin response curve (Mean ± S.E.M.)
with glucose at 8 mM and leptin at the concentrations illustrated. 
Statistically similar bars {p > 0.05) are indicated by the same letter.
Figure 36 again reveals significant inhibitory effects of leptin upon phase two 
insulin output at glucose concentration of 8mM. Duncan’s multiple range test showed 
progressive inhibition of insulin output up to and including leptin at 15ng/ml. Leptin at 
20ng/ml did not suppress insulin output, the output at this concentration being
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indistinguishable from that in the absence of leptin indicating once more a U-shaped dose 
response relationship between leptin concentration and insulin output.
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Figure 37: Total area under the phase two insulin response eurve (Mean ± 
S.E.M.) with glucose at 12 mM and leptin at the concentrations 
illustrated. Statistically similar bars are indicated by the same letter.
One way analysis of variance of the data displayed in Figure 37 again revealed 
significant effects of leptin upon phase two insulin output at glucose concentration of 
12mM. Duncan’s multiple range test showed identical inhibition at leptin concentrations
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of 5, 10 and 15ng/ml, with a small but significant (p < 0.05) reduction in the inhibitory 
effect at 20ng/ml. Once again, a U-shaped dose response relationship was demonstrated.
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Figure 38: Total area under the phase two insulin response curve (Mean ± 
S.E.M.) with glucose at 16 mM and leptin at the concentrations 
illustrated. Statistically similar bars (p > 0.05) are indicated by the 
same letter.
Effects of leptin upon phase two insulin output at glucose concentration of 16mM 
are shown in Figure 38 above. The data reveal progressive inhibition from 5 to 15ng/ml
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leptin concentration, but with a dramatic recovery at 20ng/ml to a level comparable to 
that seen in the absence of leptin. This demonstrate that at 16ng/ml, the inhibitory effects 
of leptin is overridden by the stimulatory effect of glucose upon insulin secretion.
3.4.6 D ose dep en d en cy  of g lu co se  and leptin e ffects  upon insulin 
secretion.
3.4.6.1 Overall insulin output
Clearly there are relationships between the coneentration of glucose perfusing the 
pancreas and the dose of leptin being applied under various perfusion conditions. These 
require further examination in order to quantify the dose response relationships of 
glucose and leptin dependency of insulin output. A number of linear regression analyses 
were therefore conducted upon pooled data. In order more precisely to locate the parts of 
the secretion response particularly affected by either glucose or leptin concentrations, the 
total area under the curve was examined and this was followed by examination of basal 
output, phase one and phase two areas beneath the curve. In the illustrations presented, 
the equation of the line including value of slope (and SE^) and intercept are provided 
together with the correlation coefficient (r) and the coefficient of determination (r^).
Examining first the relationship between insulin output and glucose concentrations shown 
in Figure 39 overleaf, in which the regression coefficients are presented.
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Figure 39: Regression of total insulin output upon glucose concentration, at all 
concentrations of leptin, in the perfusion medium.
As would be expected, the insulin output shows dependency on glucose in the 
perfusate. At r^=0.317, only 31.7% of the variance in total insulin output is explained by 
glucose concentration alone. Reference to Figure 40 overleaf suggests that the low value 
for the coefficient of determination is attributable to the inhibitory effects of leptin upon 
insulin output.
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Figure 40: Regression of insulin output upon leptin concentration, at all glucose 
concentrations, in the perfusion medium
When both leptin and glucose effects upon total insulin output are taken into 
account, the value of r is 0.625 with 0.391, indicating that almost 40% of the variance 
in the insulin output is attributable to the combined effect of glucose and leptin. It is 
evident that the major regulator is glucose but clearly leptin has important modulatory 
effects.
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Having examined overall insulin production it is now necessary to examine more 
closely the dependency upon glucose and leptin of the components of the overall 
response profile.
3.4.6.2 Basal Insulin output
As insulin output in the basal phase was a result, in all cases, of stimulation with 
glucose at 4mmoles/L it is necessary in this phase to examine only the effect of leptin 
concentrations. The data are shown, as total (area under the curve) output against 
perfusing concentration of leptin in Figure 41.
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Figure 41: Regression of basal phase insulin output (as area beneath the curve) 
upon leptin concentration.
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It is evident from Figure 41 above that leptin is without effect upon basal phase 
insulin output, there being no significant correlation between the variables of insulin 
output and leptin concentrations during the basal phase. In addition, the value of the slope 
of the regression does not differ significantly from zero. It therefore follows that the 
major effects of leptin must be manifested upon phase one, phase two or both. Hence, 
examination of the relationship between glucose and leptin and phase one insulin output 
is required.
3A.6.3 Phase one insulin output.
The relationship between glucose concentrations and insulin outputs, at all leptin 
concentrations, are shown in Figure 42 below. There is clearly a dependency upon 
glucose concentration in terms of insulin output as would be predicted; the above 
illustration shows that 25.3% of the variance in phase one insulin output is directly 
attributable to change in glucose concentrations.
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Figure 42: Regression of phase one insulin output upon glucose concentration 
in the perfusate.
Conversly, leptin shows an inhibitory effect upon phase one insulin output as 
shown in Figure 43 below.
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Figure 43: Regression of phase one insulin output upon leptin concentration in 
the perfusate.
It is clear that while leptin had no effect upon basal insulin secretion, there is a 
significant dose-related inhibitory effect upon phase one secretion. The data indicate that 
the inhibitory effect of leptin explains 23.8% of the total variance in phase one insulin 
output, and thus leptin is clearly a significant factor in the modulation of glucose induced 
phase one insulin output.
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3.4.6.4 Phase two output of insulin
Figure 44 shows the regression of phase two insulin output upon glucose 
concentrations in the perfusate.
r= 0.561 : p<0.001 
i^= 0.315
Y= (35.86 ± 6.27)x + 128.1
1300
1200
1100
% 1000
900
800
700
600
500
400
300
200
100
4 6 8 9 10 11 12 13 14 15 165 7
P e r f u s a te  G lu c o se  C o n c e n tra t io n  (m M )
Figure 44: Regression of phase two insulin output upon glucose concentrations 
of perfusate.
The data in Figure 44 follow the expected pattern in that glucose increases the 
insulin output and in this instant, the glucose concentration explains 31.5% of the 
variance in phase two insulin output. This apparently low proportion of explained 
variance is of course the result of the effect of leptin militating against the effects of 
glucose as displayed in Figure 45.
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Figure 45: Regression of phase two insulin output upon leptin concentrations of 
perfusate.
Notably, the correlation between insulin output and leptin concentration, as 
examined using Fisher’s z transform of r, is significantly stronger (p < 0.001) in phase 
two than in phase one of insulin output suggesting that phase two secretion is more 
consistently inhibited by leptin than phase one secretion.
Again, a significant inhibitory effect of leptin on insulin output is seen, this time 
in phase two. The data indicate that 8.3% of the variance in phase two insulin output is
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attributable to the effects of leptin. Reference to Figure 43, in relation to the above Figure 
45, shows asymmetric distribution of points around the regression lines implying 
differential effects of leptin concentrations at different glucose concentrations. This 
observation is made particularly clear by reference to Figures 46, 47, and 48 below, 
which are three-dimensional presentations of the response surfaces to both leptin and 
glucose, which varies between phases of the response profile.
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Figure 46: The total insulin secretion response surface to the combinations of 
glucose and leptin used in this study.
193
U)
o
E
8
c
.0
gQ)
CO
I
(0
c
Figure 47: The phase one response surface to the combinations of glucose and 
leptin used in this study.
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Figure 48: The phase two-response surface to the combinations of glucose and 
leptin used in this study.
As indicated in Figure 46, the insulin secretory pattern seen with increasing 
concentrations of leptin at low glucose concentrations is reversed at high glucose 
concentrations with the same leptin concentrations. Leptin concentrations of 5ng/ml show 
suppressive effect on insulin secretion as glucose concentration increases relative to 
control group (absence of leptin). At leptin concentrations of lOng/ml, insulin secretion is 
slightly increased relative to control groups, while it is decreased significantly, as the 
glucose concentration rises to reach its maximum suppression at the highest glucose
195
concentration (16 mM) used in this study. At high concentrations of leptin (>15ng/ml), 
total insulin secretion is suppressed at all of the glucose concentrations relative to the 
control group as shown in Figure 46.
The same pattern of insulin secretion was observed in both phases and with the 
same leptin concentration distribution, where the pattern is reversed as the glucose 
concentration increases as is shown in Figure 47 and 48. It is worth noting though that the 
decrease of insulin secretion with low leptin concentrations was more pronounced in the 
phase two compared with phase one. In addition, the suppression of insulin secretion was 
total at maximum concentrations of leptin and glucose in phase one as opposed to phase 
two where the maximum suppression is at the minimum concentration of both leptin and 
glucose.
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3.5 Vascular connections between the duodenum and the pancreas
It is evident from the data that insulin secretion using the ex vivo perfused pancreas 
was generating similar to those obtained from in vivo experiments. It is well established that 
the intestine acts as a source of incretins, which play a potentiating and inductive role in the 
stimulation of insulin. Since the systemic route that incretins follow to reach the pancreas 
hepatic portal vein to systemic circulation was not present in our experimental protocol, and 
since the intestine was included in our experimental design, it was hypothesized that there is 
a potential direct connection between the intestine and the pancreas through either a neural or 
humoral connection or both. A number of reports indicated a central neural connection 
between both (Fehmann 1997a; Deacon CF, Johnsen AH and Hoslt JJ 1995). Since the brain 
of the experimental rat was dead, then this option was potentially not applicable. Since there 
are no reports of any humoral connection between the gut and the pancreas in the literature, 
then either a direct humoral connection not reported before could be the link, or some cellular 
system functioning at the level of the cell to cell junctions was responsible for the transfer of 
incretins to the pancreatic endocrine cells. Following the sequence of colouration following 
injection of an appropriate dye would indicate a unidirectional flow if any exists. The 
colourant was introduced through the superior mesenteric artery to investigate the pattern of 
coloration, which might support the hypothesis of direct vascular connection between 
intestine, principally the proximal duodenum, and the pancreas.
The data are presented in Figure 49 A-G. Upon introducing 10ml of methylene blue 
directly into the superior mesenteric artery at the same rate as the perfusates were introduced, 
there was immediate coloration of the mesentery (Figure 49 C) followed by a progressive
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coloration of the duodenum (Figure 49 D). This was followed by a mild coloration of the 
head of the pancreas (Figure 49 E) after which the coloration intensified progressively. This 
was followed by a mild coloration of the pancreatic tail (Figure 49 G), during which diluted 
methylene blue started appearing in the perfusion outlet. The serial pictures of the present 
experiment, shown on the following two pages, show the coloration of the head of the 
pancreas followed by the mild coloration of the tail as a sequential set of events. This 
clearly, and for the first time demonstrate a potential direct humoral connection between the 
duodenum and the pancreas with an apparent directionality of flow within the latter. Further 
work is needed to identify and characterize the apparent vascular link between the two 
organs.
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Figure 49-A: Aortic cannula in place. Figure 49-C: Methylene-blue passing the mesenteric 
circulation before appearing in the 
duodenum.
Figure 49-B: The superior mesenteric artery 
cannula (red hilt) in place.
Figure 49-D: Methylene-blue appearing in the 
duodenal wall.
199
mFigure 49-E: The pancreatic tail raised showing Figure 49-G: Finally, the pancreatic tail showed
the head becoming coloured before mild coloration,
the tail, indicating a unidirectional 
flow from duodenum to pancreatic 
head and then tail
Figure 49-F: Further methylene-blue introduced, 
intensifying the pancreatic head 
coloration, as well as that of the 
duodenal wall.
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This experiment demonstrates for the first time, to the author’s belief, the 
existence of humoral or sub-humoral direct connection (s) between the duodenum and the 
pancreas, with significant implications for the understanding of the action of gut peptides 
upon pancreatic exo- and endocrine secretions.
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4. Discussion
The understanding of physiology of leptin regulation of insulin secretion in 
normal rats has been a controversial issue due to differing experimental designs, and 
frequently inconsistent findings. This has generated many uncertainties regarding optimal 
models and conditions for experimentation and the intracellular mechanisms involved in 
secretion of insulin and its modulation by leptin. It has been shown that leptin plays an 
important role in the central nervous system regulation of food intake hence influencing 
body weight, energy expenditure, and overall adiposity. Leptin action has also been 
reported in peripheral tissues such as muscle, liver and the pancreas. The discovery of the 
long form of the leptin receptor in the islets (Tartaglia et al 1995) supported the 
possibility of direct actions of leptin on pancreatic B-cells. Leptin clearly reduces insulin 
secretion in isolated pancreatic B-cells, isolated islets (Pallet 1997; Chen 1997) and 
isolated perfused pancreas preparations from leptin-deficient ob/ob mice with no previous 
exposure to leptin (Emilsson 1997) and presumably very high sensitivity to leptin. 
However, the administration of leptin and its effect on insulin secretion, insulin receptor 
and the common intracellular mechanisms, in normal rats has produced divergent results 
(Leclerq-Meyer and Malaisse 1997, Leclerq and Malaisse 1998).
In isolated islets from rat or mouse, and in the perfused rat pancreas, leptin has 
been reported to stimulate insulin secretion (Tanizawa et al 1997) and to have no effect 
(Scherer 1998), depending on the leptin doses employed and the experimental design. In 
the present study, an attempt was made to create an index showing the glucose-induced
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insulin response and its modulation by leptin in ex vivo experiments where relatively 
comparable responses to in vivo experiments were observed.
4.1 General Observations
Glucose-induced insulin release at concentrations of glucose of 8, 12, and 16mM 
(from ex vivo perfused pancreata) showed a glucose dose-dependent biphasic pattern of 
insulin release, comparable to those of other reports, in response to the administration of 
D-glucose. With increasing glucose concentration in the perfusion medium, the response 
manifested itself as a biphasic pattern with relatively higher insulin peaks. This was in 
concordance with reports by many researchers using in-vivo techniques (Cases et al 2001; 
Zawalich WS, Zawalich KC, Shulma GI and Rosetti L 1990), isolated perfused pancreas 
(Efendic S, Carasi E, Luft R and Gladnikoff G 1976), in vitro perfused pancreas method 
(Holz 1993; ) or by cultured isolated islets (Kulkarni et al 1997) with minor differences 
indicative of some interesting variations worth exploring. These observations are 
supported by the glucose-sensing concept of pancreatic p-cells, where a glucose sensor 
(Schuit CF, Huypens P, Heimberg H and Pipeleers DG 2001) that operates at 
physiological concentrations, in synergy with signals integrating messages originating 
from hypothalamic neurons and endocrine cells of the gut and the pancreas. Glucose- 
stimulated insulin secretion (GSIS) is initiated by the uptake of glucose by the glucose 
transporter GLUT2. Glucose is then phosphorylated by glucokinase and further 
metabolized through the glycolytic pathway. Activation of mitochondrial metabolism 
then leads to generation of coupling factors, ATP (Ashcroft et al 1994) and glutamate
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(Maechler P and Wollheim CB 1999; Maechler P, Gjinovci A, and Wollheim CB 2002), 
which trigger distal steps in insulin granule exocytosis. The high Km (6 mM) hexokinase 
IV, referred to as glucokinase (lynedjian et al 1982; Matschinsky, FM 1996), is the rate- 
limiting step in glucose metabolism by B-cells, and it therefore exerts significant control 
over the entire process which involves the rate of glucose utilization, glucose oxidation, 
and thus insulin secretion (Thorens B, Guillam MT, Beermann F, Burcelin R, and Jaquet 
M 2000). Since glucokinase is not inhibited by G6P, it establishes the basis of a 
proportional change in cytoplasmic G6P concentration when extra-cellular glucose 
concentrations increase (Wang and lynedjan 1997, Sekine et al 1994). In addition, it was 
demonstrated that the rate of glucose uptake exceeds the rate of phosphorylation 
(Heimberg H, De Vos A, Vandercammen A, Van Schaftingen E, Pipeleers D, and Schuit, 
F 1993) implicating a permissive role for GLUT2 in glucose sensing by allowing an 
unrestricted access of glucose to glucokinase (Thorens 2000). Furthermore, in rats, 
glucose stimulation results in biphasic insulin release, with a transient first phase 
followed, after 4-5 min, by a gradually increasing second phase (Curry 1968). In 
contrast, the perfused mouse pancreas exhibits a weak second phase compared with the 
first phase in response to glucose stimulation (Lenzen 1979) demostrating species 
differences. During glucose stimulation, glutamate is generated by the mitochondria and 
plays a role in stimulus-secretion coupling (Maechler 2002).
In the present study, and in concordance with the proportionality of insulin 
response to relevant glucose concentration concept mentioned above, a peak insulin 
release of 26.37, 37.05, and 79.72 pmoles/2min, as the first phase response to 8, 12,. and
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16mM D-glucose respectively, was observed. The pattern of release demonstrated a 
response lag phase of approximately 1 minutes, after shifting to the stimulating glucose 
concentration attributable to the deadspace of the apparatus. The response was manifested 
as a sharp rise followed by an immediate fall, as previously reported (Maechler 2002) and 
referred to in the introduction of this report. In response to the glucose concentrations 
examined, the first phase showed a 3, 5, and 10 fold increase from basal secretory pattern 
at 4mM glucose comparable with a number of previous reports (Ashcroft et al 1994; 
Harada E, Habara Y and Kanno T 1982; Chen and Romsos 1995; Tanizawa et al 1997; 
Maechler 2002). The pattern of increase reported is in concordance with insulin secretion 
found when B-cells were potentiated by pre-exposure to basal glucose concentrations 
after a 24-hour fast (Efendic 1976), increasing intracellular substrate phosphorylation 
(Schuit 2001). This leads to a shift in the ATP/ADP ratio (Rubi 2004), although nutrient- 
stimulated insulin secretion is limited by the inherent thermodynamic constraints of 
mitochondrial proton gradient formation (Roduit R, Nolan C, Alarcon C, Moore P, 
Barbeau A, Delghingaro-Augusto V, Przybykowski E, Morin J, Masse F, Massie B, 
Ruderman N, Rhodes C, Poitout V and Prentki M 2004). This leads to depolarization of 
the potassium channels leading to release of the docked granules (Daniel 1999; Ohara- 
Imaizumi M, Nakamichi Y, Tanaka T, Ishida H, Nagamatsu S 2002). It is worth noting 
that since the magnitude of the first phase of insulin release is apparently dependent upon 
the concentration of glucose, and since the first phase is determined by the depolarization 
of the B-cell plasma memebrane after closure of the potassium channels, it might be 
indicative that the ratio of ATP/ADP, which determines the dege of depolarization, might 
also determine the number of docked granules released by the B-cell. Since a secretory
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granule contains up to 2fg of insulin (Eliasson L, Renstrom E, Ding WG, Proks P and 
Rorsman P 1997), it might explain the different peaks of insulin secretion reached with 
the different glucose concentrations introduced.
Further potentiation by intestinal incretins, such as GIP and GLP-1, might be 
implicated. Such incretins have been shown to play a major role in potentiation (Turton et 
al 1996) and induction (Balkan and Li 2000) of glucose-induced insulin release, where 
GLP-1 receptor signaling can antagonize B-cell repolarization by reducing voltage- 
dependent currents, an effect likely to contribute to GLP-1’s glucose-dependent 
insulinotropic effect (MacDonald PE, Salapatek AMF, and Wheeler 1 MB 2002). The 
present study has also provided new evidence for a direct vascular connections between 
the digestive tract and the pancreas, whereby duodenal incretins may have direct access 
to the islet microvasculature and hence the pancreatic B-cells, which may have played a 
major role imitating the in vivo cascade of events as the intestine was included in the 
present ex vivo perfusion experiments. In addition, there is further elaboration on the 
neural connection between the portal vein and the duodenum, which acts as a potential 
stimulator of L-cells to secrete the GLP-1, thus possibly reaching the pancreas directly 
through the humoral connection reported in this study. In addition, the identification and 
characterization of glucoresponsive neurons in the enteric nervous system (Lui 1999) 
clarified further the importance of GLP-1 in potentially enhancing the glucose-induced 
insulin release. This is further supported by the fact that high glucose concentrations are 
perfused through the superior mesenteric aretery, and thus stimulating the L-cells of the 
intestinal tract, possibly leading to a stimulate myenteric nervous system.
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The second phase of insulin release was manifested as a gradual increase as 
compared to the first phase (Figure 22). It was previously attributed to increased rate of 
insulin synthesis (Curry 1986) and thus secretion (Sando and Grodsky 1973). The reserve 
pool contains around 12000 granules (Bratanova-Tochkova et al 2002), and the islets 
reserve of insulin is much more than that needed by a meal (Daniel 1999) therefore, the 
second phase is manifested by mobilization of granules from the reserve pool to the 
readily releasable pool (Bratanova-Tochkova et al 2002) secreted in a nutrient-dependent 
manner (Rorsman et al 2000). Second phase insulin output ranged between 19.6, 38.01, 
and 61.58 pmole/2min after about 40 minutes of continuous perfusion in the experiments, 
where the perfused pancreas was stimulated with 8, 12, and 16mM glucose respectively 
and maintained for as long as the glucose load was supplied to the pancreas. This pattern 
of secretion indicates that the B-cells are able to release optimum amounts of insulin, 
suggesting that the ex vivo technique used here closly represents the physiological 
situation. Since the second phase of insulin secretion requires near maximally activated 
B-cell fuel metabolism (Nesher et al 2002), and since glucose metabolism is proportional 
to the extracellular concentration, then insulin concentration secreted during phase two 
depends on the rate of glucose metabolism affecting granule mobilization (Bratanova- 
Tochkova et al 2002), docking and thus secretion. This can be exemplified by examining 
the difference of insulin secretion rate in five minutes (Figure 22, 15 to 20 min) of each 
of the experiments in which glucose alone was perfused. The difference between the 
insulin secretion rate in 8 and 12mM glucose was only 1.03 pmoles while the difference 
between 12 and 16mM glucose was a 2-fold increase. This coincided with an increase in 
the glucose utilization as its concentration increases (Figure 20) indicating a direct
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proportional relationship between them. This was relatively the case in phase one as the 
difference in glucose utilization was also significant, further supporting the concept 
indicating other contributing intracellular metabolic mechanisms involvement as 
presented by insulin and glucose (Barg 2002; Henquin 2002) stimulating phase one 
synergistically. Therefore, both first and second phase insulin outputs are dependent on 
the concentration of glucose concentration administered as illustrated in Figure 22.
The time lapse before maximal glucose concentration was reached (first 8 minutes 
in Figure 20) after introducing the stimulatory D-glucose in the perfusion medium is due 
to a dilution with the medium, already in the cannula from the basal perfusion medium, 
which fills the coeliac artery, the various vessels of the pancreas, and the portal vein 
reaching the collection tubes in the fraction collector. The first peak of insulin release 
was achieved after an average of 2 minutes (Fig 22), following the introduction of the 
stimulatory medium, in the three baseline experiments. This was followed by the 
maximal level of glucose utilization, which was reached in an average of 3 minutes (Fig 
20). This time duration was consistent with the reported four-fold stimulation of insulin 
receptor B-subunit tyrosine phosphorylation by insulin itself, acting as an autocrine agent 
(Rothenberg 1995). It is followed by a subsequent dephosphorylation to basal level by 10 
to 15 minutes, thus overlapping the timing for insulin biosynthesis, a pre-requisite 
process to support the storage pool (Bratanova-Tochkova et al 2002) for insulin secretion. 
This timing closely coincides with the insulin response pattern of the present ex vivo 
experiments, suggesting a potential dose-dependency of the first phase of insulin 
secretion on the B-cell intracellular phosphorylation pathways of insulin receptor by
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insulin and glucose metabolites. This time lapse of insulin response was previously 
reported from various perfusion experiments (Pipeleers et al 1985; Elahi 1985; Curry 
1968), evidently without clear notions of the intracellular mechanisms taking place.
The biphasic insulin secretion suggested the presence of two intracellular pools of 
insulin in the p-cells (Sando and Grodsky 1973), probably controlled by at least two 
different molecular metabolic mechanisms (Curry 1986, Aspinwall et al 2000). Aspinwall 
et al. (2000) proposed that the oscillating intracellular calcium concentration plays a role 
in the insulin release where, in response to glucose in B-cells and in intact pancreatic 
islets, it may have important physiological implications by being related to the pulsatile 
release of insulin. Furthermore, when calcium concentrations and insulin release were 
measured simultaneously, it was shown that the release of the hormone from a single islet 
was synchronized with slow calcium oscillations (Lundquist 1976; Maechler 2002). 
Grodsky et al (1969) related the biphasic insulin secretory pattern to the presence of two 
different compartments, as is evident in the response to glucose and tolbutamide 
stimulation, and as was confirmed later at the molecular level (Bratanova-Tochkova et al 
2002). Only a small proportion (-15%) of the B-cell insulin potential is stored and thus is 
available for immediate release upon stimulation (Daniel 1999). The remaining insulin 
potential, resulting from synthesis under nuclear coordination, is released at a slower rate. 
The biphasic rise in cytoplasmic Ca^^concentration ([Ca '^^Ji) induced by glucose is 
important to shape the two phases of secretion. The first phase requires a rapid and 
marked elevation of [Ca '^ J^i and corresponds to the release of insulin granules from a 
limited pool. The magnitude of the second phase is determined by the elevation of
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[Ca '^ l^i, but its development requires production of another signal. This signal 
corresponds to the amplifying action of glucose and may serve to replenish the pool of 
granules that are releasable at the prevailing [Ca '^ J^i (Henqiun JC, Ishiyama N, Nenquin 
M, Ravier M and Jonas JC 2002). Physiological concentrations of calcium were included 
in the perfusate, resulting in concordant manifestation of insulin secretory patterns. One 
of the most important signals is the reduced pyridine nucleotides (NADH and NADPH) 
that increase in glucose-stimulated islets (Rubi 2004) via the NADH shuttle system, 
which transports reducing equivalents from the cytosol to the mitochondria, and is 
essential for the coupling of glucose metabolism to insulin secretion in pancreatic B-cells. 
Biochemical measurements at selected time points in batches of rat islets have suggested 
that pyridine increase is biphasic (Malaisse 1977), and continuous recording of the auto­
fluorescence of NAD(P)H in isolated rat B-cells has shown that the response is often 
biphasic (Pralong WF, Bartley C, Wollheim CB 1990). The B-cells in the perfused 
pancreas could be undergoing this mechanism since the cyclic pattern of secretion in 
phase two appears to follow a regular course.
These reports are in concordance with the present study where the phase 1 
response lasts between 5 and 8 minutes, superimposed on a more prolonged increase in 
the rate of insulin secretion over the time span of the perfusion experiment. In this study, 
about 20% of the total insulin output was secreted during phase one. Calcium was present 
at physiological concentration in perfusates supplying adequate extracellular 
concentrations for B-cells. In addition, magnesium was also present at physiological 
concentrations to provide a shield for the negatively charged groups of ATP and thereby
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facilitating the nucleophilic attack resulting in phosphorylation of glucose by glucokinase 
(Curry 1977) during glycolysis in the B-cells.
The rapid fall in insulin secretion, which terminates phase one, has been 
suggested to indicate the existence of significant autocrine effect of insulin itself on the 
B-cells, which express components of insulin signalling systems (Aspinwall et al 2000). 
This was long ago reported to result in local increases in insulin concentration, inhibiting 
insulin secretion from isolated islets of Langerhans (Loreti L, Dunbar J, Chen S and Foa 
P 1974). Similar inhibition of insulin secretion was suggested to exist in the perfused rat 
pancreas (Iversen J and Miles D 1971). This is consistent with a short negative feedback 
loop operating through the insulin receptor present on the B-cells (Flarbeck 1996). This 
may suggest a suppressing effect upon phase one secretion 8 to 10 minutes after the sharp 
increase, a time consistent with the dephosphorylation of the insulin receptor itself (Jones 
P and Persaud S 1998), implying the end of one phase and the beginning of another. In 
turn it may also indicate overlapping of the two phases in the sense of new secretory 
granules appearing in the second phase of insulin secretion where the timing (10 to 15 
minutes after introducing glucose in perfusion) coincides with onset of insulin 
biosynthesis (Herbert et al 1998). When the sequence of events discussed are considered 
at the molecular level, insulin binding to the 97KDa insulin receptor a-subunit on the 
surface of B-cells, stimulates intrinsic protein tyrosine kinase activity, 
autophosphorylation (Kasuga 1982), and subsequent tyrosyl phosphorylation of insulin 
receptor substrate (1RS) proteins with adapter proteins such as She and Cbl/CAP, which 
are activated as a result (Rothenberg 1995; Kido 2001; Galic S, Klingler-Hoffmann M,
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Fodero-Tavoletti MT, Puryer MA, Meng TC, Tonks NK and Tiganis T 2003). Tyrosine 
phosphorylation of the insulin receptor substrates (IRS-1) (Xu 1999) is followed by an 
increase of two to fivefold association of IRS-1 with the 85kDa alpha-subunit (Cheatham 
and Kahn 1995) of the phosphatidylinositol-3-kinase, as well as with other proteins. In 
addition, protein tyrosine phosphatases (PTPs) have a prominent role in the control of 
insulin receptor (IR) signaling (Galic et al 2003). PTPs dephosphorylated the IR and its 
substrates and thus serve to inactivate the IR and terminate signaling. The IR and 1RS 
proteins are rapidly and transiently phosphorylated in response to insulin, with 
phosphotyrosine (pTyr) content in the IR returning to basal levels within minutes of 
stimulation (Goldstein BJ, Ahmad F, Ding W, Li PM, and Zhang WR 1998). This is 
consistent with the bi-phasic pattern of insulin secretion where a sharp decrease of insulin 
release is observed after around 8 minutes, keeping in mind that insulin has a dose- 
dependent inhibitory effect on its own secretion. Since tyrosine phosphorylation of the 
97KDa protein does not occur when pTC3-cells are exposed to 15mM glucose in a 
calcium-free medium (Xu 1999), this suggests that the secretion of insulin into the 
extracellular medium is necessary for glucose to induce tyrosine phosphorylation and 
thus result in the first phase secretory pattern.
It is worth noting that these signalling proteins, which accompany glucose- 
induced insulin secretion, also occur in response to exogenous insulin, in the absence of 
B-cell secretion (Rothenberg 1995). Furthermore, maximal glucose-induced production 
of phosphatidylinositol 3, 4, 5-triphosphate (PIP-3) by PI3-Kinase, which forms an 
essential link between insulin receptor and glucose transporter translocation and the
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intracellular trafficking of insulin vesicles, coincides with the early peak phase insulin 
granule secretion of cultured islets and isolated B-cells (Alter AC and Wolf AB 1995). 
Several lines of evidence suggest that phosphorylated products of phosphatidylinositol 
play critical functions in the regulation of cellular trafficking along the secretory 
pathway.
4.2 Perfusion experiments revisited
The fasted experimented rats did show a decrease in insulin secretion rate in 
contradiction to results previously reported (Malaisse WJ, Malaisse-Lagae F and Wright 
PH 1967), where 24 hour fasting period led to a decreased response of glucose-induced 
insulin release, since starvation has been reported to reduce the sensitivity of the pancreas 
to glucose, and where the vagus exerts an inhibitory activity on interdigestive insulin 
secretion that is partly mediated by the splanchnic nerves (Blat S and Malbert CH 2001). 
This is consistent with B-cell fatty acid oxidation after prolonged periods of starvation, 
which results in reduced insulin secretion. In addition, it was reported that islet c-AMP 
concentration was reduced due to low glucose availability, resulting from 24 hour fasting 
(Jhala et al 2003). This was readily reversed by caffeine, which supports the view that 
changes in c-AMP concentration could be responsible for the reportedly diminished 
insulin response in perfused pancreas experiments of rats fasted for 24 hours (Hedeskov 
CJ and Capito K 1975). The discrepancy between the results of this study and those of 
Malaisse and Blat and Malbert could be due to species differences and experimental 
protocols. Such a reduction was manifested by the elevation of the threshold of
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stimulation (higher Km) of the insulin response, where the initial and late insulin 
responses were affected in a symmetrical manner by fasting (Efendic 1976).
In the present ex vivo perfusion study, the pancreas was kept in the rat with its 
vascular connections to the intestine at least partially patent, via the mesenteric artery and 
the presently demonstrated vascular channel between duodenum and pancreas. This 
would allow insulin secretagogues, such as GLP-1 possibly to render the islets glucose 
competent (Holz and Habener 1992). GLP-1 stimulates glucose-induced insulin secretion 
in a linear manner, with a consistent increase in insulin secretory rate at each ImM 
glucose interval, but with no priming effect on subsequent insulin secretory response to 
glucose (Brandt et al 2001) as opposed to the report of Holz (1993), manifesting a 
response similar to the in vivo response even with basal glucose concentrations (4mM). 
This direct effect of GLP-1 was further supported by the significant amount of GLP-1 
receptor mRNA in pancreatic islets, with maximal expression when pancreatic islets were 
incubated at a physiologically low glucose concentration (5.5mM) (Garcia-Flores 2001). 
In addition, glucose competence allows membrane depolarization, generation of action 
potentials, stimulation of cAMP formation and Ca^ "^  influx, which are events triggering 
insulin secretion (Holz 1993). A pre-stimulatory period with 4mM glucose before any 
attempt to stimulate insulin secretion with higher glucose concentrations probably 
rendered the pancreas glucose competent although such low glucose concentration did 
not manifest competence effect on pancreatic insulin secretion as reported by Efendic et 
al. (1976). The discrepancy lies in the different experimental procedure followed. Efendic 
et al. (1976), used a completely isolated perfused pancreas, separated from the intestine
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and the stomach where they used a glucose concentration of 8.3mM for the equilibrium 
pre-stimulatory period, as compared to 4mM in the present study. This relatively high 
glucose concentration (8.3mM) was necessary to potentiate markedly the insulin response 
to subsequently used stimulants in the pancreas from fasted rats. Therefore, comparing 
the two experiments, it clearly suggests that the potentiation of B-cells is dependent on 
glucose and incretins working in synergy, and the absence of the incretins in the report by 
Efendic et al (1976) may be responsible for the marked increase in pre-stimulatory 
glucose concentrations as an attempt to compensate for the lack of incretins. These 
observations lead to the conclusion that pre-stimulatory glucose induced two distinct 
effects on the B-cell: on the one hand, it generated a time-dependent state of potentiation 
in the islet; on the other hand, it participated in initiating an acute insulin release. In either 
case, both effects appear to have operated in the present ex vivo perfusions as the results 
were in concordance with in vivo results and showed discrepancies with the wholly in 
vitro isolated perfused pancreas results mentioned above.
4.3 4mM glucose-induced insulin secretion pattern
The insulin secretion from the ex vivo perfused pancreas subjected to fasting 
glucose levels (4mM), did not manifest a biphasic insulin release response but showed a 
pattern of release with regular oscillations shown throughout the whole perfusion period. 
The cells within the intact islet of Langerhans function as a metabolic syncytium, 
secreting insulin in a coordinated and oscillatory manner in response to external fuel 
(Katzman SM, Messerli MA, Barry DT, Grossman A, Harel T, Wikstrom JD, Corkey BE,
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Smith PJS and Shirihai OS 2004). It is worth noting that leptin is without effect upon 
basal phase insulin output, there being no significant correlation between the variables of 
insulin output and leptin concentrations during the basal phase. This is believed to be due 
to a pulsatile secretion of insulin from the islets of the pancreas (Stagner 1980) which 
was probably originating from the intrinsic pancreatic nervous system and not from the 
coordinated neurogenic connections to the pancreas. The regularly repeated cyclic 
rhythms were consistent with an overall mean of 6.46 ±1.2 pmoles/2 min and a period of 
5.5± 0.4min with amplitude ranging between 4.73 ± 0.5 and 7.7 ± 0.82 pmoles/2 min. 
The characteristics of the periodicity reported here showed a lower overall mean and a 
shorter period than previously reported (Fang H and Ipp E 1990), possibly since the 
glucose concentration used was 1.5mM lower than in those studies. This is further 
supported by a proportional relationship between the glucose concentrations used and 
both the overall mean, and the period since increasing glucose concentration manifested 
itself in a higher mean value and a longer cycle period. Therefore, with increased 
glucose, the oscillatory amplitude is enhanced, leading to the hypothesis that cells within 
the islet are secreting with greater synchronization (Katzman et al 2004).
Leptin (5ng/ml) showed a suppressing effect on basal insulin secretion rates in ex 
vivo perfused rat pancreas experiments (Figure 23). This is a case that resembles 
prolonged fasting, which results in reduction of insulin secretion, and thus reduction of 
leptin secretion (Sonnenberg GE, Krakower OR, Hoffmann RG, Maas DL, Rennes MMI 
and Kissebah AH 2001). The low leptin is indicative of a decrease in ob mRNA in 
adipocytes due to decreased levels of circulating insulin (Stefan N, Fritsche A, Haring H,
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Stumvoll M 2001). Since at low glucose concentrations marked elevation of B-cell 
cAMP can be elicited without stimulation of insulin secretion, leptin may have 
manifested its suppressive effect via the cAMP route (Ahren and Havel 1999). The 
increase of cAMP could be due to the relatively small quantity of GLP-1 secreted by the 
a-cells of the pancreas after glucose stimulation, with potential local effects (Mojsov S, 
Kopczynski MG, Habener JF 1990) leading to the stimulation of insulin gene 
transcription by intracellular second messenger cascades leading to direct transcription 
factor activation or to up-regulation of insulin promoter specific transcription factors 
(Skogland G, Hussain MA and Holz GG 2000). Since the GLP-1 cascade represents one 
of the controlling mechanisms of insulin gene promoters, and since suppression of the 
insulin gene promoter could be achieved by p38 Mitogen Activated Protein Kinase 
(p38MAPK) (Kemp DM and Habener JF 2001), and since the MAPK family is controlled 
by the PI3Kinase (Cheatham B and Kahn CR 1995), a common enzyme for insulin and 
leptin receptor (Hegyia 2004), then suppressive effects of leptin on insulin gene 
expression could be manifested through this intracellular route (Figure 50). This 
suppressive effect of leptin could be manifested on the secretion of synthesized insulin 
(Kulkami et al 1997) since low glucose concentration elicits basal insulin secretion, 
although not in biphasic pattern. The suppressive effect was expressed 2 minutes after 
introducing the leptin in the stimulation medium (Figure 23), indicating an immediate 
effect in the physiologically perfused pancreas as compared to isolated rat islets where 
the suppressive effect was only evident after ten minutes (Kulkarni et al. 1999a). This 
difference in timing might be due to even lower levels of leptin administered, and the 
absence of the normal pancreatic topography, which, under glucose stimulation, increases
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the islet’s vascular flow (Styrud J, Eriksson JU and Jansson L 1992) and thus probably 
reduces the time taken to respond. In addition, in isolated islets, the lepin would have to 
diffuse through the A/D cells to get to the B-cells, while with perfusion, there is direct 
delivery to the B-cells. There was relatively no suppression of the oscillatory pattern, 
which indicates that it is controlled by a nuclear mechanism not affected by leptin’s 
intracellular cascade, where a cyclic metabolic signal drives oscillations of secretion even 
in the presence of stable [Ca^ ' J^i (Westerlund J, Gylfe E and Bergsten P 1997).
The suppressive scenario was not the case when a lOng/ml leptin concentration 
was used in the perfusion medium for the ex vivo experiments. A non-typical biphasic 
insulin secretory pattern was observed with a small first phase peak showing at about 
Sminutes after introduction of the stimulation medium indicating a delay of response. 
This was followed by a slow and progressive increase in insulin synthesis for sixteen 
minutes after phase 1, to show another sharp increase in secretion pattern, displayed by a 
sudden 3-fold increase followed by a sharp decrease, in a time span of four minutes. This 
clearly indicated a stimulatory rather than suppressive role for moderate hyperleptinaemia 
concentrations under fasting conditions for the normal rat perfused pancreas. This 
stimulating action has been previously reported (Ceddia BR, William Jr NW, Carpinelli 
RA and Curi R 1999) where at low glucose levels (ca. 3mM) and in the presence of 
50ng/ml leptin, perifused islets reached significantly higher values (50-60%) for the 
leptin group compared with the controls in the first 10 minutes of the perifusion. 
Moderate hyperleptinaemia is only observed in obese mice and rats, where 
hyperinsulinaemia is associated with obesity and where leptin has been reported to have a
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stimulatory rather than suppressive effect (Matson 1997). The mechanism by which 
leptin stimulates rather than reduced insulin is not clear. It is feasible that it may be 
achieved through IRS-2-associated PI-3 kinase activity in association with the GLUT-1 
glucose transporter, which has been shown to be responsible for basal glucose turnover, 
and hence maintenance of basal insulin secretion (Cheatham and Kahn 1995) under 
fasting conditions. IRS-2-associated PI-3 kinase activity has been reported to be 
increased about 2-fold upon exposure of insulin sensitive tissues to leptin, the effect 
being mediated through the leptin receptor long form ObRb (Kim 2000). Furthermore, 
IRS-2 expression is strongly induced by the cAMP Response Element Binding Protein 
(CREB), which is activated by cAMP agonists, including glucagon-like peptide 1 (GLPl) 
in islet B-cells (Jhala et al 2003). In addition, conventional PKC is inhibitory on 
depolarization-induced insulin secretion, but it also augments glucose induced insulin 
secretion (Zhang et al 2004), thus implying a bimodal mode of action for PKC. Such a 
bimodal effect is observed in growth hormone, which at high concentrations is a self­
antagonist (Hansen 1999). It is worth noting that both growth hormone and leptin exert 
their effects through cytokine family receptors (Hansen 1999). This link is important 
since PBKinase stimulates PKC, and since leptin receptor activates PBKinase, this might 
highlight a stimulatory action of leptin on insulin secretion through the PBKinase, IRS-2, 
GLUT-1 intracellular mechanisms. This is further supported by the low ATP/ADP ratio, 
which as mentioned above, reduces the probability of open potassium channels hence 
resulting in hyperpolarization. The time taken for the second response to appear 
(2minutes after phase one) suggests a nuclear mechanism including transcription and 
translation where the time for such mechanisms is around the above mentioned value.
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Further work is required to elucidate the stimulatory effect of leptin on basal glucose- 
induced insulin secretion and the dependency of leptin on GLP-1 to exert its suppressive 
action on insulin secretion when the pancreatic islets are exposed to basal or fasting 
glucose levels using ex-vivo perfusion as an experimental technique.
Leptin (Ing/ml) inhibited insulin secretion in response to 5.5mM glucose by 11% 
in isolated human islets studied in static incubation, and by 56% at lOng/ml leptin in 
mouse pTC6 cells seen at 10 minutes, a timing that implicates the end of phase one and 
the beginning of phase two, where newly synthesized insulin is produced (Kieffer TJ and 
Habener JF 2000). In addition, leptin suppressed insulin mRNA expression in both rat 
islets and pTC6 cells by 38% and 28% respectively under the same conditions mentioned 
above (Kulkami et al 1997). This direct effect was supported by the presence of leptin 
receptor OhRb mRNA in B-cells, demonstrated by RT-PCR (Leclerq-Meyer V, 
Considine RV, Sener A and Malaisse W 1996). Similar responses to leptin were observed 
in the rat cell lines RIN5AH cells and RIN5F cells with an inhibitory effect at Ing/ml 
(Kulkami et al 1997). It was further reported by the same author that when leptin 
concentration was increased 10 fold on a basal glucose concentrations background, there 
was a decrease in its suppressive effect in isolated islets. This decrease in suppression 
was observed with increasing leptin concentration displaying an inverted U-shape pattern 
of dose response relation between leptin and insulin production as seen in the ex vivo 
perfusion experiments reported here. Maximum suppression was observed using 5ng/ml 
leptin, after which leptin stimulated insulin release at lOng/ml. At 15 and 20 ng/ml leptin 
there is a mild increase in insulin secretion as shown in Figure 23. This discrepancy
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between perfused pancreas and isolated islets in the pattern of insulin secretion when 
subjected to increasing concentrations of leptin is probably related to differences in the 
experimental techniques. Islets in the perfused preparation are kept in the anatomical and 
physiological microenvironment of the pancreas as compared with perifused islets, and 
delivering of exogenous humoral signals is direct to the B-cells in the perfused pancreas, 
as opposed to indirect diffusion through the A and D cell mantle in perifused islets.
4.4 8mM glucose-induced insulin secretion pattern
In the presence of 8mM glucose and with increasing concentrations of leptin, 
there was a significant suppressive response displayed, again in a U-shape pattern with 
maximum suppression shown with the leptin concentration of 15ng/ml, as used in the 
present experiments and depicted in Figure 28. As the leptin concentration increased 
from zero to 15ng/ml, there is a progressive increase in the suppressive effect, reaching 
maximum at 15ng/ml. This might indicate that as more leptin molecules are attaching to 
the receptors on the B-cell, the suppressive effect is increasing. Maximum effect was 
evident at the concentration of 15ng/ml, which might be explained by the saturation of 
the leptin receptors. Furthermore, the suppressive effect was reduced at a higher 
concentration (20nM) used, which might be explained by a down-regulation of the 
receptors when exposed to high concentrations of leptin. When dissecting the inhibitory 
effect upon phase one and phase two, the same pattern was observed where 15ng/ml 
manifested the maximal effect (Figure 32 and 36). Within the same context, leptin at 
15ng/ml also manifested the same pattern indicating that a possible down regulation was
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evident. In addition, there was no significant difference in leptin effect on phase one at 5 
and lOng/ml, while the opposite is true for phase two. This could be explained by the 
more pronounced effect on the metabolically induced insulin secretion as compared to 
that induced by depolarization. In support of this, leptin has been reported to suppress 
cAMP induced insulin release (Ahren and Havel 1999).
Two major patterns were observed in the effect of leptin on insulin secretion in 
the ex vivo perfused rat pancreas reported here. The first was a delay in the bi-phasic 
secretory pattern, especially in the first phase (Figure 24). The second is a moderate, to 
extreme suppression of the first phase, followed by similar effects on the second phase. 
No inhibitory effect was seen upon the oscillatory pattern of insulin secretion, again 
implying that leptin at glucose concentration of 8mM does not affect insulin oscillatory 
pattern of secretion. The oscillatory pattern is increased in amplitude but not in 
frequency, a phenomenon previously reported (Westerlund 1997).
In the perfusion experiment with 5ng/ml leptin introduced, there was a 
suppression of phase one insulin release that covered its whole timing and some 
overlapping time of the second phase. Since the first phase of insulin secretion is due to 
release of docked granules’ content upon depolarization of the B-cells membrane (Ohara- 
Imaizumi 2002), then leptin’s effect may have been on the mechanisms involved in non- 
metabolizable secretagogues leading to depolarization of the membrane (Barg 2002). 
This suggests that not all the vesicles were discharged in the first phase as it depended on 
the quantity of calcium channels recruited in the depolarization. It was not until 15
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minutes after shifting to stimulatory medium containing the leptin that the rise in insulin 
secretion regained pace in a cyclic pattern to reach values equivalent to control at the end 
of the perfusion. Because insulin secretion closely followes [Ca^ '^ Ji oscillations imposed 
by repetitive depolarizations of B-cells with high and was stable during sustained 
elevation of [Ca^ ' J^i (Ravier MA, Gilon P and Henquin JC 1999), it was concluded that 
Ca^^ is the direct regulator of insulin pulsatility. This is supported here by the observation 
that the cyclic pattern of insulin secretion upon exposure to 8mM glucose was not 
abolished by co-perfusion with 5 ng/ml leptin.
In perifusion experiments with rat isolated islets, leptin inhibited physiological (8 
mM) glucose-induced insulin secretion, (Kulkarni et al 1997), where a 53% decrease in 
glucose-stimulated insulin release was observed when mouse leptin (0.Ing/ml) was 
incubated with rat islets. This observation is concordant with the results obtained in this 
study where leptin’s suppressive value ranged between 20 and 65% covering the whole 
range of leptin (5 to 20ngml) at similar glucose concentrations. There was a relatively 
small suppressive effect of leptin (20ng/ml) on the insulin secretion rate of the first phase 
in the present study as shown in Figure 32. This is comparable with the finding by Chen 
et al. (1997) in which 20ng/ml human leptin and lOng/ml glucose were incubated with 
islets from 4-week-old ob/oh mice and their lean counterparts, with relatively no 
detectable influence of leptin on islets from the lean mice. The difference is due to the 
experimental setup where they used isolated islets, while in the present study the islets 
were maintained in their physiological topography using ex vivo perfusion, which led to a 
more efficient response due to the possible intercellular communication between cells of
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the islets (Pipeleers 1982; Pipeleers DG 1987). Leptin at 20 ng/ml totally prevented 
(within 3 min) the excess PLC-mediated insulin secretion in the presence of lOpM 
acetylcholine in the islets of obese animals (Chen 1997). The ex vivo perfusions reported 
here had no central neuronal connections as the rats were brain dead during the perfusion 
while the present results show concordance in the level of suppression of insulin 
secretion by leptin at 20ng/ml. These results could be explained by the possible action of 
leptin on the post-insulin receptor pathway where the latter, as mentioned before, played 
an autocrine affect when B-cells stimulated with glucose at various concentrations 
(Aspinwall et al 2000) or the common intracellular pathways used by acetylcholine and 
other secretagogues, and which might reduce its role in favour of another pathway as a 
compensation (crosstalk concept) (Hegyi 2004). Since the first phase of insulin secretion 
largely comprises insulin from secretory vesicles, and since the insulin receptor is closely 
linked to this process through the 1RS-1/PI3-kinase link, leptin might be acting to 
suppress insulin output through the down stream candidates of second messenger 
systems. This possible mechanism is suggested as addition of insulin to dispersed B-cells 
evoked a rise in intracellular [Ca^^] by mobilization of calcium stores from the 
endoplasmic reticulum of the B-cells (Aspinwall et al 2000). Calcium is of course 
required for insulin-stimulated exocytosis of the insulin vesicles. The 5- 
hydroxytryptamine (5HT) method (Aspinwall et al 2000) uses amperometry to detect 
5HT accumulated in the secretory vesicles of the B-cells. The detection of a series of 
electrical spikes at the microelectrode is indicative of exocytosis and subsequent 
detection of packets of 5-HT diffusing to the electrode. This was further supported by the 
fact that insulin-stimulated insulin secretion, when measured by exocytosis events
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detected per stimulation per cell, was not significantly affected by removal of 
extracellular calcium, contradicting previous work (Holz 1993). One possible explanation 
for the increase in intracellular calcium concentration that drives insulin secretion may be 
inhibition of smooth endoplasmic reticulum calcium (SERCa) pumps responsible for the 
re-uptake of calcium into the endoplasmic reticulum. IRS-1 has been shown to inhibit 
SERCa pumps (Xu 1999). This would shed light on the leptin suppression of phase one 
insulin secretion, possibly by enhancing intracellular re-uptake via SERCA pumps, 
stimulated by the potassium channel opening, resulting in hyper-polarization. This may in 
turn reduce cytoplasmic calcium concentration resulting in either reduced or blocked 
insulin vesicle mobilization to the cell membrane and thus reduced exocytosis (Ohara 
2002). Furthermore, an important coupling point between intracellular calcium increase 
and exocytosis in B-cells is protein kinase C (Mochly-Rosen and Kauvar 1998; Nesher et 
al 2002), which regulates the PI3-kinase (Henqiun 2002). This forms an essential link 
between the insulin receptor and glucose transporter translocation and intracellular 
trafficking, which again raises the possibility that it may be directly implicated in the 
altered phase one insulin secretion level and duration reported here (Figure 24).
These results are in concordance with those obtained by Leclerq et a l  (1997) 
where 8.3mM glucose was used as a stimulatory medium and where a rise in D-glucose 
concentration from 3.3 to 8.3mM provoked a biphasic stimulation of insulin release. 
Furthermore, the results were similar in that leptin failed to interfere with the pulsatility 
of insulin release (Kjems LL, Ravier MA, Jonas JCh, and Henquin JC 2002). This again 
suggests that the oscillatory pattern of insulin secretion was originating from the intra
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pancreatic nervous system as the perfusion study by Leclercq et al. (1997) was done free 
of adjacent organs and with a remaining pulsatility. This part of the present study 
strongly contradicts the report of Leclercq et al. (1997) since leptin did have inhibitory 
effect on basal and glucose-induced insulin release at physiological concentrations of 
glucose. This discrepancy may be related to the method for perfusion adopted by 
Leclercq’s team, where the pancreas was completely isolated from adjacent organs, while 
here the perfusion was ex vivo. This indicates the requirement for the presence of the 
intestine and adjacent organs to have physiologically realistic effect of leptin on insulin 
secretion. It has been shown that GLP-1 plays a major role in induction of glucose- 
induced insulin release (Fehmann 1997a; Balkan and Li 2000, and Brandt et al 2001) and 
leptin may exert its effect through this intracellular pathway (Ahren and Havel 1999). It 
is worth noting that in Leclercq’s work the significant difference between the 
experiments conducted in the presence and absence of leptin indicated a small relative 
increase of insulin output in the presence of leptin, which showed tendency towards a 
slightly augmented secretory response to glucose. This might indicate that leptin 
inhibition of insulin through cAMP cascades using p38 MAPK (Kemp and Habener 
2001) is potentially valid as in Leclercq’s work, no source of extra pancreatic GLP-1 was 
present.
4.5 12mM glucose-induced insulin secretion
Addition of leptin to the 12mM glucose perfused pancreas produced significant 
decreases in insulin secretion of both phases (Figures 25, 29, 33 and 37). Introducing
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5ng/ml leptin produced comparative decreases in both phases of insulin secretion. This 
indicated that leptin (5ng/ml) acutely suppresses insulin secretion and synthesis in the ex 
vivo perfused rat pancreas with moderate hyperglycaemia. The effect was observed by 
approximately 3 minutes after the introduction of leptin, and the suppression continued in 
the second phase to a maximum of 3-fold decrease compared to the control group. This is 
directly comparable with data reported by Cases et al. (2001) where, in a 240 min 
moderate hyperglycemia clamp study in the rat, with glucose levels maintained at a little 
below 12mM, plasma insulin concentrations were abruptly and significantly decreased by 
leptin. Moreover, this inhibitory effect on insulin secretion was of rapid onset occurring 
at 5min after leptin infusion and was dose dependent. The discrepancy between the 
present study and that of Cases et al. (2001) may lie in the nervous system’s contribution 
to the effect of leptin, which manifested itself in a somewhat less suppressive action 
suggesting a neuro-modulatory role. It is worth noting in Case’s report that two hours of 
sustained hyperglycemia before the infusion, to avoid the confounding effects of the 
acute rise in insulin levels during the first phase of insulin secretion, indicated a 
suppressing effect on the newly synthesized insulin of phase two. This has previously 
been inferred (Zawalich 1990) and was clearly demonstrated in this study as seen in 
Figures 35. This view is further supported by a perifusion study where INS-1 B-cells 
incubated with ll.lm M  glucose, lOng/ml GLP-1 and 6.25ng/ml leptin showed complete 
inhibition of preproinsulin mRNA production (Ahren and Havel 1999). In addition, the ex 
vivo perfusion experiments reported here showed a decrease in insulin secretion of more 
than 50% in phase one, and in all the different leptin concentrations used. The results 
reported in vivo by Cases et al. (2001) are similar to the data presented here showing the
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ex vivo technique to be closely simulating the true physiological situation. The abrupt 
inhibition of insulin secretion and synthesis with leptin treatment in both techniques 
mentioned above (both ex vivo and in vivo) strongly suggests that this effect is mainly 
caused by leptin’s action on pancreatic islets. There is probably some incretin and neural 
interference that manifesting itself in the degree of suppression as clearly indicated in the 
regression of insulin output upon leptin concentration, at all glucose concentrations in the 
perfusion medium where almost only 40% of the variance in the insulin output is 
attributable to the combined effect of glucose and leptin (Figure 40).
Since the primary proposed mechanism of leptin action is through a reduction of 
c-AMP, it was further tested by the addition of a selective inhibitor of phosphodiesterase- 
3 (PDE-3). This completely inhibited the glucose (12mM) and GLP-1 induced insulin 
release in vitro (Zhao et al 2000), but to a lesser extent in vivo (Cases et al 2001) 
indicating probable involvement of a neural mechanism. Since in the present study the 
suppressive effect of leptin was more pronounced (3-fold) than in vivo (2-fold), it draws 
our attention to a possibility of a local neural mechanism modulating the effect of leptin 
in vivo. It has been shown that acetylcholine at various doses induces insulin secretion, 
and leptin suppresses acetylcholine induced insulin secretion (Kieffer 1997). This 
suppression was dose dependent with 5ng/ml leptin showing 2-fold suppression of insulin 
secretion in islets of ob/ob, but not normal mice (Chen and Romsos 1995). This might 
indicate that the neurotransmitter acetylcholine might counteract the leptin effect leading 
to a moderate suppression in vivo as compared to a more pronounced suppression in vitro 
as compared in turn to ex vivo. This led to the conclusion that the most probable pathway
228
of leptin action in normal rat perfused pancreas is through the suppression by PDE-3 of 
cAMP in the B-cell, stimulated by glucose and incretins of which GLP-1 shows the most 
potent effect on B-cells. Indeed, changes in the firing rate of hepatic afferent and 
pancreatic efferent nerves have been demonstrated after administration of GLP-1 in the 
hepatoportal system (Nakabayashi 1996). According to Balkan and Li (2000), the 
potentiation of the insulin response was discernable within 1 minute of administration of 
glucose and GLP-1, suggesting a neural rather than a neurohumoral reflex loop. It was 
demonstrated in this study that there is a potential humoral connection between the 
duodenum and the head and the tail of the pancreas as shown by methylene-blue 
introduction via the superior mesenteric artery, which eventually reached the tail with 
mild coloration consequently bypassing the hepatic circulation. This implicates a direct 
non-neural connection between the intestine and the pancreas possibly working in 
conjunction with the well-established neural network.
In addition, numerous studies have investigated direct effects of GLP-1 on B-cells 
both in vitro and in vivo. Endogenous GLP-1 is limited in its action by very rapid 
inactivation by dipeptidyl-peptidase IV that cleaves two NH2-terminal amino acids, 
thereby rendering the hormone inactive for its B-cell effect (Deacon 1995), within an 
average of one minute. Furthermore, 50% of the GLP-1 released by the L-cells is 
estimated to be inactivated in the capillary bed surrounding these cells (Nakabayashi 
1996), and a single pass through the liver inactivates a large fraction (>40%) of the 
remaining active GLP-1 (Deacon CF, Pridal L, Klarskov L, Olesen M and Holst JJ 1996). 
This implies that these two processes, together with inactivation in the circulatory system
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and in other organs, can be expected to inactivate or remove most of GLP-1 released 
from the intestine before the active form of the peptide can reach the pancreas via the 
systemic circulation. This concept was supported in the present ex vivo perfusions since 
the perfusates were collected through the portal vein and through which the different 
glucose concentrations were detected. These data suggest that B-cell stimulation by portal 
GLP-1 is evoked via neural reflexes that may be triggered between the portal vein and the 
pancreas via the intestine enteric nervous system (Balkan and Li 2000) and are non- 
muscarinic in nature which again is supported by the ex vivo perfusion where the animal 
had no central nervous system activity. In further support of this hypothesis, GLP-1 is 
known to potentiate insulin secretion by elevating cAMP levels in B-cells, and the 
inhibitory effect of leptin on insulin secretion has been tested to check whether cAMP is 
involved through the PI3-K enzyme (Zhao et al 2000). In the presence of elevated 
glucose concentrations (ll.lm M ), GLP-1 (5ng/ml) elevated the cAMP level in HIT cells 
about three-fold, and leptin was able to suppress cAMP level in a dose-dependent 
manner, and activate PI3-kinase by about three fold. Addition of low concentrations of 
PI-3-kinase inhibitors inhibited phosphodiesterase 3-B (PDE-3B) activation by leptin 
implying that the activation of the latter by leptin could be mediated through the 
activation of PI-3-kinase, which is a common secondary intermediate of the tyrosine 
phosphorylation cascade of the insulin receptor. The present data support the inhibitory 
effect as shown by a relative 60% suppression of phase one by leptin at 5ng/ml, reaching 
a high degree of inhibition with the physiological leptin concentrations of lOng/ml in rats. 
A relative inhibition of insulin output observed with a higher leptin concentration 
(15ng/ml) and inhibition was reduced at 20mM leptin. Hence the observed U-shaped
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dose response with increasing concentrations of leptin. It is worth noting that the peak of 
the first phase of insulin secretion reached 51.72 pmoles a level equivalent with the value 
reported for insulin secretion with ll.lm M  glucose and physiological concentration of 
GLP-1 (0.Ing/ml). This implies again that the ex vivo perfusion permits additional 
parameters affecting insulin secretion to be taken into account. This is further supported 
by the fact that PI-3-kinase is necessary for GLUT-2 translocation (Novelli 2000; 
Thorens 2000), glucose uptake, and its involvement in actin polymerization associated 
with cytoskeletal alterations (Janmey PA and Stossel TP 1989). These have a direct 
involvement in the movement of insulin storage vesicles to the B-cell membrane and 
release of their content in phase one insulin secretion (Bratanova-Tochkovaet al 2002). 
Our study clearly shows that leptin has a maximal suppressive effect on phase one 
(Figure 33), at all concentrations of leptin, where the intracellular machninery responsible 
was affected indicating a dose-dependent factor for the effect of leptin on insulin 
secretion.
It has also been reported that leptin (6.25ng/ml) inhibited proinsulin mRNA 
expression in islets at ll.lm M  glucose, but not 5.6mM glucose (Kolaczynski et al 
1996b). Leptin reduced islet proinsulin mRNA levels that had been increased by 
treatment with lOng/ml GLP-1 in the presence of either 5.6 or 11.1 mM glucose. These 
findings demonstrated a direct suppressive effect of leptin on insulin-producing B-cells in 
humans at levels of both stimulus-secretion coupling and gene expression. The present 
results tend to confirm the suppressive effect of leptin on insulin output at high glucose 
levels (12mM), demonstrated by at least 50% suppression in phase 2. This suppressive
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effect was not significant when 8mM glucose was used, further indicating the 
dependency of the action leptin upon the concentration of glucose. In addition, this 
discrepancy could be due to the difference in the techniques used.
4.6 16mM glucose-induced insulin secretion pattern
Addition of leptin to rat perfused pancreas showed a decrease in insulin secretion 
rate that ranged between 45 and 88% depending on the leptin concentrations and again 
showing the U-shaped dose-response relationship (Figure 30). Maximum suppression 
was manifested with 10 and 15ng/ml leptin while 5 and 20ng/ml leptin (Figure 30) 
showed less suppressive effects. Leptin suppressed insulin secretion more than 50% at 
most concentrations with the exception of 15ng/ml where the suppression reached about 
80%. When leptin was introduced, there was a progressive suppressive effect with 
increasing concentrations up until the 15ng/ml where relatively maximum suppression 
was recorded. The most probable explanation is that leptin, at this concentration, is bound 
to most of the Ob receptors available on the B-cells manifesting maximal suppression, as 
this is evident in both phases of insulin secretion (Figures 34 and 38). At the highest 
leptin concentration used in this study (20ng/ml), leptin showed a reduced suppressive 
effect at this glucose concentration (Figure 30). By dissecting this response as phase and 
phase two, the same pattern of reduced suppression is evident (Figures 34 and 38). This 
may be explained by a down regulation of leptin receptors on the B-cell’s surface. This 
would result in a reduction of the activity of the intracellular machinery used to manifest 
the suppressive effect of leptin.
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This model (16mM glucose/ 20ng/ml leptin) represents hyperphagic obesity 
where high glucose levels increase in the plasma, resulting in hyperinsulinaemia leading 
to hyperleptinaemia and thus, obesity (Mark 2000). Hypersecretion of insulin from the 
pancreas is among the earliest detectable alterations in leptin-deficient ob/ob mice (lida et 
al 1996). Glucose-induced calcium entry has been reported to activate various kinases in 
the B-cells, including p44/42 mitogen activated protein (MAP) kinases (also called 
extracellular signal-related kinase 1/2, ERKl/2) (Briaud I, Lingohr MK, Dickson LM, 
Wrede CE, Rhodes CJ 2003; Jones and Persaud 1998). Glucose (16mM), by activating 
the ERKl/2 cascade, induces phosphorylation of cytoplasmic proteins implicated in 
exocytosis of insulin granules such as synapsin I (Matsumoto K, Ebihara K, Yamamoto 
H, Tabuchi H, Fukunaga K, Yasunami M, Ohkubo H, Shichiri M and Miyamoto E 1999). 
The majority of ERKl/2 activity induced by glucose, remains in the cytoplasm and 
physically interacts with synapsin I, allowing phosphorylation of the substrate. Blocking 
activation of ERKl/2 using the MEKl/2 inhibitor PD98059 or using small interfering 
RNAs (siRNA)-mediated silencing of ERKl and ERK2 expressions resulted in “partial” 
inhibition of glucose-induced insulin release, indicating that the ERKl/2 pathway 
participates in the regulation of insulin secretion. It is worth noting that siRNAs have 
become a standard tool in functional genomics. Once incorporated into the RNA-induced 
silencing complex (RISC), siRNAs mediate the specific recognition of corresponding 
target mRNAs and their cleavage (Truss M, Swat M, Kielbasa SM, Schafer S, Herzel H 
and Hagemeier C (2005). Moreover, using the pancreatic islet perifusion model, ERKl/2 
activity participates irv the first and in the second phase of insulin release induced by 
glucose (16.7mM) (Longuet C, Broca C, Costes S, Hani EH, Bataille D and Dalle S
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2004). This partial inhibition mediated through the ERKl/2 activity is concordant with 
the partial inhibition of insulin secretion caused by leptin through its receptor and its 
intracellular mechanism, which include ERKl/2 (Bjorbaek et al 2001). This inhibition is 
clearly shown in this study (Figure 26) with maximum suppression at 15ng/ml. this 
indicates that the most probable mechanism to explain this inhibition is a cross talk 
between intracellular cascades of leptin receptor and the glucose-induced calcium entry, 
which has been reported to activate various kinases in the B-cells.
It is worth noting that GLP-1 receptor expression in pancreatic islets was minimal 
when islets were incubated at 16.7mM glucose (Garcia-Flores 2001). Since such high 
concentration of glucose can stimulate insulin secretion with minimal induction by 
incretins to reach maximal insulin secretion, then it is reasonable for the GLP-1 receptor 
to down regulate at such high glucose concentration. Since leptin suppresses cAMP 
induced insulin secretion (Ahren and Havel 1999), it is consistent with the reduced 
inhibition of leptin on glucose-induced (16mM) insulin secretion demonstrated in this 
study (Figure 26) as compared to lower concentration (12mM). Furthermore, the area 
under the curve of total insulin secretion showed significant reduction of inhibition 
between glucose concentration of 12 and 16mM (Figures 29 and 30).
Interestingly, islets from young ob/ob mice initially exhibit normal insulin 
secretion in response to glucose (Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, 
Yun UJ, Cooksey RC, Boudina S, and Abel ED 2004). Only later in life is glucose- 
induced insulin secretion enhanced implying that the regulatory step for glucose-induced
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insulin secretion is altered secondary to other regulatory pathways, and that glucose- 
induced insulin secretion may not be a primary target for leptin. Before the onset of 
hyper-responsiveness to glucose, islets from young ob/oh mice exhibit a specific 
enhancement in insulin secretion in the presence of acetylcholine (Kieffer 1997). To 
further test this hypothesis, isolated perfused rat pancreas presented a monophasic initial 
insulin output induced by sustaining stimulation with 0.1 pM acetylcholine while 
sustaining stimulation with IpM acetylcholine induced the initial phase followed by an 
indistinct second phase of insulin release concentration (Chen 1997). In addition, a 
sustained stimulation with lOpM acetylcholine induced a biphasic insulin release 
manifested by a rapid increase followed by a prolonged slower increase in release. The 
time course of this biphasic release was analogous to that induced by sustained 
stimulation with high concentrations (16.7mM) of glucose in normal rats. Since 
acetylcholine intracellular signalling relies on the phosphoinositide/ diacylglycerol 
pathway activating PLC, overlapping the mechanism for insulin stimulation in the 
presence of high calcium concentration, this implies a common intracellular signalling 
pathway from the insulin, acetylcholine and leptin receptor pathways in order to regulate 
B-cell intracellular mechanisms. A possible candidate would be the PI-3kinase as 
interpreted before. Although it was reported earlier (Fehmann 1997a) that leptin does not 
inhibit glucose or GLP-1 induced insulin from islets of ob/ob mice or lean mice, the 
present study suggested the opposite with leptin (<15ng/ml) showing a suppressive effect 
on insulin hyper secretion. The exact mechanism is not clear, but since PI-3 kinase is a 
common crossroad for insulin, acetylcholine and leptin receptor, then the latter seems to
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have enhanced action in the ex vivo perfusion resulting in the suppression and 
compensating for the lack of extra pancreatic nervous connections.
This was not in concordance with the finding that acetylcholine (lOpM), via 
activation of muscarinic receptors generating diacylglycerol and subsequent stimulation 
of the PLC signal transduction pathway in rat isolated islets, enhanced insulin secretion 
more from young ob/ob mice than from lean mice (Chen and Romsos 1995). In addition, 
cholecystokinin also stimulated the PLC signal transduction pathway and caused more 
insulin release from islets of ob/ob mice than lean mice. The neurotransmitter 
acetylcholine and the gastrointestinal peptide cholecystokinin activated a common PLC- 
mediated step to cause hypersecretion of insulin from islets of young ob/ob mice, which 
manifest deficiency of leptin. So it is probable that leptin targets this pathway to constrain 
the enhanced insulin release from ob/ob mice islets, which is supported by the fact that 
leptin did not reduce the insulin secretion rate in ob/ob mice below levels observed in 
their lean littermates (Weigle et al 1995). It seems that this pathway may be down 
regulated in islets from lean mice, probably because they have been pre-exposed to leptin 
in vivo.
It has been reported that acute static exposure of both rat and mouse islets to 
concentrations of leptin within the physiological range (lOng/ml) did not alter the basal 
insulin secretion nor the insulin secretion stimulated by glucose (16mM) alone (Scherer 
1998). This contradicted the inhibitory effect observed in ob/ob mice where Kieffer et al. 
showed that the suppressive effect of leptin in islets from ob/ob mice was mediated
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through the activation of the ATP-sensitive potassium channels of the B-cells. This 
suggests that the defect in leptin-mediated action resides in the cAMP pathway. In 
addition, no effect of leptin was observed on insulin secretion in cultured islets stimulated 
by glucose or ketoisocaproic acid (KIC), which does not support this mechanism of 
action in normal rodents. It can however be concluded that KIC does not act through the 
K-ATP channel-independent pathway, as shown by Kieffer et al. (1997) in oh/ob mice 
where leptin mediated its action through the activation of ATP-sensitive potassium 
channels of B-cells (Morton 1999). Leptin (lOng/ml) specifically inhibited glucose 
(16.7mM) + IB MX induced insulin release in B-cells, probably by decreasing 
intracellular levels of cAMP acting upon its down stream effect on insulin secretion 
(Scherer 1998). This suggests that in normal rodents leptin does not act on the main 
pathway of coupling between glucose and insulin release in the B-cell, involving 
activation of the ATP-sensitive potassium channels, membrane depolarization, and 
calcium entry through voltage sensitive calcium channels. This again brings to the fore 
the crucial role of GLP-1 for the suppressive effect of leptin. This concept may have 
been supported in the present study where adenosine, an inhibitor of cAMP 
phosphodiesterase, was included as a vasodilator in the perfusion media. Clearly the 
effects of lOng/ml leptin used in the study by Poitout et al. (1998) (lOng/ml) on 16.7mM 
glucose induced-insulin secretion in the presence of adenosine and incretins manifested 
itself by an approximate 45% decrease in phase one secretion, and to a lesser extent in 
phase two. Whether suppression of leptin was due to the presence of adenosine in not 
clear since GLP-1, which stimulates the cAMP of B-cells, may have potentiated insulin 
release. To further consider this point, 50ng/ml leptin were added by Ceddia et al. (1999)
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to lean male albino Wistar rat islets. This did not present a rapid first-phase insulin 
secretion response in the presence of supra-physiological glucose concentrations 
(16.7mM). However, with continuation of perifusion, the quantity of insulin secreted 
reached close to those of the control group as the experiment progressed. These results 
supported the hypothesis that leptin acted as a modulator of the insulin secretion process 
in the B-cells, instead of imply inhibiting or stimulating. The experiments in the present 
study with 16mM glucose in combination with 5, 10 and 15ng/ml leptin supported this 
observation where the first phase was either abolished or suppressed and with the second 
phase progressively increasing to reach values close to control (Figures 32 and 36). 
Adding 15ng/ml leptin proved to significantly suppress both phases of insulin secretion 
(Figures 32 and 36), hence, leptin at 20ng/ml partially reversed the previous suppression.
This suppressive effect of leptin on insulin secretion could be a consequence of a 
double effect. On the one hand leptin enhances insulin-induced glucose utilization in 
peripheral tissues (Chinookoswong 1999), an effect mediated by the leptin receptor 
(Mizuno A, Murakami T, Otani Sh, Kuwajima M and Shima K 1998), while on the other 
hand, it decreases insulin secretion in order to avoid hypoglycemia resulting from 
hyperinsulinaemia. The present study shows one arm of this double effect where leptin, 
at concentration reported previously (Chinookoswong 1999) of lOng/ml suppressed 
insulin secretion in the presence of high glucose levels and in a dose-dependent manner. 
This situation resembles diabetic rats, and which was manifested by a 50% decrease of 
insulin release, following a presumed similar and even more pronounced suppression of 
insulin synthesis. This was convincing since leptin has been reported (Rossetti et al
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1997; Sivitz 1997) to correct hyperglycemia by restoring normal rates of glucose 
turnover. Interestingly, the highest concentration of leptin substantially reversed the 
suppression of insulin output, indicating that the hyperglycaemic drive to produce insulin 
was able to override the suppressive effects of leptin.
Perifusion studies have demonstrated that leptin (lOng/ml) significantly inhibits 
insulin secretion, only at glucose concentrations >16mM, within 5 minutes; removal of 
leptin from the perifusate led to an equally rapid reversal of this inhibitory response 
(Kolaczynski et al 1996). In contrast to the perifusion results, the inhibition reported in 
the present perfusion experiments showed almost immediate inhibition at all four doses 
of leptin (5, 10, 15, and 20ng/ml) used. In addition, sub-chronic treatment of islets with 
leptin (lOng/ml) for a 6hr period led to a more pronounced percentage decrease in insulin 
secretion, which again suggests an inhibitory effect of leptin on insulin synthesis 
(Zawalich 1990). This was evident in the present results, where the inhibitory effect was 
most pronounced at a leptin concentration of 15ng/ml. It is worth noting that leptin (1 
and lOng/ml) rapidly inhibited glucose induced insulin secretion by isolated rat islets, at 
glucose concentrations greater or equal to 16mM (Seufert J, Kieffer TJ, Leech CA, Holz 
GG, Moritz W, Ricordi C and Habener JF 1999).
Subjecting the pancreas to high concentrations of leptin (15ng/ml) caused a 
substantial decrease in insulin secretion, which is not the case in obesity-prone rats where 
increase in leptin is a result of hyperinsulinaemia leading to adipose tissue enlargement 
(Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T and Collins F
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1995). The present set of experiments imitated the case of overfeeding as prediabetes, 
where high glucose is associated with high insulin secretion (Figure 22). This could 
induce the production of leptin in adipose tissue leading to a rise in plasma leptin 
(15ng/ml) as simulated by this experiment. Since hyperleptinaemia is indicative of 
increased fat depot size, as part of a negative feedback loop, the pancreas reduced the 
total production of insulin under the suppressive effect of leptin (Figure 32). This may 
prevent hyperinsulinaemia as a result of high glucose and which might leads to insulin 
resistance in the long term. This is supported by the concept that the activation of 
biological responses to increased availability of nutrients is muted in obesity-prone 
individuals subjected to hyperphagia. This altered response could contribute to the onset 
of weight gain and insulin resistance, and it may involve a partial failure of the leptin 
system (Wang et al 2000). This is further supported by the fact that the first 
manifestations of impaired insulin action are the transient increase in post-absorptive 
glucose production hence raised plasma glucose levels with marked resistance to the 
action of insulin.
As a general conclusion, a combination of all the systems including, PKC-PKA 
and cAMP is believed to be combined in a coordinated time-based process in normal rats. 
It is frequently found that when a defect occurs in a particular mechanism in the cell, a 
compensatory mechanism raises its efficiency in order to compensate. A probable 
scenario for the sequence of events leading to the secretion of insulin and its suppression 
by leptin in normal rats could be as follows. ; The early stage for insulin secretion would 
be most probably coordinated by an autocrine effect of insulin on its own receptors where
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the tyrosine phosphorylation occurs after 10 to 12 seconds of ligand binding to the alpha- 
subunit of the insulin receptor on the surface of the B-cell. Glucose uptake at the same 
time promotes phosphorylation of the B-subunit of the insulin receptor to make it reach 
maximal activity in 30 seconds, a timing which coincides with the auto-phosphorylation 
induced by insulin on its receptor. Directly following this event, intracellular calcium is 
mobilized from the endoplasmic reticulum as a result of inhibition of the SERCA pump 
on the surface of the Endoplasmic Reticulum (E.R.) and which is inhibited by a down 
stream candidate molecule, IRS-1 of the insulin receptor. At the same time IRS-1 in turn 
activates PI-3 kinase which produces PIP-3 activating PLC-y and which in turn causes 
the release of intracellular calcium from inositol 1, 4, 5-triphosphate sensitive calcium 
stores on the E.R. furthermore, stimulating Ca^ "^  release into the cytosol. Inositol 1 ,4 ,5 -  
triphosphate plays a major role in polymerization of cytoskeleton elements, a process 
required for the mobilization of the insulin vesicles to reach the B-cell membrane and 
undergo exocytosis. This is followed by a subsequent dephosphorylation of the insulin 
receptor B-subunit to basal level after 10 to 15 minutes and thus overlapping the timing 
for insulin biosynthesis, a characteristic of phase two insulin secretion.
The addition of leptin activates channels resulting in hyperpolarization 
manifested by decreased calcium release into the cytosol (Gembal M, Detimary P, Gilon 
P, Gao ZY, Henquin JC 1993; Barg 2002). GLP-1 antagonizes the channel 
hyperpolarization, and as the rise in intracellular calcium concentration is closely 
associated with insulin vesicle mobilization observed as phase one secretion in perfusion 
experiments, it is suggested that leptin suppresses phase one secretion via the potassium
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channels. Hence, when glucose and insulin activate insulin release through vesicle 
mobilization and release, the latter will stimulate leptin secretion at the adipocytes. Upon 
reaching the B-cells shortly thereafter, leptin, in a dose dependent manner and dependent 
on the presence of glucose, acutely suppresses the phase one release via the potassium 
channel, sharply decreasing in insulin release. Since insulin is a potent stimulant of leptin 
release in adipose tissue and since insulin decreased to pre-stimulatory levels, then leptin 
production is reduced and thus its inhibitory effect as a result is attenuated as shown by 
the progressive increase in insulin secretion during phase 2. Since most of the vesicles 
were secreted in phase one, phase two must involve synthesis of proinsulin leading to 
insulin incorporation in vesicles and their release throughout the remaining perfusion 
period. The reverse of the suppressive effect is further supported by the concept of 
desensitization of the leptin receptor upon acute exposure to high concentrations, which 
may at least, in part explain the transient period between the two phases of insulin 
secretion. This immediate response supports the concept of a common path between 
leptin and insulin receptor second messenger systems. Several intracellular molecules 
have been recognized as common to both pathways. These include PI-3 kinase, GRB-2, 
ras-raf molecules, MARK kinase and probably others to be discovered. These 
observations indicate that common molecules, probably via simple phosphorylation- 
déphosphorylation mechanisms, could change the intracellular mechanism of action 
between insulin reception, and leptin reception targeting different genes in the nucleus. 
This combination of effects has been supported in this study where a 31.7% of the 
variance in total insulin output is explained by glucose concentrations alone, and the low 
value for the coefficient of determination is attributable to the inhibitory effects of leptin
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upon insulin output. An illustration of this proposed model is presented in Figure 50 
overleaf.
243
0r
03 (U) Q J  < U
|ji) liiil lîilî.
P  o3
Since at moderately high concentrations of glucose (12mM), leptin appears to 
maximally inhibit insulin synthesis and release, this suggests the existence of a negative 
feedback loop where leptin inhibits insulin secretion in order to prevent 
hyperinsulinaemia, which eventually leads to hyperleptinaemia leading further to leptin 
resistance and presenting insulin resistance. This suppression was not manifested to that 
extent upon exposure to 8 or 16mM glucose. This implies that as plasma glucose 
concentration increases; insulin secretion will increase leading to increase in leptin 
production mainly from the adipose tissue in order to bring insulin secretion back to the 
normal level, either to prevent hypoglycemia or possibly to prevent insulin resistance. 
Since high plasma glucose is often associated with insulin resistance, then the islets may 
be predicted to respond to high leptin concentrations by reducing insulin production. 
This is shown by suppression of mostly phase 1 at BmM glucose, and both phases at 
12mM glucose. This indicates the aggressive action of leptin to suppress insulin 
secretion at 12mM in order to prevent over expression of glucose-induced insulin 
secretion that might precede insulin resistance. When supra-physiological levels of 
glucose were administered, the suppressive effect of leptin was less prominent, indicating 
reduced negative feedback possibly due to down regulation of leptin receptor. This 
variable action of leptin clearly showed its dependency on the glucose concentration, 
which implicates a direct dynamic interaction between leptin and B-cells demonstrated 
by the pattern of insulin release.
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4.7 Future research
Further studies need to be done to elaborate on the modulatory action of leptin on 
insulin, when higher glucose concentrations and other parameters are introduced in ex 
vivo experiments. The strategy for future research should take into consideration 
parallelism in experimental procedures, one at the physiological level and the other at the 
molecular level. Using physiological experiments would present the over all picture, 
while molecular experiments would shed light on specific sections of this picture in order 
to build an inductive conceptualization to the idea studied.
At the physiological level, the perfusion procedure should be further updated 
where the experimental rat would be left alive throughout the whole procedure. This 
approach would demonstrate the actual endocrinological mechanisms involved, and it 
would allow the investigation of reversable effects taking place in a reversible manner. 
The updates should involve cannulation and ligation amendments to the current ex vivo 
technique. At the cannulation level, an aortic by-pass should be introduced between 
dorsal aorta posterior to the diaphragm and the dorsal aorta anterior to the renal arteries 
laterally. The aortic cannula should be introduced anterior to the bypass at the renal artery 
zone laterally. Another cannula should be introduced into the hepatic portal vein for 
collecting the perfusates. At the level of ligatures, the left and right gastric arteries should 
be opened to allow gastric hormones to flow into the circulation. The splenic arteries, 
esophagus, adrenal and hepatic artery should be kept ligated. The flow rate should be 
standardized to insure regular physiological flow into the organs. In parallel, introduction
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of methylene blue would help determine the time needed to enter and exit the cannulated 
system.
At the level of the apparatus, four additional oxygenators should be introduced 
into order to diversify the parameters introduced at various concentrations. In order to 
allow various concentrations of the parameters into the system, a synchronized set of 
peristaltic pumps should be introduced where their rotatory speeds vary when a new 
parameter is introduced and its quantity is being changed to suit the concentrations 
needed. This synchronized variation in the speed would insure a constant flow rate with 
changing introduced parameter concentrations. The multiple exchange key (MEK) should 
be amended to fit the four newly added oxygenators. The tubings should be short to 
minimise the dead space.
It is important to determine the fasting and non-fasting plasma concentrations of 
all the hormones involved, which could include leptin, insulin glucagon, somatostatin, 
ghrelin, cholecystokinin, adiponectin, epinephrine, nor-epinephrine, GLP-1 and GIF. 
Building on the index we covered in this report, the modulatory effect of other hormone 
in parallel to leptin on the secretion of insulin could be studied.
At the molecular level, quantification of mRNA for leptin receptor, insulin gene, 
and insulin receptor is important to detect the immediate effect at the genetic level after a 
dose-dependent introduction of the parameters. Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR) is a very accurate technique that can be used. This set of minor
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procedures would set a broader index that can be used as a reference to dissect further the 
mechanisms involved in insulin secretion at the molecular level.
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APPENDIX 1 Schematic diagram of the screen-cylinder 
oxygenator
Side view
10 12
Legend:
1 ) Perspex end plate 1
2) Perspex end plate 2
3) Perspex cylinder jacket
4) Screen cylinder, pore diam: 3mm
5) Stainless steel shaft
6) Metal nuts
7) Gas inlet
8) Gas outlet
9) Glass gas outlet
10) Perfusate inlet
11) Brass pulley
12) Rubber circular ring
13) Stainless steel shaft bearing
14) Perfusate outlet
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APPENDIX 2 Schematic diagram of the perfusion assembly
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See over page for legend.
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Legend:
1) Oxygenator 8) Peristaltic pump
2) Surgery platform 9) Multiple exchange key (MEK)
3) Vapor pollection protrusions 10) Main water bath
4) Surgery platform grids 11) Glass-coil heat exchanger
5) Gas inlets 12) Mercury manometer
6) Containers of variable concentrations 13) Dissolved oxygen meter
7) Magnetic stirrer
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APPENDIX 3 Schematic diagram of the perfusion assembly
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See over page for legend
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Legend:
1. Surgery platform 7. Water bath supports
2. Gas inlet tubing 8. Oxygenator
3. Electric motor 9. Thermometer
4. Multiple exchange key 10. Mercury manometer
5. Mercury manometer connection 11. Oxygen probe
6. Polythene tubing 12. Perfusion outlet
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